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Abstract 
 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that 
affects about 1% of the world population. This common disease is characterized 
by chronic inflammation of the synovium that leads to destruction of cartilage and 
bone in the join, and the cause of this exacerbated inflammatory reaction remains 
unknown. Periodontitis (PD) is also a chronic inflammatory disease characterized 
by destruction of bone and other connective tissue that shares notable similarities 
with RA. Over the last 20 years, numerous studies have found an epidemiological 
connection between RA and periodontitis. However the biological mechanisms 
that explain the interrelations between the two conditions are not known. The 
main hypothesis sustains that periodontal bacteria (mainly Porphyromonas 
gingivalis) could have a role in the progression of RA.  Also, recent investigations 
suggest that periodontal therapy could reduce inflammation in RA, but the results 
are not conclusive.  
 
The aim of this thesis was to investigate the role of periodontitis in RA and the 
effect of periodontal therapy on immunological and microbiological parameters. 
To do that, different biological samples were collected from two pilot studies, 
comparing RA and periodontitis patients to the appropriate controls (i.e. RA 
periodontally healthy, no RA periodontitis and no RA no periodontitis) and from a 
selected group of randomized RAPD patients before and after periodontal 
therapy. The antibody response and subgingival microbiome of patients with RA 
and periodontitis were compared to the appropriate controls (no RA no PD, RA 
no PD, no RA PD). The effect of periodontal therapy on these parameters and on 
the cytokine changes in gingival crevicular fluid was also investigated.  
 
The findings from this thesis lend further credence to the link between RA and 
the oral microbiome, with RA patients having a disrupted and more anaerobic 
microflora and an exacerbated immunological reaction against periodontal 
bacteria and citrullinated proteins 
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1. INTRODUCTION 
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1.1. Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that 
affects about 1% of the world population, being more prevalent in women and in 
the 4th and 5th decade of life (Sacks, Luo et al. 2010). It is believed that the 
prevalence of RA in the first world is increasing, and in the UK 26,000 patients 
are being diagnosed every year (Garcia Rodriguez, Tolosa et al. 2008), (Cross, 
Smith et al. 2014). While the cause of RA remains unknown, the pathogenesis is 
characterized as chronic inflammation of the synovium that leads to destruction 
of cartilage and bone (Feldmann, Brennan et al. 1996).  This constant state of 
inflammation and degradation of the joint structures causes deformations, 
functional impairment and disability accompanied by chronic pain and 
constitutional symptoms. In addition, the mortality of RA patients is increased due 
to comorbidities associated with RA such as cardiovascular disease (Wållberg-
Jonsson, Johansson et al. 1999). 
 
The understanding of the pathogenesis of RA has increased over the last decade, 
with the study of the role of inflammatory cells such as macrophages, B cells and 
CD4+T cells, and pro-inflammatory cytokines and degradative enzymes, which 
are elevated in the RA synovium and are capable of digesting the extracellular 
matrix, causing joint destruction. The inflammatory process that occurs in the 
synovium of RA patients produces pro-inflammatory cytokines including Tumor 
necrosis factor (TNF)-alpha, Interleukins (IL) 1, 6, 15, 18, granulocyte-
macrophage colony-stimulating factor (GM-CSF). In the presence of these 
cytokines, T-cells and synoviocytes activate osteoclast maturation, which leads 
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to bone degradation. In addition to the inflammation of the synovium, the pannus 
(an anomalous fibrovascular coating) invades and destroys the joint surface 
(Firestein 2003), (Niu and Chen 2014).  
 
The typical signs and symptoms of RA are general pain and swelling of joints 
(often symmetrically), morning stiffness and limitation to movement that last more 
than one hour and that can be reduced by gentle movements. These clinical signs 
help the differential diagnosis with osteoarthritis (OA), which is not normally 
presented with swelling, the morning stiffness lasts less than an hour and the joint 
movement can worsen the pain instead of helping it, as OA is caused by cartilage 
degeneration and mechanical wear (Ropes, Bennett et al. 1957).  
 
The 2010 American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) devised new classification criteria, which uses a score-
based algorithm considering type and number of joints involved, serology 
parameters (Rheumatoid Factor and Anti Citrullinated Protein Antibody results), 
acute-phase reactants (C-reactive protein and Erythrocyte Sedimentation Rate) 
and duration of the symptoms. A score of 6 out of 10 is needed to diagnose the 
patient with definitive RA (Aletaha, Neogi et al. 2010). One of the new diagnostic 
tools of this classification criteria are the presence of antibodies against 
citrullinated proteins (ACPA), which are found in 80% of RA patients and have 
approximately 99% specificity, being the most disease-specific antibody in 
Rheumatoid Arthritis, appearing even before clinical signs (Van Gestel, Anderson 
et al. 1999).  
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The pharmacological treatment of RA aims to relieve pain, reduce inflammation 
and prevent destruction of cartilage and bone. Rheumatologists often use a 
number of different drugs to achieve this, such as non-steroidal anti-inflammatory 
drugs (NSAIDs), corticosteroids (most often by injection) and conventional 
disease-modifying anti-rheumatic drugs (DMARDs). This last group of drugs acts 
on the immune system to retard the inflammatory progression of RA. Biological 
therapies, a subcategory of DMARDs, target specific steps of the inflammatory 
process and have been proved to be very effective in patients with active RA that 
have not responded to other treatment. A very common biological therapy, anti 
TNF, in combination with conventional DMARDs provides clinical benefits and 
halts the progression of joint damage (Lipsky, van der Heijde et al. 2000). 
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1.2. Chronic periodontitis  
 
Periodontitis is a disease characterized by destruction of the connective tissues 
supporting the teeth. Chronic periodontitis one of the most prevalent diseases 
affecting humans and, according to the last European Workshop on 
Periodontology, 11% of the adult population is affected by severe periodontitis 
(Papapanou and Susin 2017). However, the prevalence of chronic periodontitis 
(often referred to as periodontitis) is difficult to estimate due to the lack of 
consensus in the definition and diagnosis of the disease (Holtfreter, Albandar et 
al. 2015). 
 
Chronic periodontitis is characterized by the presence of gingival inflammation 
that leads to destruction of the periodontal ligament. This state of chronic 
inflammation also results in resorption of the alveolar bone supporting the teeth 
(Armitage 1995), being a major cause of tooth loss in adults, especially in the 
elderly (Phipps and Stevens 1995). Although it often appears as asymptomatic, 
clinical signs like swollen and tender gums, bleeding after brushing or 
spontaneously, recession of the gums, increased space between teeth, 
pathological movement of teeth, bad taste and halitosis are common in 
periodontitis patients (Armitage 1995).  
 
Some of these symptoms also appear in gingivitis, which precedes periodontitis 
but, in gingivitis, the inflammation of the gums can be reversible as there is no 
loss of alveolar bone. To clinically distinguish between gingivitis and periodontitis, 
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it is necessary to determine whether there has been loss of the supporting tissues 
of the teeth.  Although there is no consensus on the clinical definition of 
periodontitis, the diagnosis is based on the radiographic bone loss and the clinical 
evaluation of the loss of periodontal tissue using a periodontal probe to measure 
the clinical attachment loss (CAL) and probing depth (PD) (Armitage 1995) 
(Savage, Eaton et al. 2009).  
 
The pathogenesis of periodontal disease is initiated by periodontal bacteria but 
propagated by the destructive response of the host immune system. Periodontal 
pathogens are mainly Gram-negative anaerobes and spirochetes. The main 
organisms that have been associated with periodontitis are Aggregatibacter 
actinomycetemcomitans, Tannerella forsythia, Treponema denticola, 
and Porphyromonas gingivalis (Socransky, Haffajee et al. 1998). These 
microorganisms produce enzymes and toxins that damage the periodontal tissue 
and activate an inflammatory immune response releasing chemotactic peptides 
that attract immune cells to the site of infection (Kinane 2001). The activated 
immune cells and damaged epithelial cells generate chemotactic signal 
molecules (interleukin-8, complement C5a, etc) to recruit neutrophils. As a 
collateral effect, neutrophils release elastase, matrix metalloproteinases and 
reactive oxygen species causing significant tissue damage (Cooper, Palmer et 
al. 2013). These cytokines released, especially IL-1 and IL-6 activate the 
expression of receptor activator of nuclear factor-kappa B ligand (RANKL) in 
osteoblasts, which binds to RANK from osteoclasts activating their differentiation 
and survival. Breaking the ratio between RANKL and its decoy receptor OPG 
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(Osteoprotegerin) results in bone resorption (Lu, Chen et al. 2006).  In response 
to this bone loss, the epithelial cells migrate apically and the periodontal pocket 
becomes deeper, facilitating the accumulation of subgingival plaque, the survival 
of anaerobic pathogens and disease progression (Phipps and Stevens 1995).  
 
The aim of periodontal therapy is to restore the pro-inflammatory state of the 
gingival tissues by reducing the pathogenic subgingival-microflora. This consists 
of manual and/or ultrasonic sub-gingival debridement and scaling and root 
planing (Cobb 2002). Some researchers recommend the local use of 
chlorhexidine as an adjunct to periodontal therapy (Soskolne, Heasman et al. 
1997) (Greenstein, Berman et al. 1986). In general, effective sub-gingival scaling 
improves the clinical parameters such as BoP, probing depth and CAL and it also 
shifts the periodontal microflora by reducing the load of Gram-negative microbes 
which allows an increase in the Gram-positive microbes associated with gingival 
health (Takamatsu, Yano et al. 1999) (Hinrichs, Wolff et al. 1985). In general, the 
consensus regarding the criteria for success used for periodontal treatment is to 
stop further clinical attachment loss and to restore the clinical parameters to 
health.  This includes achieving a probing depth lower than 4mm, no BoP, no 
mobility, etc. (Lindhe, Westfelt et al. 1984), (Yaghini, Tavakoli et al. 2011). 
However, the effectiveness of the treatment decreases in deep pockets, 
especially when probing depths exceed 5 mm (Cobb 1996). Residual pockets of 
more than 4 mm post-treatment have been associated with the presence of P. 
gingivalis (Mombelli, Schmid et al. 2000). 
 
1.3. Epidemiological association between Periodontitis and RA 
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The relationship between periodontitis and systemic diseases has become of 
great interest in the last twenty years. Periodontitis has been strongly associated 
with the development of diabetes (Preshaw, Alba et al. 2012) (Chapple and 
Genco 2013) and cardiovascular disease (Friedewald, Kornman et al. 2009) 
(Haraszthy, Zambon et al. 2000). Furthermore, there is evidence of association 
between periodontitis and adverse pregnancy outcomes and with other systemic 
diseases such as COPD or rheumatoid arthritis (Hajishengallis 2015).  
 
Over the last 20 years, numerous studies have identified an association between 
periodontitis and tooth loss and rheumatoid arthritis (Table 1. 1). While two of 
these studies reported negative results, the majority observed a higher risk and 
prevalence or periodontitis in rheumatoid arthritis patients and vice versa.  
 
In cross sectional studies, researchers found that, patients with RA had a 
significantly increased prevalence of periodontitis compared to systemically 
healthy controls, with odds ratios (OR) ranging between 1.82  (de Pablo, Dietrich 
et al. 2008) and 8.1 (Pischon, Pischon et al. 2008).  Furthermore, patients with 
periodontitis have higher prevalence of RA, with OR ranging between 1.16 
(Potikuri, Dannana et al. 2012) to 2.05 (Demmer, Molitor et al. 2011). Some of 
these studies, after adjusting for confounding factors, showed that this 
relationship is independent of smoking (Potikuri, Dannana et al. 2012), oral 
hygiene (plaque) (Mercado, Marshall et al. 2001), (Pischon, Pischon et al. 2008) 
and genetic factors (Marotte, Farge et al. 2006). 
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In the National Health and Nutrition Examination Survey (NHANES) data reported 
by De Pablo et al., 50% of RA patients were identified as edentulous, with these 
patients maybe representing severe cases of periodontitis (de Pablo, Dietrich et 
al. 2008). Similarly, in one of the largest cohort studies investigating the 
Taiwanese National Health Insurance Research Database (NHIRD), authors 
found a significant and independent association between RA and history of 
periodontitis (Chen, Huang et al. 2013). Another study reported that from the 74 
RA patients examined, 94% suffered from moderate to severe periodontitis (48% 
moderate and 46% severe) (Monsarrat, Vergnes et al. 2014). 
 
However, there are also studies that did not find such associations. In a large 
cohort study, using data from 91,132 nurses followed over 12 years, there was 
no evidence of a higher risk of developing RA patients among those with 
periodontitis; however, periodontitis was defined based on history of periodontal 
surgery and therefore included individuals with treated and not active 
periodontitis (Arkema, Karlson et al. 2010). More recently, no difference in the 
prevalence of periodontitis was observed in a Swedish case-control study 
including 2,740 RA patients in whom periodontitis was defined by self-report 
(Eriksson, Nise et al. 2016).  
 
The most recent systematic review with meta-analysis considering the 
epidemiological evidence from 8 case control studies, concluded that there is a 
strong and significant association between RA and to PD. However, the authors 
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highlight the need of rigorous studies using consistent definition of periodontitis 
and a more defined population to avoid bias due to invalid control groups (Tang, 
Fu et al. 2017). 
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Table 1. 1 Summary of observational studies published since 2000 (with study 
population>60) studying the association between rheumatoid arthritis (RA) and 
periodontitis. Abbreviations: OR, odds ratio; RR, risk ratio; Pl, plaque index; GI, 
gingival index; RF, rheumatoid factor; anti-CCP, anti-cyclic Citrullinated Peptide. 
Author & Year Study population Results Type of study 
(Mercado, 
Marshall et al. 
2000) 
1412 patients 
attending dental 
hospital 
Periodontitis: 
higher 
prevalence of 
RA (3.95%) vs 
no RA 
 
Cross 
sectional 
(Mercado, 
Marshall et al. 
2001) 
65 patients (RA 
vs. non-RA) 
-RA: higher 
number of 
missing teeth, 
deeper pockets. 
No difference in 
bleeding or 
plaque index 
Case control 
(Marotte, Farge 
et al. 2006) 
147 patients 
(RA) 
-Association 
between 
periodontal bone 
loss and wrist 
bone destruction  
(χ2 = 11.82) and 
shared epitope 
HLA-DR 
Cross 
sectional 
(de Pablo, 
Dietrich et al. 
2008) 
4,461 patients 
(NHANES III) 
-RA: higher 
prevalence of 
periodontitis 
(OR:1.82), 
edentulous 
(OR:2.27), less 
decay (p<0.001) 
Cross 
sectional 
(Pischon, 
Pischon et al. 
2008) 
109 patients (57 
RA, 52 non-RA) 
RA: higher 
prevalence of 
periodontittis 
(OR:8.05), 
statistically 
significant after 
adjusting to 
confounding 
factors (PlI, GI) 
Case control 
(Dissick, 
Redman et al. 
2009) 
69 RA patients 
vs. 35 
Osteoarthritis 
(controls) 
patients 
-RA: higher 
prevalence of 
periodontitis and 
more severe  
-RA patients 
with periodontitis 
associated with 
RF positive and 
anti-CCP 
Case control 
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(Arkema, 
Karlson et al. 
2010) 
81,132 patients 
(Nurses’ Health 
Study 
prospective 
cohort) 
No evidence of 
higher incidence 
of RA in 
periodontitis 
Cohort study 
(Demmer, 
Molitor et al. 
2011) 
9,702 patients 
(NHANNES I) 
Periodontitis: 
higher 
prevalence of 
RA (OR:2.05) 
 
 
Cross 
sectional 
(Potikuri, 
Dannana et al. 
2012) 
91 RA (DMARD 
naive, non-
smokers) vs 
healthy controls 
RA: higher 
prevalence of 
periodontitis 
(OR:4.28) 
Case control 
(Smit, Westra 
et al. 2012) 
95 RA, 420 
matched 
controls 
RA: higher risk 
of periodontitis 
(RR: 3.7) 
Cross 
sectional 
(Chen, Huang 
et al. 2013) 
13,779 newly 
diagnosed RA, 
137,790 non-RA 
Periodontitis: 
higher 
prevalence of 
RA (OR:1.16) , 
Cohort study 
(Monsarrat, 
Vergnes et al. 
2014) 
74 RA patients 94% of RA had 
periodontitis 
(48% moderate 
and 46% 
severe) 
Cross 
sectional 
(Eriksson, Nise 
et al. 2016) 
2,740 RA cases 
and 3,942 non-
RA 
No difference in 
periodontitis 
prevalence 
between groups 
Case control 
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1.4. Outcomes of periodontal treatment in RA  
 
For a long time, researchers have believed that treating oral health problems 
improved rheumatoid arthritis. The first records date to the time of Hippocrates, 
who suggested that, the cure of arthritis included tooth extraction. Many years 
later, in the 17th century, Benjamin Rush proposed that rheumatism could be 
cured by removal of infected teeth. During the 1950s-60s,“total dental clearance” 
was used for treatment of RA (Rothschild 2017).  
 
A few small clinical studies evaluating the effect of non-surgical periodontal 
therapy on RA suggest that treatment of periodontitis may have a significant 
positive effect on RA severity (Table 1. 2) (Ribeiro, Leao et al. 2005) (Ortiz, 
Bissada et al. 2009) (Okada, Kobayashi et al. 2013) (Erciyas, Sezer et al. 2013). 
Due to its high prevalence, periodontitis may represent an important modifiable 
factor for RA incidence and severity. If proved, treatment of periodontitis could be 
an inexpensive and safe, non-pharmacological treatment with direct benefit for 
patients with RA. Although results are promising, some authors failed to see this 
effect (Zhang and Zhang 2010). In a randomized clinical trial, Pinho and 
collaborators did not observe a reduction in acute phase reactants after 
periodontal therapy in RA and these systemic markers of inflammation were not 
correlated with periodontal improvement (Pinho, Oliveira et al. 2009).  
 
To date, only a few randomized clinical trials have investigated the effect of 
periodontal therapy on RA and these studies have a short follow-up period 
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(ranging between 8 weeks and 6 months) and a small sample size (<75 patients). 
Furthermore, each study uses different definition of periodontitis and uses 
different parameters to measure RA status, being the most used the Disease 
Activity Score known as DAS28, based on subjective measures like the Visual 
Analog Scale (VAS) and number of tender joints. Due to the heterogeneity in all 
the studies connecting RA and periodontitis, in the systematic review completed 
by Kaur et al., only a few parameters could be included for meta-analysis; ESR 
being the only test found to be significantly reduced after periodontal treatment 
(Kaur, Bright et al. 2014). One of the most recent studies found a significant 
reduction in DAS28, ESR and CRP in 30 RAPD patients undergoing periodontal 
therapy, compared to controls (Khare N 2016). Therefore, researchers in the field 
agree that there is a gap in the scientific literature as more long controlled 
randomized controlled trials are needed to demonstrate an outcome in RA 
through periodontal treatment.  
 
In the workshop between the European Federation of Periodontology and the 
American Academy of Periodontology in 2013, it was concluded that more 
rigorous clinical controlled trials and research was needed in the field (Linden and 
Herzberg 2013).    
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Table 1. 2 Clinical trials evaluating the effect of periodontal therapy in Rheumatoid 
arthritis (RA). Abbreviations: PD, periodontitis; RA, Rheumatoid Arthritis; RF, 
Rheumatoid Factor, ESR, Erythrocyte Sedimentation Rate; HAQ, Health Assessment 
Questionnaire; DAS, Disease Activity Score; VAS, Visual Analogue Scale; TNF, 
Tumor Necrosis Factor; CRP, C-Reactive Proteins; AAG, alpha-1 acid glycoprotein. 
Author&
year 
Duration  Patient number Parameters 
evaluated 
Results 
Ribeiro 
2005(Ri
beiro, 
Leao et 
al. 
2005) 
 
3 
months  
42 RA+PD 
-16 periodontal 
treatment 
-26 oral hygiene 
and supragingival 
cleaning 
RF, ESR, 
HAQ 
RF 
significantl
y reduced 
Al-
katma  
2007(Al
-Katma, 
Bissada 
et al. 
2007) 
 
8 weeks 29 RA+PD 
-17 periodontal 
treatment 
-12 no treatment 
DAS 28, 
ESR 
VAS, DAS 
and ESR 
reduced 
Khare 
2016 
(Khare 
N 2016) 
3 
months 
60 RAPD 
-30 periodontal 
treatment 
-30 no treatment 
OHI, BoP, 
PPD, CAL, 
SJ, TJ, 
ESR, VAS, 
DAS28, 
CRP 
ESR, 
DAS28, 
VAS, CRP 
significantl
y reduced 
Ortiz  
2009(O
rtiz, 
Bissada 
et al. 
2009) 
 
8 weeks 40 RA+PD 
-10 periodontal 
treatment and 
DMARDs only. 
-10 periodontal 
treatments and 
DMARDs with 
anti-TNF drugs. 
-10 no periodontal 
therapy, DMARDs 
only 
-10 no periodontal 
treatment, 
DMARDs with 
anti-TNF drugs. 
ESR, TNF-
alpha, signs 
and 
symptoms 
VAS and 
DAS 
improved 
in 
treatment 
groups. 
ESR not 
significantl
y reduced 
Anti-TNF 
drugs 
improved 
PPD and 
CAL 
Pinho 
2009(Pi
nho, 
Oliveira 
et al. 
2009) 
 
6 
months 
75 patients: 
-15 RA+PD with 
periodontal 
treatment 
-15 RA+PD no 
periodontal 
treatment 
DAS 28, 
CRP, ESR, 
AAG (alpha-
1 acid 
glycoprotein
) 
No clear 
relation. 
AAG, ESR 
and CRP 
not 
significantl
y reduced 
with 
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-15 PD with 
periodontal 
treatment 
-15 PD no 
periodontal 
treatment 
periodontal 
therapy. 
Okada 
2013(O
kada, 
Kobaya
shi et 
al. 
2013) 
8 weeks 55 RA+PD 
-26 supragingival 
cleaning 
-29 no treatment 
DAS 28, 
CRP, anti-
CCP, RF, 
TNF-alpha  
and levels 
of IgG to P. 
gingivalis 
Reduction 
of DAS 28 
and levels 
of IgG to 
P. 
gingivalis 
and 
citrulline. 
Erciyas 
2013(Er
ciyas, 
Sezer 
et al. 
2013) 
3 
months 
60 RA and PD 
-30 RA moderate-
severe disease 
activity 
-30 RA low 
disease activity 
ESR, CRP, 
TNF-alpha, 
DAS28  
 
Significant 
reduction 
of  
ESR, 
CRP, TNF-
alpha, 
DAS28  
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1.5.  Possible biological mechanisms:  
The notable similarities between RA and periodontitis have been object of study 
for many years (Bingham III and Moni 2013). However, it is still unclear the 
biological mechanisms that explain the interrelations between the two conditions 
and different possible theories have been described:  
 
 Shared risk factors 
The HLA-DR4 epitope (human leukocyte antigen, alleles DR4) is located in the 
surface of leukocytes and has been found to be associated with both RA and 
periodontitis (Gregersen, Silver et al. 1987). Numerous studies have reported an 
association between periodontitis and the HLA gene. The most recent systematic 
review reported a protective association with HLA-A2 and B5 and a susceptibility 
factor for periodontal disease with HLA-A9 and B15 (Stein, Machulla et al. 2008). 
However, the HLA associations alone are not enough to explain the link between 
RA and PD (Marotte, Farge et al. 2006) (Potikuri, Dannana et al. 2012). 
 
Oral hygiene has also been proposed to be the link between rheumatoid arthritis 
and periodontitis. A common misconception is that RA patients have impaired 
dexterity and accordingly likely to have poorer oral hygiene than healthy control 
subjects. Although, due to the joint and bone deformities typically affecting the 
hands of RA patients, it seems logical that these patients would have an 
impediment to maintain a good oral hygiene, studies have consistently failed to 
show a difference in plaque control that could explain the association with 
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periodontitis (Torkzaban, Hjiabadi et al. 2012) (Mercado, Marshall et al. 2001) 
(Pischon, Pischon et al. 2008). 
Smoking is also a shared risk factor for RA and periodontitis. RA patients have 
higher prevalence of PD but also patients with new-onset RA exhibit a high 
prevalence of PD at disease onset, despite their young age and low smoking 
history (Scher, Ubeda et al. 2012). Although periodontitis and RA share genetic 
(HLD-DR4) and risk factors (smoking) and similar inflammatory pathways, it is 
not believed to be enough to explain this connection (Kaur, White et al. 2013). 
 
 Citrullination 
Citrullination or deimination is a post-translational modification in which the amino 
acid arginine is transformed into citrulline, catalysed by the enzyme Peptidyle-
Arginine Deiminase (PAD). In the presence of calcium, PAD substitutes the 
ketamine group (=NH) with a ketone group (=O), converting arginine into citrulline 
and neutralising the previous positive charge of the amino acid (Baka, György et 
al. 2012) (Figure 1. 1). 
 
Citrullination occurs as a physiological phenomenon in healthy individuals and it 
is essential for skin physiology, gene regulation and correct functioning of the 
immune system (Baka, György et al. 2012). However, it has also been implicated 
in autoimmune diseases such as psoriasis and rheumatoid arthritis.  
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Figure 1. 1 Protein citrullination by Peptidyl-Arginine Deiminase (PAD). In the presence of calcium, PAD catalyses the 
conversion of Arginine in to citrulline, changing the ketamine group (=NH) for a ketone group (=O). 
Page 20 
 
 
In rheumatoid arthritis the expression of PAD 4 and PAD 2 in synovium is 
correlated with intensity of inflammation (Foulquier, Sebbag et al. 2007). These 
enzymes, during oxidative stress or apoptosis, become active and citrullinate 
proteins.  
 
While elevation of citrullination is relatively common in other diseases, the 
production of auto-antibodies against these epitopes, is rather specific to RA. 
ACPAs are found in 80% of patients with RA and are synthetized by plasma cells 
to target citrullyl residues. These auto-antibodies are highly specific for RA (98%) 
and have been found in serum of patients years before they develop any clinical 
signs, being the earliest and most specific autoantibodies in RA (Schellekens, 
Visser et al. 2000), (Nielen, van Schaardenburg et al. 2004). This unique 
production of auto-antibodies in RA suggest the necessity of an external factor to 
trigger this auto-immune reaction.  
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 Porphyromonas gingivalis citrullination 
 
Porphyromonas gingivalis (PG) is one of the bacteria associated with 
periodontitis and is considered key to the disruption of the host-microbial 
homeostasis that causes this disease (Darveau, Hajishengallis et al. 2012). 
Among the variety of virulence factors that PG uses for tissue destruction and 
host evasion, this Gram-negative anaerobe has a family of enzymes called 
gingipains, which not only helps the bacteria in colonization and nutrition but it 
can neutralize the host defenses and manipulate the inflammatory response 
(Amano 2003).  
 
However, the most unique characteristic of P. gingivalis is the expression of 
peptidyl arginine deiminase (PPAD), capable of citrullinating both host and 
bacterial peptides (Wegner, Wait et al. 2010). It has been observed that, unlike 
human PAD2 and PAD4, PPAD can only citrullinate C-terminal arginine and not 
internal arginine, creating citrullinated peptides that wouldn't occur in the absence 
of P. gingivalis, as human PAD prefers internal arginine substrates. To that end, 
P. gingivalis uses its gingipain enzyme to cleave peptides and generate arginine 
residues that PPAD would then citrullinate (Abdullah, Farmer et al. 2013). Also, 
in contrast to human PAD, PPAD is not calcium dependant and this enzyme is 
capable of auto-citrullination, becoming a citrullinated bacterial protein itself 
(Quirke, Lugli et al. 2013). These characteristics provide a plausible pathway in 
which, by presenting neoepitopes to the immune system, P gingivalis  (in 
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susceptible individuals, such HLA-DRB1 carriers) would break the tolerance to 
citrullinated proteins and lead to the consequent antigen response characteristic 
in RA patients. (Figure 1. 2). 
 
It is believed that P. gingivalis uses these mechanisms for its survival in the 
gingival pocket. As a result of citrullination, ammonia is generated, which 
neutralizes acidity and energy is released for P. gingivalis to use during anaerobic 
growth (Nomura 1992) and also as a strategy to suppress the inflammatory 
activity of C5a by citrullinating it, which reduces its chemotractant nature for 
neutrophils (Bielecka, Scavenius et al. 2014). 
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Figure 1. 2 Model of the biological link between rheumatoid arthritis and periodontitis. 
Porphyromonas gingivalis breaking the immune tolerance to citrullinated proteins in 
rheumatoid arthritis by bacterial citrullination of proteins through PPAD, initiating an 
immune response leading to loss of tolerance to citrullinated proteins in the joints. 
Abbreviations: P. gingivalis, Porphyromonas gingivalis; PPAD, peptidyl arginine 
deiminase from P. gingivalis; APC, antigen presenting cell; TNF, tumor necrosis 
factor; IL, interleukine; GMCSF, granulocyte-macrophage colony-stimulator growth 
factor.  
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Numerous researchers have investigated the role of P. gingivalis in RA. The first 
to suggest that P. gingivalis and PPAD could break the tolerance and trigger an 
antibody response against citrullinated antigens was Rosenstein et al. 
(Rosenstein, Greenwald et al. 2004). Later, Martinez-martinez et. al (Martinez‐
Martinez, Abud‐Mendoza et al. 2009) found DNA from P. gingivalis in synovial 
fluid of patients with rheumatoid arthritis, and hypothesized that periodontal 
pathogens could be the trigger for the autoimmune response in RA.  
 
Wegner et. al showed that P. gingivalis citrullinates fibrinogen and alpha-enolase 
and other peptides from human and bacteria (Wegner, Wait et al. 2010), and 
Hitchon et al. (Hitchon, Chandad et al. 2010) reported an association between 
immune responses to P. gingivalis and the presence of anti-citrullinated protein 
antibodies (ACPA) in a population with a high background prevalence of RA 
predisposing HLA-DRB1 alleles. They suggested that this gene-enviroment 
interaction might be the cause of the break of tolerance of the immune system to 
citrullinated proteins that leads to RA. A study by Mikuls et al., has shown that 
high levels of anti-P. gingivalis antibodies in RA subjects correlates with levels of 
anti-CCP IgM and IgG suggesting that this bacterium plays a role in risk and 
severity of RA (Mikuls, Thiele et al. 2012).  
 
Interestingly, it has been observed that the periodontium of patients with no signs 
of RA but diagnosed with periodontitis express citrullinated proteins (Nesse, 
Westra et al. 2012) and serum of periodontitis patients contains higher levels of 
antibodies to citrullinated and non-citrullinated human peptides compared to 
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controls (de Pablo, Dietrich et al. 2014). De Pablo and collaborators suggest that 
the greater citrullination and loss of tolerance to citrullinated and uncitrullinated 
peptides that occur in periodontitis, may lead to epitope spreading to citrullinated 
epitopes, and evolve to Rheumatoid Arthritis. 
 
Based on these findings, researchers propose that bacterial and human PADs 
could be a powerful target for therapy in RA (Mangat, Wegner et al. 2010). 
Moreover, it has been hypothesized that by removing subgingival plaque with 
periodontal therapy, the load of P. gingivalis and PPAD can be decreased, and 
therefore create a reduction of the generation of antigens and weaken the 
autoimmune response in RA.  
 Other bacterial citrullination 
More recently, other periodontal bacteria have been investigated as a source of 
citrullination and possible link between periodontitis and RA. Among the different 
periodontal pathogens and oral commensals investigated in a recent study, only 
Aggregatibacter actinomycetemcomitans could induce hypercitrullination of 
human neutrophils (Konig, Abusleme et al. 2016). A. actinomycetemcomitans 
induces neutrophil hypercitrullination through the secretion of leukotoxin A (LtxA), 
a bacterial pore-forming toxin that induces calcium influx and subsequent 
hyperactivation of PAD enzymes in the neutrophil. Interestingly, the effect of 
human lymphocyte antigen–DRB1 shared epitope alleles on auto-antibody 
positivity was limited to RA patients who were exposed to A. 
actinomycetemcomitans. These studies identify the periodontal pathogen A. 
actinomycetemcomitans as a candidate bacterial trigger of autoimmunity in RA 
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 Citrullinated human proteins targeted in RA  
Anti-cyclic citrullinated peptide (CCP) kits are regularly used by rheumatologists 
to measure antibodies against citrullinated proteins and diagnose patients as 
ACPA+ and ACPA- which can anticipate disease severity and treatment 
response (Seegobin, Ma et al. 2014). This test uses a synthetic citrullinated cyclic 
peptide as an antigen to capture antibodies against any citrullinated proteins 
present in patient sera. Investigating the proteins that are citrullinated in RA is 
important, as it can help understand the development of the autoimmune 
response and development of the disease. To date, numerous studies have 
reported that proteins such as Fibrinogen, Vimentin, Enolase and Tenascin are 
targeted in RA and antibodies against these citrullinated proteins are associated 
with severity of the disease (Montgomery, Venables et al. 2013), (Nielen, van 
Schaardenburg et al. 2004) (Raza, Schwenzer et al. 2016). 
 
Fibrinogen is an acute-phase reactant protein, synthetized in the liver, involved 
in clot formation by its conversion to fibrin by thrombin. Fibrinogen is elevated in 
numerous inflammatory diseases, such as periodontitis and RA, and antibodies 
against citrullinated fibrinogen are elevated and correlated to clinical and 
laboratory RA parameters (Zhao, Okeke et al. 2008) (Gilliam, Reed et al. 2011).  
 
Vimentin is a type III intermediate filament, responsible for maintaining 
mesenchymal cell (mucoid connective tissue) structure. In RA, antibodies against 
citrullinated vimentin and mutated vimentin (MCV) are used as diagnostic tool, 
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especially in RF negative patients (Dejaco, Klotz et al. 2006). These antibodies 
are found before the onset of RA and also estimate bone destruction (Mathsson, 
Mullazehi et al. 2008). In systemically healthy periodontitis patients, antibodies to 
cit-Vimentin are elevated compared to controls (de Pablo, Dietrich et al. 2014).  
 
Enolase 1, commonly known as α-enolase, is a glycolytic enzyme present in most 
tissues that has numerous functions (surface protein, tumor supresor, oxidative, 
stress, etc). Antibodies against enolase are elevated in numerous autoimmune 
diseases such as RA, ulcerative colitis and Crohn's disease  (Pancholi 2001). In 
the joints of patients with RA, enolase is up regulated in response to inflammation. 
While high levels of anti-enolase are associated with a variety of autoimmune 
diseases, antibodies against citrullinated enolase are only found in RA (67% of 
RA, only 3% of healthy individuals) (Lundberg, Kinloch et al. 2008) and correlated 
with disease severity (Kinloch, Tatzer et al. 2005).  Elevated antibodies against 
cit-enolase 1 are higher in CCP positive and smoking RA patients (Mahdi, Fisher 
et al. 2009) and are also present in early-RA patients (Saulot, Vittecoq et al. 
2002). Interestingly, the human enolase and P. gingivalis enolase have been 
found to share 82% homology, with antibodies to CEP-1 cross-reacting to P. 
gingivalis-enolase (Lundberg, Kinloch et al. 2008). Therefore, it has been 
hypothesized that this similarity and crossreactivity could be the link between P. 
gingivalis and RA (Lundberg, Wegner et al. 2010). 
 
Tenascin-C is a large extracellular glycoprotein that stimulates inflammation 
activating toll-like receptor 4 (TLR4). This protein is absent in most healthy tissues 
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and up-regulated during inflammatory stages, such as in the RA joint, maintaining 
tissue damage and inflammation (Midwood, Sacre et al. 2009). Antibodies 
against an epitope of citrullinated TNC5 (cTNC5) have been detected in 40-50% 
of RA patients, correlated with bone erosion and associated with RA development 
in early stage of the disease (Raza, Schwenzer et al. 2016, Schwenzer, Jiang et 
al. 2016). 
 P. gingivalis antigens targeted in RA: 
It has been proposed that proteins from P. gingivalis could be recognized as an 
antigen by the host and initiate an immune response that, in RA, could break the 
tolerance to human antigens such as citrullinated proteins. For this reason, 
recently, researchers have investigated the antibodies against some P. gingivalis 
-antigens and its role in RA.   
 
Antibodies against citrullinated PPAD (specifically epitopes CPP3 and CPP5) are 
increased in ACPA+ RA patients as well as in periodontitis patients (CPP5) 
(Quirke, Lugli et al. 2013). In RA and pre-RA patients, anti-CPP3 antibodies are 
elevated  (Johansson, Sherina et al. 2016), although other authors did not find 
an association between anti-PPAD and early RA (Fisher, Cartwright et al. 2015).  
 
Gingipain enzymes are a family of trypsin-like cysteine proteinases that are 
secreted by P. gingivalis and contribute to its virulence, as well as to the 
pathogenesis of periodontitis and is the most potent virulent factor produced by 
P. gingivalis (Potempa, Sroka et al. 2003). Antibodies against gingipain are 
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significantly increased in periodontitis but are not clearly correlated with RA 
(Quirke, Lugli et al. 2014) (Kharlamova, Jiang et al. 2016).  
 
P. gingivalis enolase, due to its similarity with human enolase, has been proposed 
to be the link between RA and PD in which, antibodies against human cit-enolase 
cross-react with a conserved sequence on citrullinated P. gingivalis enolase. 
Lundberg and colleagues hypothesized that this molecular mimicry between 
human and bacterial enolase is involved in the etiology of RA (Lundberg, Wegner 
et al. 2010). 
 
Considering these results, researchers support the hypothesis that P. gingivalis 
-antigens might break tolerance in RA, and if proven, these epitopes could be 
targeted in RA patients (Quirke, Lugli et al. 2014).
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 The role of the oral microbiome in RA 
The human microbiome is defined as the genes carried by the particular 
community of microorganisms that live in and on the human body. This human 
microbiota is diverse and lives in symbiosis with the human body and the balance 
of this ecosystem impedes the appearance of pathogens, as they compete for 
the resources available in the environment. This "normal" microbial community 
has been investigated with cultivation techniques, which is not applicable for most 
of the complex ecosystems in our body, such as the oral cavity. However, the 
Human microbiome project using DNA-based technologies has opened a new 
horizon in the understanding of the microbes that live in and on us (Turnbaugh, 
Ley et al. 2007).  
 
Bacterial identification through the study of the DNA can target the entire DNA 
present in a sample (genome) or can target a specific gene. By studying highly 
conserved genes, such as the gene that codes for the 16 S ribosomal RNA (16S 
rRNA), we can identify the different species according to the different sequences 
of this gene. The gene 16S rRNA, which codes for the small part of the ribosome 
complex, is the most analyzed as is contained in the genome of all bacteria and 
is never translated into a protein, as it is structural RNA. This gene has conserved 
regions, which are very important and carried by all bacterial species, and other 
regions with mutations according to the different species, the variable regions. 
Sections of the genes that contain both variable and conserved regions allow 
researchers to differentiate between species (Morgan and Huttenhower 2012). 
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To investigate a particular region, primers (a manufactured short nucleotide 
sequence of 12 nucleotides used as a probe) are added to match the conserved 
region just before and after the selected section that need to be sequenced. To 
study the oral microbiome, Kumar and collaborators concluded that use of 4 
primers on the 2 regions V1 (27F)-V3 (534R) and V7-V9, are the best to identify 
the largest amount of species (Kumar, Brooker et al. 2011). While the Sanger 
method used to be the gold standard, it is very slow and expensive, and Next 
Generation Sequencing (NGS) technologies use regions to identify taxa, 
reducing the cost and increasing the speed (Goodwin, McPherson et al. 2016). 
Different high-throughput sequencing platforms have been established since the 
mid-2000s although each method comes with limitations, that lead to the 
development of pipelines to reduce errors and biases produced as a results of 
these methods (Dabdoub, Fellows et al. 2016) (Caporaso, Kuczynski et al. 2010) 
(Edgar 2013).  
 
Using these technologies, researchers have found that individuals with non-
infectious systemic diseases (especially autoimmune diseases such as Cronh's 
disease, Colon cancer and food allergies) have a different human microbiome. 
The study of this disease-associated species is fundamental to elucidate the role 
of oral microbiome and its potential use in diagnosis (Blaser1 2012). While the 
cause of RA remains unknown, it has been hypothesized that oral microbiota 
might have a role in its etiology and pathogenesis (Wegner, Wait et al. 2010) 
(Brusca, Abramson et al. 2014) (Scher, Bretz et al. 2014),.  
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The oral cavity is the site of the body with the richest core microbiome, which is 
defined as the common microbiome shared by most or all subjects sampled 
(Huse, Ye et al. 2012). Although the decreases in cost and increase in speed of 
Next-Generation Sequencing (NGS) technologies have resulted in an explosion 
of 16S data, the current literature available on the oral microbiome is more limited 
compared to the gut microbiome (Turnbaugh, Ley et al. 2007).  
 
As the data acquired from microbiome studies is so complex, novel and specific 
analysis is required. Alpha diversity is used to measure the diversity of bacteria 
within a group or sample, which can be determined by the richness (how many 
different species there are) and the evenness (the differences in abundance of 
those species). To measure differences between bacteria diversity between 
groups, Beta diversity is used to study the differences between habitats (Morgan 
and Huttenhower 2012). 
 
Currently, two next generation sequencing studies have investigated the oral 
microbiome in RA (Zhang, Zhang et al. 2015) (Scher, Ubeda et al. 2012). In the 
metagenome study of Zhang and collaborators, they found that subgingival, oral 
and gut microbiome are altered and certain species were identified as potential 
targets or diagnostic tools for RA. In the study from Scher and colleagues, in early 
RA patients some bacterial taxa were identified to be significantly different in 
abundance but overall measures of diversity were not different to systemically 
healthy controls. 
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However, in these studies, more than 75% of the new-onset RA and RA patients 
studied had moderate to severe periodontitis (Scher, Ubeda et al. 2012) or 
periodontal status was not considered (Zhang, Zhang et al. 2015). Since the oral 
microbiome is known to be altered in periodontitis, the contradicting results from 
these studies might be confounded by the presence of periodontitis. Thus, it is 
necessary to examine the oral microbiome in periodontally healthy RA patients 
and study the possible differences compared to systemically healthy controls to 
verify if this described shift in the oral microbiome is due to RA and not just as a 
consequence of the high prevalence of periodontitis in this group.  
 
It has also been proposed that, in RA patients, the use of DMARDs and biologic 
therapies restores the dysbiotic oral microbiome (Zhang, Zhang et al. 2015). 
However, the effect of periodontal therapy on the oral microbiome has not been 
fully investigated using NGS techniques and the effect in RA patients is not 
known.  
 
 The cytokine imbalance in RA and Periodontitis 
In RA, there is an imbalance in the main cytokine system (Feldmann, Brennan et 
al. 1996) in a similar manner that occurs in periodontitis patients (Gemmell, Carter 
et al. 2001). Understanding the cytokines involved in the pathomechanisms of 
RA has led to a revolution in the therapeutics of this disease in the last decade 
(Azizi, Jadidi‐Niaragh et al. 2013) and therefore, this cytokine imbalance could 
be the biological link between RA and periodontitis.  
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The human microbiota lives in cross-talk with the human immune system and can 
trigger an immune response to their benefit. In periodontitis, cytokines such as 
IL-1β can help the growth of some species such as A. actynomicetemcomitans, 
which in the presence of this cytokine, decrease their metabolism and increase 
their biomass (Pöllänen, Paino et al. 2013).  
 
Investigating the cytokine profile and correlating this with the microbial 
communities would help understand the complex mechanisms that link 
periodontitis, and subgingival microbiota with the aetio-pathogenesis of RA.  
The imbalance between pro-inflammatory and anti-inflammatory cytokines and 
growth factors is comparable: In RA and periodontitis high levels of IL-6 and TNF-
α (now named TNF) systemically and locally are found, which are known to 
activate the inflammatory response. On the other side, lower levels of IL-10 and 
growth factor-b, are known to have anti-inflammatory effect are found to be 
decreased in RA and PD (Kobayashi and Yoshie 2015).  
 
Of special importance is the pro-inflammatory cytokine TNF, as it plays a key role 
in the immune response for both RA and periodontitis. TNF modulates the 
inflammatory response as it can increase the inflammatory response by binding 
to the receptor p55 (TNF receptor type 1; CD120a), whereas binding to receptor 
p75 (TNF receptor type 2; CD120b) attenuates the inflammatory response 
(Peschon, Torrance et al. 1998). In periodontitis, TNF has been associated with 
the breakdown of connective tissue attachment and bone loss (Assuma, Oates 
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et al. 1998). RA patients suffering with periodontitis have higher levels of TNF  
compared to non-periodontitis and these levels are positively correlated with RA 
severity (Kobayashi and Yoshie 2015).  
 
To date, several small and short studies have evaluated the effect of TNF 
inhibitors in periodontitis and RA (Ortiz, Bissada et al. 2009) (Pers, Saraux et al. 
2008) (Mayer, Balbir-Gurman et al. 2009) (Üstün, Erciyas et al. 2013) 
(Kobayashi, Yokoyama et al. 2014). Although the authors concluded that anti-
TNF therapy could benefit periodontal status, they suggest that it is very difficult 
to predict the harm that may result from targeting cytokines and the study from 
Pers and colleagues, anti-TNF therapy increased gingival inflammation in RA 
patients, although decreased clinical attachment loss. Therefore, it is not clear if 
anti-TNF therapy is beneficial for periodontitis. 
 
Interestingly, periodontal therapy has been shown to reduce serum TNF levels 
(O'connell, Taba Jr et al. 2008) (Nishimura, Iwamoto et al. 2003). For this reason, 
some researchers highlight the importance of investigating periodontal therapy 
as a possible safe and easy way to reduce inflammation in systemic inflammatory 
conditions such as RA.  
 
Likewise, other cytokines such as IL-6 are associated with both RA and 
periodontitis. IL-6 is a pro-inflammatory cytokine with numerous functions and  
anti-IL-6 therapy is shown to reduce periodontal parameters such as BoP, GI and 
CAL (Kobayashi, Okada et al. 2014). A variety of studies have shown that 
Page 37 
 
periodontal treatment reduces serum levels of cytokines like IL-6 (Shimada, 
Komatsu et al. 2010) (D’aiuto, Nibali et al. 2005) (Duarte, da Rocha et al. 2010). 
In RA patients suffering with periodontitis, IL-6, MMP-8 and PGE2 were reduced 
in the gingival crevicular fluid after periodontal therapy (Kurgan, Fentoğlu et al. 
2016). These findings suggest that periodontal therapy could be a non-
pharmacological method to reduce the pro-inflammatory cytokines locally and 
systemically in patients with RA.  
 
 Other theories on the link between RA and periodontitis 
1.5.7.1.  Neutrophils and neutrophil extracellular traps  
 
Neutrophils are one of the first white blood cells to arrive at the site of infection. 
They represent 60% of all leukocyte cells and their main functions include 
phagocytosis of microorganisms, recognition and activation of humoral immunity. 
In healthy periodontium, the gingival crevicular fluid (GCF) contains neutrophils, 
which contribute towards maintaining a balanced gingival microbiota. If an 
invasion from a pathogen is detected, macrophages in the gingival tissue activate 
receptors in the vascular endothelium to facilitate neutrophil recruitment and 
diapedesis to the site of infection. Once in the site, neutrophils phagocytose the 
microbe to destroy it with their lethal enzymes contained in the granules. This 
process happens within the safe confines of the membrane of the neutrophil cell. 
Then the neutrophil enters into apoptosis and releases signals that attract 
macrophages to remove the apoptotic bodies. However, when activated by 
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specific signals, neutrophils release their enzymatic content to the exterior of the 
cell, together with its DNA, forming a net with the aim of trapping and rapidly 
killing the microbes, called neutrophil extracellular traps (NETs). Although this is 
an effective tool to kill bacteria (Brinkmann, Reichard et al. 2004), the release of 
this contents, along with Reactive Oxygen Species (ROS) provokes collateral 
damage to the surrounding tissues and exacerbates the inflammatory response 
and expose possible autoantigens (Liou and Campbell 1996).  
 
Aberrant NETs release has been observed in RA synovial fluid and serum 
compared to healthy controls and Osteoarthritis, and NET release was correlated 
with ACPA and RF levels (Khandpur, Carmona-Rivera et al. 2013). Interestingly, 
in RA patients, NETs were induced by IL-17, TNF and ACPAs such as anti 
citrullinated-Vimentin antibodies, contained proteins and neutrophils undergoing 
NETOsis, in turn, externalized citrullinated antigens and activated the release of 
other pro-inflammatory cytokines (Khandpur, Carmona-Rivera et al. 2013).  
 
Moreover, it has been shown that PAD-4 activation is necessary for NET 
production. In PAD-4 deficient mice, neutrophils did not undergo NET formation, 
compared to the control group. Also in this study, it was noticed that histone 
citrullination by PAD4 leads to chromatin decondensation, facilitating the 
production of NETs (Li, Li et al. 2010). These results suggest that in RA, NETs 
contribute to the maintenance of the inflammatory response and become a 
source of citrullinated antigens in RA. 
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Elevated NET formation also occurs in periodontitis patients. This might be due 
to chronic exposure to periodontal pathogens that results in an elevated number 
of apoptotic neutrophils which, overtime, would lead to increase inefficient 
chemotaxis and elevated NET production (Cooper, Palmer et al. 2013). 
 
Taken together, these results suggest that, in periodontitis, a chronic exposure of 
gingival tissues to PAD4 and citrullination, may lead to breakdown of tolerance 
against citrullinated peptides in susceptible individual, leading or contributing to 
RA pathogenesis. NET generation not only contributes to periodontal and RA 
pathogenesis, but also provides a potential causal link between these two 
conditions (Figure 1. 3).  
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Figure 1. 3 Hypothesis of the role of NETs in the connection between RA and periodontitis. Abbreviations: NETs, neutrophil extracellular 
traps; PPAD, peptdyl-arginine deiminase from Porphyromonas gingivalis. 
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 "Two-hit" model  
Golub et al. were the first researchers to describe a theory in which the 
association between periodontitis and systemic diseases could be explained by 
a "two hit" model. In this theory, a first "hit" occurs within the periodontum, initiated 
by an infection or inflammation of gingiva, that activates a destructive 
inflammatory cascade in the periodontal tissues. In susceptible patients, a 
second systemic "hit" occurs, characterized by increased serum levels of 
inflammatory cytokines that amplify the inflammatory cascade, lead to the release 
of local and systemic inflammatory mediators (cytokines and prostaglandins), a 
rise of RANKL and MMPs, along with other destructive proteinases, that leads to 
bone destruction and periodontal breakdown (Golub, Payne et al. 2006). 
 
Years later, a similar "two hit model" was described to explain the breakdown of 
tolerance to citrullinated proteins in RA patients triggered by smoking. Based on 
this model, in the first hit, antibodies to citrullinated proteins are produced due to 
the break of tolerance to these proteins, which are citrullinated due to cigarette 
smoking.  In a second hit years later, ACPAs are released systemically and 
specifically in the joint structure, as it has been observed that synovium is 
especially sensitive to inflammatory stimuli (Farquharson, Butcher et al. 2012). 
 
Similarly to smoking, periodontitis could represent a first hit of citrullinated 
peptides. In people who are genetically susceptible, a first hit of chronic 
periodontitis could break the tolerance to citrullinated proteins, due to abnormal 
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and bacterial citrullination by P. gingivalis. These bacterial citrullinatied proteins 
are recognized as an antigen and presented to B cells, which secrete antibodies 
against proteins citrullinated by P. gingivalis. The transition to the autoimmune 
response occurs years before the clinical onset of RA, due to the recognition of 
new epitopes through epitope spreading, which perpetuates and amplifies 
autoimmune diseases. Activated B cells can process and internalize molecules 
closely associated with the initial antigen (such as CEP and P. gingivalis 
enolase), via endocytosis and present the new peptides to T cells. This way, B 
cells can act as antigen presenting cells for peptides that are different from the 
antigen that initiated the immune response (Murphy 2012). Through this epitope 
spreading, a second auto-immune hit could happen years later in the joint 
structure, where ACPAs are released against a variety of human citrullinated 
peptides such as fibrinogen, enolase and vimentin. This model describes a 
primary "hit" of chronic inflammation via chronic periodontitis followed by a 
secondary "hit" in the joint, that induces rheumatoid and an increased 
inflammatory response (Kaur, White et al. 2013) (Lundberg, Wegner et al. 2010) 
(Figure 1. 4).  
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Figure 1. 4 Two hit model proposed to explain the link between periodontitis and RA. Abbreviations: PAD, peptidyl arginine deiminase ; 
PPAD,  PAD from P. gingivalis; Cit- citrullinated; CEP, cit-enolase ; REP, arginated (non-cit) enolase; CCP, cyclic citrullinated peptide., 
.  
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Although promising, none of the theories described explain why this inflammatory 
response that is hypothetically initiated or exacerbated by periodontitis would be 
specific to the joint structure in RA. While it seems that there is an epidemiological 
relation between the two conditions, it is not proven whether this is coincidental 
or due to common risk factors or if there is indeed a causal relationship. Future 
research is needed to clarify the gaps in the literature in this matter since, if 
proven, periodontitis prevention and therapy could ameliorate the progression of 
RA. 
1.6. Thesis aims 
The role of periodontitis in RA severity and pathogenesis has not yet been 
revealed. The results from the small clinical trials published, although promising, 
do not show enough evidence to conclude that periodontal therapy could help 
improve RA parameters. Using a variety of biological samples collected from a 
pilot clinical trial (OPERA, further explained in methods section Chapter 2) the 
overall aim of this thesis is to investigate the role of periodontitis in RA and the 
effect of periodontal therapy not only in clinical parameters, but on different 
markers that could be related to RA severity or elucidate the role of periodontitis 
in RA.  
 
Objective 1: To investigate the antibody response to citrullinated and un-
citrullinated peptides in sera of patients with RA and Periodontitis compared to 
RA alone, Periodontitis alone and the systemically and periodontally healthy 
controls and possible changes after periodontal treatment. 
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Objective 2: To investigate the antibody response to periodontal bacteria 
antigens in sera of patients with RA and Periodontitis compared to RA alone, 
Periodontitis alone and the systemically and periodontally healthy controls and 
possible changes after periodontal treatment. 
Objective 3: To compare the subgingival microbiota of patients with RA and 
periodontitis, RA alone, periodontitis alone and the systemically and periodontally 
healthy controls and effect of periodontal therapy. 
Objective 4: To investigate the differences in the cytokine response in gingival 
crevicular fluid in patients with periodontitis and RA (compared to controls: RA 
alone, periodontitis alone) and how non-surgical periodontal therapy changes 
immune response signatures. 
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2. MATERIALS AND METHODS  
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2.1. Study volunteers 
For the purpose of this thesis, biological samples collected from two different pilot 
clinical studies were analyzed. The three types of human samples studied were 
serum, gingival crevicular fluid (GCF) and plaque. Different sample sizes were 
selected from these cohorts according to resources and availability of the 
samples. Figure 2.1 shows the study populations and the quantitiy of samples 
utilized for the different analyses.   
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Figure 2. 1 Study population included for the different studies of this thesis. Plaque,  
and serum samples were collected (methods described in section 2.1) for the analysis 
of the immunological and microbiological relationship between RA and periodontitis. 
When samples were available, the same patients were investigated from each 
baseline group, which overlapped in the majority of the experiments. Patients 
diagnosed with mild periodontitis are not represented in this diagram and are 
excluded for baseline comparisons. Abbreviations: N, number of patients; RA, 
rheumatoid arthritis; PD, periodontitis. ELISA, enzyme-linked immunosorbent assay; 
OMA, outer-membrane antigen; PG, Porphyromonas gingivalis.  
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  Rheumatoid arthritis patient volunteers: OPERA clinical trial 
To address the objectives of this thesis, samples were collected as part of the 
OPERA study (Outcomes of Periodontal Therapy in Rheumatoid Arthritis).  
Approval for this study was obtained from the South Birmingham Research Ethics 
Committee, UK (Approval codes: OPERA - 11/WM/0235) and the study was 
funded by the National Institute of Health Research (NIHR) (Grant Reference 
Number PB-PG-0609-19100). 
 
The described OPERA study was a randomized feasibility clinical trial which 
aimed to collect feasibility information for a future pivotal study to address if 
periodontal therapy could improve RA clinical parameters. Although the clinical 
data of this study could not answer the final question, a range of periodontal and 
RA clinical samples were collected from a large number of RA patients with 
different periodontal characteristics and from the longitudinal part of the trial. 
These samples were investigated in this thesis to examine the involvement of the 
immunological and microbiological characteristics in the interplay between RA 
and PD.  
2.1.1.1.  Recruitment of OPERA study  
 
Recruitment started in January 2014 and finished in October 2015. Patients 
diagnosed with Rheumatoid Arthritis (according to the revised 1987 ACR criteria) 
from three different hospitals in Birmingham (Queen Elisabeth Hospital, 
Heartlands Hospital and City and Sandwell Hospital) were contacted and 
informed about the study by post or by nurses in the rheumatology department. 
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If patients were interested in the study, full verbal explanation and written 
information was given in a Patient Information Sheet. If the patients were willing 
to take part on the study, they signed an Informed Consent Form and were given 
a date to attend an appointment at the Birmingham Dental Hospital for a 
screening visit.  
 
A total of 296 patients from the 3 different hospitals were consented to the study. 
However, 98 patients (33%) either did not attend this appointment or dropped out 
at the recruitment stage (Figure 2. 2 )  
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Figure 2. 2 CONSORT diagram of the OPERA clinical trial. Abbreviations: OPERA, 
Outcomes of periodontal therapy in rheumatoid arthritis; n, number of patients per 
group; DNA, did not attend the appointment. 
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n= 30
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2.1.1.2. Screening appointment: clinical assessment  
 
A total of 198 patients were screened for the study. The screening appointment 
started with an assessment of the general health using a detailed medical 
questionnaire and taking the blood pressure, weight and height of the patient.  
The assessment was followed by an examination of the swelling and pain 
(tenderness) of 28 joints according to the disease activity score (DAS) 28 
(Prevoo, Van't Hof et al. 1995): the shoulders, elbows, wrists, metacarpo-
phalangeal joints, proximal interphalangeal joints and the knees. To calculate the 
DAS 28 a visual scale analogue (VAS) was given to the patients and used to 
assess the negative impact that RA had in their life for the last 2 weeks, in a scale 
from 0 to 100. These parameters together with the erythrocyte sedimentation rate 
(ESR) value from the hospital notes, was entered in the formula for the calculation 
of the DAS28: 
 
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 
* VAS 
 
For the assessment of periodontal status, a Periodontal Pocket Chart was 
performed recording the clinical attachment level, bleeding on probing, pocket 
depth and gingival recession. To guarantee consistency, the same operator 
which was calibrated and trained by expert periodontists from the periodontology 
Page 53 
 
department (the author of this thesis) performed the periodontal examination at 
baseline and in the review visits of the longitudinal part of the trial. 
Established questionnaires were used to assess the patient physical function, to 
assess quality of life in relation with oral health, and the RA and general health 
status: Arthritis impact measurement scales 2 (AIMS2), Multidimensional Health 
Assessment Questionnaire (R808-NP2), Multidimensional assessment of fatigue 
scale (MAF-scale), Patient Health Questionnaire (PHQ-9), Oral health impact 
profile (OHIP) and Euro Quol questionnaires (Slade 1997).    
 
Covariate data was collected at baseline such as age, gender, ethnicity, socio-
economic status, education, marital status, smoking habits, alcohol consumption, 
comorbidities and medication. 
 
2.1.1.3. Sample collection 
 
During the screening appointment, if the patient accepted and consented, 
samples of blood, saliva, gingival crevicular fluid (GCF) and subgingival plaque 
were collected. If the patients participated in the longitudinal study, these samples 
were collected also after 3 and 6 months of the hygienist visit. 
 
2.1.1.3.1. Gingival crevicular fluid 
 
Gingival crevicular fluid (GCF) was collected after carefully drying the area with 
low-pressure air and cotton roll isolation to avoid saliva contamination. The 
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collection was performed inserting PerioPaper® strips in the periodontal pocket 
for 30 seconds from 4 selected sites in the upper jaw: mesial of the first premolar 
and mesial of the first molar of each side. If selected teeth were not present or 
there was contamination, adjacent teeth were selected and annotated to ensure 
consistency if GCF was collected in future visits. After measuring the volume of 
GCF in a Periotron® 8010 (Oraflow Inc., USA), PerioPapers were immediately 
snap-frozen with liquid nitrogen and stored at the end of the screening visit at -
80°C in a 1.5ml Star Lab tube (E1480-0306). 
 
2.1.1.3.2. Saliva samples 
 
Samples of saliva were collected using a sterile marble to stimulate saliva 
production for 5 minutes. The volume of saliva produced during the initial 5 
minutes was used for the calculation of the salivary flow rate (ml/min). The saliva 
collected in a Falcon tube (Corning Incorporated, USA) was immediately stored 
in wet ice and taken to the laboratory once the appointment finished where 
samples were centrifuged at 1000 rcf at 4°C for 10 minutes (Rotina 380R, 
Hettich®), supernatant and pellet separately were transferred into a 1.5ml 
cryogenic vial (Star Lab, UK) and stored at -80°C for future analysis.  
 
2.1.1.3.3. Blood samples 
 
Blood samples (approximately 30 ml) were collected from the antecubital fossa 
into heparinized tubes to separate the plasma (E1390-0304, Star Lab) and 4 
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serum-separating tubes (E1480-0302, Star Lab) vacutainer® 5ml tubes. Plasma 
tubes were immediately stored on ice while serum tubes were left undisturbed for 
15 to 30 minutes before storing on ice. After the appointment, samples were taken 
to the laboratory and tubes were centrifuged at 1000 rcf at 4°C for 30 minutes 
(Rotina 380R, Hettich®), aliquoted into 1.5 ml cryotubes and stored at -80°C. 
 
2.1.1.3.4. Plaque samples 
 
Subgingival plaque was collected after careful removal of supragingival plaque 
using a cotton pellet. Subgingival plaque collection was performed using a 
Gracey curette from 6 representative sites, one per sextant as distant as possible. 
These samples were collected from 3 deep sites (>3 mm) and from 3 shallow 
sites (<3mm). If patients had healthy periodontium or no deep sites, 3 shallow 
sites were selected. The total plaque collected per patients was pooled into 1 ml 
Eppendorf tubes containing 1ml of Tris-EDTA (50 mM Tris, 
Ethylenediaminetracetic acid, pH 7.4). These sites were annotated to ensure 
consistency if plaque was collected in future visits. Subgingival plaque from deep 
sites (>3 mm) and shallow sites (<3 mm) were collected separately for each 
patient in the systemically healthy group with periodontitis, to allow the 
comparison between the two locations. 
 
 
 
2.1.1.4. Inclusion and exclusion criteria 
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The main purpose of these criteria was to assure a sufficient disease activity for 
both RA and periodontitis (Table 2.1 and Tabel 2.2). To that end, a compilation 
of validated questionnaires were given to patients, disease activity score (DAS28) 
was calculated, and full dental and periodontal assessment was performed during 
the screening visit. The main inclusion criteria had the aim to assure enough RA 
and periodontitis activity, which standardized through a DAS 28 higher than 3.2, 
and moderate to severe periodontal disease. To include patients with a sufficient 
level of inflammation, cumulative probing depth higher than 40 mm was defined 
as inclusion criteria, this being the sum of the highest probing depth per tooth 
when probing depths were higher or equal to 4 mm. The purpose of the exclusion 
criteria was to assure all patients started the study with stable medication 
(treatment with DMARD for >3 months and stable dose for >2 months). The 
exclusion criteria aimed to reject patients with other types of periodontal disease 
and rheumatic or systemic autoimmune disease other than RA. Also patients that 
had underwent periodontal treatment (within 12 prior to baseline), surgical 
procedures (within 12 weeks prior to baseline) or glucocorticoids injections (within 
4 weeks prior to baseline) were excluded from the study. 
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Table 2. 1 Inclusion and exclusion criteria for the OPERA (Outcomes of 
Periodontal Therapy in Rheumatoid Arthritis) study.  Abbreviations: RA, Rheumatoid 
Arthritis; ACR, American College of Rheumatology; DAS, Disease Activity Score; DMARD, 
Disease Modifying Anti-Rheumatic Drug; CAL, Clinical Attachment Loss. 
Inclusion Exclusion 
Age 18+, accepting to participate 
in the study and willing to sign a 
consent form  
Other rheumatic autoimmune diseases 
different from RA, or significant systemic 
involvement secondary to RA  
Diagnosed according to the 
revised 1987 ACR criteria for the 
classification of rheumatoid 
arthritis (RA) 
Other inflammatory joint disease (past or 
current) different from RA 
DAS28 ≥3.2 Juvenile idiopathic arthritis (JIA) or 
juvenile rheumatoid arthritis (JRA) and/or 
diagnosis of RA before the age of 16 
DAS28 >5.1 if biologics drugs 
being administrated 
Any surgical procedure, including 
bone/joint surgery/synovectomy 
(including joint fusion or replacement) 
within 12 weeks before included in the 
study or scheduled to be administrated 
during study or Intra-articular or 
parenteral glucocorticoids within 4 weeks 
before commencement of the study 
Treatment with DMARD for ≥ 3 
months and stable dose for ≥ 2 
months 
Significant concomitant disease, which 
would impede patient participation in the 
investigators opinion 
Generalized moderate to severe 
chronic periodontitis as 
evidenced by pocketing with 
clinical attachment loss (CAL>=4 
mm on at least 2 non-adjacent 
teeth AND cumulative probing 
depth>=40mm). Cumulative 
pocket depth is the sum of the 
deepest probing depths of at 
least 4mm on each tooth 
Periodontal treatment received within 12 
months of the inclusion in the study or 
other dental problems contraindicate the 
participation in the study 
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2.1.1.5. Randomization 
 
Patients that qualified for the intervention study according to the 
inclusion/exclusion criteria were offered a verbal and written explanation of the 
study and a consent form (Patient Information Sheet -Treatment, and Informed 
Consent Form - Treatment). If willing, patients were randomized into one of the 
two treatment arms, stratified by their ACPA status. Randomization was 
performed through the Birmingham Clinical Trials Unit, which used a web-based 
system developed by the unit. Investigators were blinded from the group 
allocation for the duration of trial. 
 
2.1.1.6. Intervention and Control group 
 
Patients allocated in the intervention group received, within 2 weeks of baseline, 
2-4 sessions of non-surgical periodontal treatment by a qualified dental hygienist 
from the Periodontal Department of Birmingham Dental Hospital. Using ultrasonic 
scalers and curette instruments, this treatment (scaling and root surface 
debridement) aims to reduce or eliminate the pathogenic subgingival flora.  
 
Patients allocated in the control group received oral hygiene instructions by a 
competent and trained NHS dental hygienist (same operator for all subjects 
throughout the trial). At the end of the trial, they were offered the same periodontal 
treatment as that received by the intervention group. If during the study, a patient 
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suffered an increase of more than 2 mm of CAL in one site, they received site-
specific rescue treatment (scaling and root planning of the specific pocket).   
 
All patients were reviewed after 3 and 6 months of visiting the hygienist. During 
this review appointments, periodontal and RA data were collected together with 
biological samples by the same investigator and following the same methods as 
in the screening visit. All data was collected and stored using an internal database 
at School of Dentistry.  
 
  Systemically healthy volunteers 
 
Approval for this study was obtained from the South Birmingham Research Ethics 
Committee, UK (Approval codes: Inspired - 15/WM/0006) and the study was 
funded by the NIHR (Grant Reference Number: DRF-2014-07-109). Biological 
samples from systemically healthy volunteers were obtained as part of the 
INSPIRED feasibility study (Influence of Successful Periodontal Intervention on 
Renal and Vascular Systems in patients with Chronic Kidney Disease). 
 
2.1.2.1. Recruitment of systemically healthy volunteers 
 
A total of 40 systemically healthy patients were recruited as part of the INSPIRED 
feasibility study from the periodontal and oral surgery department of Birmingham 
Dental Hospital as well as non-dentist/hygienist staff from within the hospital.  
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2.1.2.2. Screening appointment: clinical assessment 
 
The screening appointment started with a first assessment of the general health 
in a detailed medical questionnaire and by taking the blood pressure, weight and 
height. Covariate data was collected at baseline such as age, gender, ethnicity, 
socio-economic status, education, marital status, smoking habits, alcohol 
consumption, comorbidities and medication. 
 
For the assessment of periodontal status, a Periodontal Pocket Chart was 
performed recording the clinical attachment level, bleeding on probing, pocket 
depth and gingival recession.   
 
2.1.2.3. Sample collection 
During the screening appointment, if patient accepted, samples of bloods, saliva, 
gingival crevicular fluid (GCF) and subgingival plaque were collected. However, 
for this thesis, only serum and subgingival plaque were analyzed.  
 
Blood samples were collected using the same method described in section 
2.1.1.3.3 
 
Subgingival plaque was collected upon careful removal of supragingival plaque 
using a cotton pellet. Plaque collection was performed inserting for 10 seconds 4 
endodontic paper points of size 40 per site. This procedure was repeated in 6 
representative sites, one per sextant as distant as possible. The 6 selected sites 
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in periodontitis patients were from 3 deep sites (>3 mm) and 3 shallow sites 
(<3mm). If patients had healthy periodontium 3 shallow sites were selected. The 
total plaque collected per patients was pooled into 2 ml tubes containing tris 
buffer. These sites were annotated to ensure consistency if plaque was collected 
in future visits. Although the plaque collection methodologies were different 
between the two trials, it has been previously described that these methods have 
a good agreement and both can be used (Jervøe-Storm, AlAhdab et al. 2007) 
 
2.1.2.4. Inclusion/exclusion criteria 
 
To participate in the systemically healthy group (for both periodontitis and 
periodontally healthy groups), patients were excluded if they suffered from any 
self-reported systemic illness including hypertension or diabetes or if they had 
received periodontal treatment within the last year. 
 
-Periodontitis group: the inclusion criteria was to be diagnosed with moderate to 
severe periodontitis, defined as Clinical attachment level (CAL) >4mm in at least 
2 non-adjacent teeth and cumulative probing depth>40 mm. Cumulative pocket 
depth is the sum of the deepest probing depths of at least 4mm on each tooth. 
 
-Periodontally healthy group: the specific exclusion criteria for periodontal health 
was probing depth of >4mm at any site. 
 
  Definition of periodontitis in all study participants  
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The classification criteria used for periodontal status was a modification of 
Eke&Page 2007 case definition (Table 2.2). To classify patients as periodontally 
healthy, a more strict criteria was used (no more than 4 sites with 4mm PD, no 
pockets with 5mm CAL). Clinical characteristics of patients are described in 
section 3. 
 
 
 
Table 2. 2 Modification of Eke & Page 2007 clinical case definition for 
periodontitis. Moderate, mild and moderate periodontitis were classified following 
the author’s recommendation. Healthy status were specified in patients with no 
more than 4 sites with 4mm PPD and no pockets with 5mm CAL. PD: pocket depth; 
CAL: clinical attachment loss. 
Periodontal 
status 
PPD CAL 
Health <= 4 sites with <= 4 mm AND < 2 sites with <=4 mm 
Mild Nor health, Nor 
moderate/severe 
Nor health, Nor 
moderate/severe 
Moderate >= 2 sites with >= 5 mm OR   >= 2 sites with >= 4 mm 
Severe >= 2 sites with >= 6 mm AND  >= 1 sites with >= 4 mm 
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2.2. Antibodies to bacterial and citrullinated human proteins analysis 
 
Based on the findings from the study of de Pablo et al., 8 citrullinated and non-
citrullinated human proteins were analyzed by Enzyme-linked immunosorbent 
assay (ELISA) to investigate antibody production in RA and its correlation with 
periodontitis. These antibodies were measured in serum collected from RA 
patients periodontally healthy and patients with periodontitis before and after 
periodontal treatment, and compared to the systemically healthy control groups 
with and without periodontitis. 
 
 Biological sample used 
 
Sera from patients diagnosed with Rheumatoid Arthritis (RA) and periodontitis 
and the appropriate controls were analyzed using Enzyme Linked 
Immunosorbent Assay (ELISA) to quantify the antibody response to citrullinated 
peptides (samples=205, patients 146). 
 
  Study population 
 
For the baseline group comparison, sera from 87 patients diagnosed with RA 
(from the OPERA trial) was used to performed antibody ELISAs. Longitudinal 
samples of patients with RA and periodontitis (visit 1 n=42, visit 2 n=42), were 
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also analyzed to evaluate the effect of periodontal therapy in the auto-antibody 
production in RA patients. 
 
Samples from systemically healthy controls were acquired through the INSPIRED 
trial and serum was available from 17 systemically healthy with periodontitis and 
20 systemically and periodontally healthy controls (Figure 2. 1).  
 
 Detection of antibody to human proteins by ELISA 
 
To measure ACPA levels, 5 human peptides in citrullinated and arginated form 
were used (Table 2. 3: Peptides used for the detection of human antibodies 
to citrullinated proteins in serum. ): Fibrinogen (C-Fib and Fib), Vimentin (C-
Vim and Vim), Enolase 1 (CEP) and Tenascin 5 epitope (C-TNC5, TNC5). The 
peptides used for the assay were provided by our collaborators in Dr Venables 
group (Kennedy institute of rheumatology, Oxford, UK) and previously analysed 
by our group (de Pablo, Dietrich et al. 2014). Sequences of the reactive epitopes 
have been previously described (Montgomery, Venables et al. 2013). 
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Table 2. 3: Peptides used for the detection of human antibodies to 
citrullinated proteins in serum. X represent the citrulline residue. Data acquired 
from collaborators Montgomery et. al, 2013 (Montgomery, Venables et al. 2013). 
Antigen 
Sensitivity Reactive epitope Stock 
concentration 
Fibrinogen 
66% 36GPXVVEXHQSACKDS50 10 mg/ml 
Vimentin 
40% 59VYATXSSAVXLXSSVP74 10 mg/ml 
α-Enolase 
50% 5KIHAXEIFDSXGNPTVE21 5 mg/ml 
Tenascin5 
47% EHSIQFAEMKXPSNFXNLEGXXKR 10 mg/ml 
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  Identification of standard controls for ELISA protocols 
 
Preliminary experiments were necessary to find appropriate positive controls 
from sera patients to use in all plates. For CEP and Vim, pooled samples from a 
past cohort acquired by our collaborators was used as positive controls. Also, 
some patients’ sera served as standards to create calibration curves for C-Vim, 
C-Fib, C-TNC5, Vim and CEP (Table 2. 4). Dilutions from C-Vim, C-Fib, Vim and 
CEP started at 1:50 and followed 8 2-fold dilutions to 1:3200 whereas dilutions 
for C-TNC5 started at 1:100 to end at 1:6400. However, no appropriate control 
was found for arginated enolase, fibrinogen and tenascin, as no patients had a 
strong enough positive result to the antibody ELISA. Once selected, the 
standards were run on each plate along with the patients samples, leaving space 
for a blank that only contained RIA buffer. 
 
Table 2. 4: Standard dilutions for antibody ELISAs. Methods explained in section 
2.2.3.1. Abbreviations: C-, citrullinated; Vim, Vimentin; Fib, fibrinogen; TNC,5 
tenascin 5; CEP, citrullinated human enolase. 
 
Stand
ard 
Antigenic peptide 
C-Vim Vim C-Fib CEP C-TNC5 
1 1/50 1/50 1/50 1/50 1/100 
2 1/100 1/100 1/100 1/100 1/200 
3 1/200 1/200 1/200 1/200 1/400 
4 1/400 1/400 1/400 1/400 1/800 
5 1/800 1/800 1/800 1/800 1/1600 
6 1/1600 1/160
0 
1/1600 1/1600 1/3200 
7 1/3200 1/320
0 
1/3200 1/3200 1/6400 
Type 
of 
standa
rd 
Pt 1087 
V1 
Colla
borat
ors 
(Raz 
29) 
Pt 1117 Collaborators 
(Raz 18) 
Pt 1158 
V1 
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  ELISA methods 
 
The stock concentration of the peptides (donated by our collaborators from the 
Kennedy Institute of Rheumatology) was 10 mg/ml for all analytes except for REP 
and CEP, which were at 5 mg/ml. Coating peptides were diluted to a final 
concentration of 10 ug/ml with Coating Buffer (detailed in buffers and reagents 
section) and added to a 96 well plate (100 ul/well). After an overnight coating at 
4° C on a rocking platform (Biometra, Germany), plates were washed 4 times 
with wash buffer (1xPBS, 0.05 % Tween-20) and peptides were blocked with a 
freshly prepared dilution of 1x Phosphate-buffered Saline (described in section 
Buffers and reagents) with 2% Bovine Serum Albumin for 2 hours at room 
temperature (RT) on a rocking platform. 
 
 After removing (not washing) the blocking buffer, sera diluted 1:100 in RIA buffer 
and the appropriate standard dilutions (Table 2. 4) and positive controls were 
incubated for 1.5 hours at RT on rocking platform. After 4 washes, secondary 
antibody was added (diluted 1:3000 in RIA buffer) and incubated for 1 hour ar RT 
on a rocking platform. After another 4 washes, 100 ul/well of mixed TMB 
Substrate (Thermo scientific) was incubated for 5 minutes at RT inmediately 
followed by 100 ul/well of Stop Solution (6% Sulphuric acid). Plates were read at 
450 nm by a spectrophotometer (Infinite® 200 PRO, Tecan Trading AG, 
Switzerland). This process followed a trusted, standard protocol developed by Dr 
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AM Quirke (Oxford University) (Quirke, Lugli et al. 2014) (de Pablo, Dietrich et al. 
2014).  
 
  Buffers and reagents for ELISA assay 
 
2.2.6.1. RIA buffer 
RIA buffer was prepared by adding 10ml of Triton-X100 into a measuring cylinder 
containing 500ml of distillate water, to get a final concentration of 1%. Once 
stirred on a magnetic plate until fully dissolved, the rest of the reagents were 
added and topped with 500ml of water. For a final volume of 1L of buffer, the rest 
of the reagents were added: Bovine Serum Albumin (BSA)(10g) , 10ml of 1M 
trizma hydrochloride (previously prepared by dissolving 15.7 g into 100ml of dd 
water at pH 7.6), sodium chloride (20.4g), 1M 2-Amino-2-hydroxymethyl-
propane-1,3-diol (10 ml), Triton-X 100 (10ml), sodium-deoxycholate (5 g) and 10 
ml of 10% sodium dodecyl sulphate (previously prepared by diluting 1g in 10ml 
of water). This buffer was then stirred (Corning® PC-420D, USA) at RT until 
dissolved for 2 hours and stored at room temperature for a maximum of 3 months.  
 
2.2.6.2. Coating buffer 
Coating buffer was prepared using 1 L of distilled water adding 1.59 g of sodium 
carbonate, 2.93 g of sodium hydrogen carbonate and 0.19 g of sodium azide. 
This buffer was then stirred (Corning® PC-420D, USA) at RT until dissolved for 
2 hours and stored at room temperature. 
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2.2.6.3. PBS buffer 
Phosphate-bufferred saline (PBS) used for the wash buffer and blocking buffer 
was stored in a 10x concentrate stored at room temperature and prepared 
dissolving in 1L of distilled water in 80 g of sodium chloride, 2g of potassium 
chloride, 14.2 g of sodium hydrogen phosphate and 2.4 g of potassium 
dihydrogen phosphate at pH of 7.4. PBS was stored at room temperature for a 
maximum of 1 month.  
 
2.2.6.4. Wash buffer 
Wash buffer was freshly prepared every day, dissolving 0.5 ml of Tween-20 in 1L 
of PBS. 
 
2.2.6.5. Blocking buffer 
Blocking buffer was freshly prepared every day, dissolving 2g of BSA in 100ml of 
PBS.  
 
2.2.6.6. Stop solution 
Stop solution was prepared by adding 27.8 ml of sulphuric acid (stock 
concentration of 98%) into 500ml of distilled water. This solution was stored at 
room temperature for 4 months.  
 
 Anti CCP kit assay  
To measure Cyclic Citrullinated Peptides antibodies we performed the EDIA™ 
anti CCP assay offered by Euro Diagnostica, based on highly purified synthetic 
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peptides containing citrulline residues. This kit is based on an ELISA method: 96 
well plates were coated with the citrullinated cyclic peptide (antigen) and diluted 
patients sera (1:1000) was added to the wells. After incubation for 1 hour at room 
temperature, unbond materials were washed away and alkaline phosphatase-
labelled goat polyclonal antibody to human IgG were added and incubated for 30 
minutes at RT, followed by a second washing step and incubation with a 
chromogenic substrate (phenolphthalein monophosphate) that result in the 
development of color, proportional to the quantity of serum antibody in your 
sample and measured at 450nm by a photo spectrometer. 
 
 Detection of antibodies to P. gingivalis -related antigens 
To measure human antibodies against P. gingivalis -antigens, 5 peptide were 
used (Table 2. 5): whole PPAD and immunodominant epitope 3 (citrullinated and 
arginated), gingipain (RgpB) and P. gingivalis -enolase. The peptides used for 
the assay were provided by our collaborators in Prof Venables group (Kennedy 
Institute of Rheumatology, Oxford, UK) that were previously used in studies 
(Quirke, Lugli et al. 2014) with the exception of RgpB that came from Prof Jan 
Potempa (Krakow, Poland). 
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Table 2. 5: Peptides used for the detection of antibodies to Porphyromonas gingivalis 
(PG) -related antigens.  Abreviations: PPAD, P. gingivalis -peptydil arginine 
deiminase; CPP3, citrullinated immunodominant epitope 3 (RPP3, arginated); RgpB, 
gingipain . 
Peptide Sequence Stock 
concentration 
Coating 
concentrati
on 
Supplier 
PPAD CATATC-GGTACC-
TGAAAAAGCTTTTACAGG
CTAAA 
GCCTTGATTC 
7 
mg/
ml 
10 µg/ml Oxford 
Univers
ity 
CPP3 CAKTDSYWT-Cit-
DYTGWFAMYDC 
5 
mg/
ml 
10 µg/ml Oxford 
Univers
ity 
RgpB RgpB-6xHis 0.81 
mg/
ml 
5 µg/ml Krakow 
institut
e 
PG-
enolase 
ckiig-X-eilds-X-gnptvec 1 
mg/
ml 
10 µg/ml Oxford 
Univers
ity 
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 Identification of standard controls for ELISA protocols 
Preliminary experiments were necessary to find appropriate positive controls 
from patients’ sera to use in all plates. In addition, some patients’ sera served as 
standards to create calibration curves (Table 2. 5). However, due to the low 
antibody response found for the anti-RPP3 and PPAD no standard was found to 
calculate a curve (Appendix figures). 
 
 ELISA methods and reagents 
ELISA methods are described in section 2.2.5, using the appropriate peptides 
(Table 2. 6) to coat the plates for the identification of the antibodies. Same buffers 
and reagents from section 2.2.6 were used for the antibody ELISAs to P. 
gingivalis -related antigens. 
 
Table 2. 6 Standard concentrations for antibody ELISAs to P. gingivalis -related 
antigens. Abbreviations: PPAD, P. gingivalis -peptydil arginine deiminase; CPP3, 
citrullinated immunodominant epitope 3 (RPP3, arginated); RgpB, gingipain. 
 
 
 
 
 
 
 
  
Standard Antigenic peptide 
RgpB CPP3 
1 1/75 1/100 
2 1/15
0 
1/200 
3 1/30
0 
1/400 
4 1/60
0 
1/800 
5 1/12
00 
1/1600 
6 1/24
00 
1/3200 
7 1/48
00 
1/6400 
Type of 
standard 
Patient 
1295 
Patient 
1115 
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2.3. Antibodies to membrane proteins from Porphyromonas gingivalis, 
Fusobacterium Nucleatum and Tannerella Forsythia analysis 
 Biological samples and study volunteers 
Serum samples from systemically healthy controls and a subgroup of the OPERA 
trial were aliquoted (100 µl) and sent to the Nebraska immunology laboratory in 
96 well plates that contained anonymized samples from all groups in each plate 
to assure consistency.  
 
 Detection of antibodies against bacterial proteins by ELISA 
A collaboration with the University of Nebraska medical Centre (Dr Ted Mikuls) 
was arranged to investigate this novel technique to semi-quantify serum 
antibodies to bacterial proteins that the experimental immunology laboratory has 
developed. After a Material Transfer Agreement was created, serum samples 
were organized in 96 well plates and sent in dry-ice to Nebraska. No patient data 
was sent to our collaborators to assure blindness. Outer Membrane Antigens 
were prepared by collaborators in the Nebraska immunology laboratory, using a 
broth bacterial culture containing the bacteria of interest (Porphyromonas 
gingivalis, Fusobacterium Nucleatum and Tanerella Forsythia). These processes 
have been previously described (Mikuls, Payne et al. 2014). 
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2.4. Effect of periodontal therapy in the cytokine response in RA 
 Multiplex assay for cytokine quantification 
Gingival crevicular fluid (GCF) was analyzed for the semi-quantification of 
inflammatory cytokines (sample collection explained in section 2.1.1.3.1). Once 
PerioPaper strips were thawed, all 4 strips from each patient were pooled into a 
single cryotube and  eluted by adding 200 μl of elution buffer containing BSA 
0.5% and 1x PBS and incubated for 1 hour at room temperature. 200 µl of the 
eluted samples were then aliquoted into 96 well masterplates.  
Cytokine analysis was performed using a commercially available multiplex bead-
based assay designed to quantitate multiple cytokines (Bio-Plex Pro™ Human 
Cytokine Panel, 27-Plex from Bio-Rad™ Platform) following manufacturer’s 
instructions (Table 2. 7). A panel containing 27 cytokines was selected (Table 2. 
7). 
Magnetic beads were diluted to a 1x concentration in Bio-Plex assay buffer and 
were vortexed for 30 seconds. After pre-wetting the plate with Bio-Plex buffer 
(100µl), beads (50µl) were added into each well and incubated for 30 minutes at 
RT. 
To wash the plates, wash buffer (150 µl) was added to each well and plates were 
attached in the magnetic holder for 30 seconds. After flicking out the liquid, plates 
were detached from the magnetic holder and wash buffer was again added. This 
process was repeated 3 times in every wash step.  
Standards were prepared as 1 in 8 dilutions. Samples and standards (50 µl) were 
added in the plates and incubated for 30 minutes, covering the plate with sealing 
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aluminum foil at RT on a shaker (Luckham R11/TW, speed 2). After repeating the 
washing step, detection antibody (25 µl) was added in each well in a 1x 
concentration (diluted in detection antibody diluent) and incubated for 30 minutes, 
covering the plate with sealing aluminum foil at RT on a shaker. 
After repeating the wash step, streptavidin-phycoerythrin reporter (50 µl) was 
added and incubated for 10 minutes. After a final wash step, beads were 
suspended in assay buffer (125 µl) and shaken for 30 seconds. Fluorescence 
was detected on a Luminex 100/200 (USA).  
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Figure 2. 3 General overview of the Bio-Plex Pro™ Human Cytokine Panel assay for 
multiple cytokine quantification. Magnetic beads are used to indicate where the 
biomarker is found and the fluorescent reporter intensity indicates the quantity. 
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Table 2. 7 Cytokines analyzed with the Bio-Plex Pro™ Human Cytokine Panel assay. 
Abbreviations: IL, interleukin; FGF, Fibroblast growth factor; GM-CSF, Granulocyte-
macrophage colony-stimulating factor; G-CSF, Granulocyte colony-stimulating 
factor; MIP, Macrophage inflammatory protein; RANTES, regulated upon activation, 
normal T cell expressed and secreted; TNF, tumour necrosis factor; PDGF-BB, 
Platelet-Derived Growth Factor-BB ; MCP, Monocyte chemoattractant protein. 
Analyte Bead 
location 
Analyte Bead 
location 
Analyte Bead 
location 
IL-1β 39  IL-10 56 IFN-γ 21 
IL-1ra 25 IL-12 
(p70) 
75 IP-10 48 
 IL-2 38  IL-13 51 MCP-1 
(MCAF) 
53 
 IL-4 52 IL-15 73  MIP-1α 55 
IL-5 33 IL-17A 76 MIP-1β 18 
 IL-6 19 Eotaxin 43 PDGF-
BB 
47 
 IL-7 74 FGF 
basic 
44 RANTES 37 
IL-8 54 G-CSF 57 TNF 36 
 IL-9 77 GM-
CSF 
34 VEGFs 45 
 78 | P a g e  
 
 
2.5. Oral microbiome analysis in rheumatoid arthritis  
 Biological samples used 
Subgingival plaque samples were collected, after removal of supragingival 
plaque with cotton pellet, from the 6 representative sites selected, one site per 
sextant, as distant as possible from each other (methods of sample collection 
explained in section 2.1.1.3 and 2.1.2.3). The method of collection in the 
systemically healthy group was inserting an endodontic paper point in the pocket 
and for the RA group was using the appropriate Gracey curette (described in 
section 2.1.1.3 and 2.1.2.3). Plaque samples from each patient were pooled 
together and stored in a cryotube containing Tris buffer and stored at -80°C until 
sent to Ohio State University in dry ice for the analysis of the samples.  
 
 Study volunteers  
Subgingival plaque samples (n=281) were sequenced from the OPERA and 
INSPIRED participants according to availability of the subgingival plaque sample. 
17 patients were discarded due to drop-outs or not enough clinical data available, 
resulting in a total number of patients included of 264 (Figure 2. 1 Study 
population included for the different studies of this thesis. Plaque,  and serum 
samples were collected (methods described in section 2.1) for the analysis of the 
immunological and microbiological relationship between RA and periodontitis. 
When samples were available, the same patients were investigated from each 
baseline group, which overlapped in the majority of the experiments. Patients 
diagnosed with mild periodontitis are not represented in this diagram and are 
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excluded for baseline comparisons. Abbreviations: N, number of patients; RA, 
rheumatoid arthritis; PD, periodontitis. ELISA, enzyme-linked immunosorbent 
assay; OMA, outer-membrane antigen; PG, Porphyromonas gingivalis. 
Subgingival samples from two types of sites (deep pockets and shallow pockets) 
were selected from each patient in the systemically healthy with periodontitis 
group (n=17) to compare the two locations. To investigate the effect of 
periodontal therapy in RA, plaque samples were collected from the two 
randomized groups (intervention and control) after 3 and 6 months after 
randomization (n=240) 
 
 DNA isolation 
Bacterial DNA was extracted from the plaque samples in the research 
laboratories of the Ohio State University School of Dentistry. Plaque samples 
collected with currettes were diluted in PBS (200µl) and centrifuged (8000 rpm 
for 1 minute) to remove the Tris-buffered saline and other salts. Plaque samples 
were collected with paper-points, 200 μl of the solution was added to the vial 
containing 0.25 g glass bead and beat for 60 seconds at 500 rpm twice followed 
by centrifuging (1400 rpm) for 2 minutes. Supernatant was carefully aspirated 
and placed in a labelled sterile 1.5 ml tube.    
Bacterial DNA was isolated using Qiagen DNA MiniAmp® kit (Qiagen, Valencia, 
CA, USA) and protocol manufacturer instructions were followed. 
  
  Sequencing 
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Library preparation and sequencing (the reading of the nucleotides present in 
DNA) was conducted in the Mr DNA laboratories (Mrdnalab, Shallowater, TX, 
USA) (Figure 2. 4). PCR primers of the V1-V3 (spanning E.coli 16S gene regions 
8-27 and 519-536) and V7-V9 (spanning E.coli 16S gene regions 1099-1114 and 
1528-1541) of the 16S rRNA gene were used (Kumar, Brooker et al. 2011). Two 
sets of primers were used, since each set is capable of detecting a range of 
genera that the other fails to recover. Together they allow the recovery of a wider 
range of the microbiome than is possible with a single primer alone. As some 
genera were picked up by both sets of primers, to prevent overcounting, the 
number of sequences assigned to an OTU by both primers was reduced by half. 
The 16s amplicons were quantified using the Quant-iT PicoGreen dsDNA reagent 
and kit (Invitrogen). Equimolar concentrations of each amplicon were pooled and 
sequenced on the HiSeq 2500 system (Illumina). Paired-end sequencing was 
used to sequence both ends of the fragment and generate high-quality, alignable 
sequence data.The sequence lengths obtained (mean +/- std) were 501.5 +/- 
18.7, with a total of 29,107,462 sequences found in all 281 samples investigated 
and a median of 103,208 sequences per sample. 
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Figure 2. 4 Workflow of 16s r-RNA analysis with Ilumina MiSeq.  After extraction 
of DNA from the plaque samples, 16S rRNA sheared genes were tagged with unique 
tags and primers were added which contained Illumina adapter sequences. Genes 
were then amplified via PCR using primers (4) complementary to the adapter 
sequences. Library samples were be pooled and sequenced on the MiSeq platform, 
incorporating a nucleotide into the strand of DNA releasing a unique fluorescent 
signal that generates the genetic reads. Adapted from www.illumina.com. 
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 Sequence data pre-processing 
Once the sequences of DNA have been generated, Phylogenetic Tools for 
Analysis of Species-level Taxa (PhyloToAST) version 1.4.0rc1 and Quantitative 
Insights Into Microbial Ecology (Qiime) version 1.9.1 pipelines were used to pre-
process the sequences to reduce errors and bias produced in the sequencing 
(Figure 2. 5).  
Quality control of 98% was required for adaptor sequences and sequences of 
less than 300bp were discarded. The sequences were binned by sample and 
denoised using denoise_wrapper.py to reduce sequencing errors. All denoised 
sequences were aggregated and de novo operational taxonomic units (OTUs) 
were identified. Chimeric sequences were depleted using ChimeraSlayer (v. 
1.9.0, identify_chimeric_seqs.py). All quality filtered sequences were aggregated 
and clustered into OTU at 97% similarity using the UCLUST65 method. 
Sequences with an average quality score of 30 over a sliding window of 50bp and 
length >200 bp were assigned a taxonomic identity by alignment to the HOMD 
database using the Blastn algorithm at 97% identity.  
 
An OTU was included in the analysis if it was present in more than 5% of samples, 
at an abundance of at least 0.001% as previuosly described (Mason, Preshaw et 
al. 2015).  
 
After merging the two primers, the number of species assigned to an OTU by 
both primers was reduced by half to prevent doubling sequences picked by both 
primers. Primer averaging was carried out as previously described [4, 5, 6]. To 
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parse the OTU-sequence data, first any OTUs that occurred in less than 5% 
percent of samples and/or OTUs that make up less than 0.01% of the overall 
sequences were removed. The removed OTUs are separated in a file for future 
examination. For the following steps, a representative sequence was picked from 
the database for each OTU (instead of operating with the entire dataset). Finally, 
taxonomic identity was assigned to each OTU by alignment of the representative 
sequence to the HOMD database [7] using the Blastn algorithm.  
 
 
Figure 2. 5 PhyloToAST pipeline analysis process. Modified with the permission from 
Dabdoub et. Al (Dabdoub, Fellows et al. 2016).  
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 Microbiome data analysis 
Rarefaction analysis was performed to confirm if saturation was reached for all 
the samples, using the alpha_rarefaction.py script (Qiime).  
 
Beta diversity (between-group) was investigated performing Principal 
coordinates analysis (PCoA) using both distances matrices: phylogenetic 
(UniFrac weighted and unweighted) and non-phylogenetic (Bray–Curtis). 
Significant differences between clusters was calculated using the Adonis and 
ANOSIM tests. PCoA plots were generated by the python package PhyloToAST 
using PCoA.py script.  
 
Alpha diversity (within group) was analyzed using Abundance Coverage 
Estimator (ACE) and Shannon diversity using alpha_diversity.py script, and 
differences between group-wise alpha diversities was measured using Mann-
Whitney U test.  Phylogenetic trees were created with iTOL (http://itol.embl.de/, 
version 3.4.1). 
 
The core species in each group were identified using Qiime’s script 
(core_microbiome.py) when species were present in at least 80% of the patients 
in each group. 
 
Differences between species relative abundance in each group were calculated 
using Deseq (differential_abundance.py) and significance was obtained from 
adjusted p values for multiple comparisons (FDR-adjusted Wald Test). This 
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function uses a negative binomial distribution of raw counts to estimate between-
group differences, while accounting for sampling effort (library size) and 
dispersion of each category (taxon or functional gene). 
 
Network correlations were investigated to test for differences in co-occurrence 
patterns between microbial communities from different ecosystems. Significant 
correlations were calculated using Spearman’s correlation (p<0.05 and ≥0.75) 
in JMP (SAS Institute Inc.) and inserted in Python (Networkx package {Schult, 
2008) to create the graph structures. These correlations were then visualized 
using the web tool Gephi (https://gephi.org/). Network anchor OTUs were defined 
as significant different abundance between the 2 groups, high betweenness 
centrality (top 20%) and belonging to the core microbiome of each group. 
 
2.6. Statistical analysis 
 
  Clinical data 
Clinical results to describe the study population were presented as median and 
interquartile range (IQR) for continuous data and proportions for categorical data 
  Raw data 
Calibration curves were interpolated from Optical Density Concentrations to 
calculate the concentration of antibody levels, which were presented in Arbitrary 
Units per ml (AU/ml) when standard dilutions were available. In cases of non-
available standards, results were presented in optical density units (ODs). Raw 
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data was processed using Graphpad Prism 7.0 (GraphPad Software Inc, 
California, USA). Graphs were generated with Graphpad Prism. Raw data 
produced by the cytokine experiments was processed using xPONENT® 
software (USA), which interpolated the fluorescence measure against the 
calibration curves for each standard to calculate the concentration (AU/ml). After 
interpolating the standards to calculate AU/ml, rare out of range units were found. 
As the amount of peptide and kits were limited to be able to dilute those samples 
and repeat the experiments, the raw data was used for the statistical analyses, 
for the out of range data. 
 
  Group comparison and correlations 
 
Statistical tests were run using IBM Statistics SPSS 23.  To test normality, 
Kolmogorov-Smirnov test was used. Statistical tests were run using IBM 
Statistics SPSS 23. Group comparisons between patients classified as 
Rheumatoid arthritis periodontally healthy (RA), Rheumatoid with periodontitis 
(RAPD), systemically healthy with periodontitis (PD) and systemically and 
periodontally healthy (H) were conducted using Kruskal-Wallis test and 
significance between each group comparison was calculated using Dunn’s 
multiple comparison test (significance p<0.05).  
 
Differences between level of antibodies at baseline (V1) and 6 months post-
intervention (V2) were discovered using Wilcoxon test (significance at p<0.05), in 
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each randomization group. Significant correlations between the serum antibodies 
to bacterial antigens, relative abundance of these bacteria and clinical 
parameters, were calculated performing the Spearman’s correlation test (p<0.05 
and ≥0.75) in JMP (SAS Institute Inc.). Correlations between the changes in this 
parameters (differences between baseline and visit 3) and between the serum 
concentration of cytokines and clinical parameters and its changes were 
investigated in the same manner. 
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3.  RESULTS – CIRCULATING 
ACPAS IN RA AND 
PERIODONTITIS 
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Introduction 
The hypothesis of the study presented in this chapter was that, in rheumatoid 
arthritis, patients with periodontitis have higher level of serum antibodies to 
citrullinated proteins compared to those with healthy periodontium and that, after 
periodontal therapy, these antibody levels are reduced. 
The aims were:  
1) To compare the level of serum antibodies to human citrullinated (and non-
citrullinated) proteins in groups of patients diagnosed with RA and periodontitis 
and the appropriate control groups.  
2) To analyse the effect of periodontal therapy on the level of these antibodies in 
RA patients compared to a control group that did not receive such therapy.  
RA antigens were detected in collaboration with Prof Patrick Venables and his 
group in Oxford University, which had developed RA citrullinated antigens in 
established ELISA protocols for the semi-quantification of antibodies to 
citrullination.  
This chapter presents the results from serum antibody ELISAs to cyclic 
citrullinated peptide (CCP) and 4 human (citrullinated and arginated) proteins: 
Fibrinogen (C-Fib and Fib), Vimentin (C-Vim and Vim), Enolase 1 (CEP and 
REP), and Tenascin 5 (C-TNC5 and TNC5). ELISA methods are described in 
detail in chapter 2.2. 
  
 90 | P a g e  
 
 
3.1.  Study volunteers 
 
For this project, sera collected from 124 patients from the OPERA and INSPIRED 
cohorts (recruitment and study population explained in chapter 2) were analysed, 
of which 87 patients were diagnosed with RA and 37 patients were systemically 
healthy (Table 3. 1 Clinical characteristics of study population. Continuous data 
reported as median (IQR), as most of the variables followed a non-normal 
distribution, categorical data represented as proportions (%).  
From all patients diagnosed with RA, only 24 patients (27%) were periodontally 
healthy, showing a majority of RA patients presenting different degrees of 
periodontal disease (73%). Periodontitis severity ranged from 13 patients with 
mild periodontitis (16% of total RA) and 50 patients (60% of total RA) with 
moderate/severe periodontitis according to the Eke&Page case definition (Eke, 
Page et al. 2012). Patients with mild periodontitis were not included in the main 
cross-sectional analysis. These periodontitis patients were selected from the 
OPERA cohort randomly in order to have variety of periodontal status, so 
percentages of severity of PD does not necessarily reflect the RA population 
(Figure 3. 1.)  
 
A group of systemically healthy PD (moderate and severe) of 17 patients and a 
group of systemically healthy and periodontally healthy group of 18 patients, were 
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selected as controls for this study, after the exclusion of 2 patients diagnosed 
with mild periodontitis. 
 
Patients with periodontitis and active RA were selected from the longitudinal part 
of the OPERA study (exclusion/inclusion criteria described in Chapter 2.1). 
Serum from a total of 42 patients were analyzed in this chapter, excluding those 
patients who did not have enough clinical data, dropouts or those patients that 
did not donate serum samples at one of the visits.  The majority of patients in this 
group were diagnosed at baseline with moderate/severe periodontitis and only 2 
patients diagnosed at baseline with mild disease. From the 42 eligible patients, 
20 patients were randomly allocated in the immediate group and 22 in the delayed 
group. Differences in clinical parameters at baseline between immediate and 
delayed group were not significant (Table 3. 2).  
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Figure 3. 1 Flow diagram of cross-sectional study population subgroup from the 
OPERA and INSPIRED trial (explained in section 2.1). Abbreviations: RA, 
rheumatoid arthritis; RA noPD, rheumatoid arthritis and healthy periodontium; RAPD, 
rheumatoid arthritis and periodontitis; NoRA, systemically healthy. NoRA noPD, 
systemically healthy with healthy periodontium; noRA PD, systemically healthy with 
periodontitis. 
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Table 3. 1 Clinical characteristics of study population. Continuous data reported 
as median (IQR), as most of the variables followed a non-normal distribution, 
categorical data represented as proportions (%). DAS28, ESR, VAS, tender and 
swollen joints not recorded for systemically healthy controls (“-“). Data from mild 
periodontitis patients excluded. Abbreviations: RA, rheumatoid arthritis; PD, 
chronic periodontitis; n, number of patients; CumPPD, cumulative probing depth; 
PPD, probing pocked depth; BoP, blooding on probing; CAL, clinical attachment 
loss; DAS, disease activity score; ESR, erythrocyte sedimentation rate; VAS, 
visual analogue score (for activity of RA in the past week). 
 RAPD 
(n=45) 
RAnoPD 
(n=24) 
noRAPD 
(n=18) 
NoRA NoPD 
(n=19) 
Female 
proportion 
72% 71% 55.6% 63% 
Ethnicity 
-Asian 
-White 
-Black 
 
14% 
36% 
6% 
 
4% 
49% 
0% 
 
5.6% 
78% 
11% 
 
11% 
89% 
0% 
Smoker 
-current 
-former 
-never 
 
22% 
22% 
48% 
 
4% 
21% 
67% 
 
5.6% 
55.6% 
33.3% 
 
5% 
11% 
84% 
Alcohol 
-Never 
-1-4 
times/month 
-1-4 
times/week 
- >4 times/week 
 
40% 
24% 
10% 
16% 
 
45% 
17% 
18% 
20% 
 
11% 
16% 
44% 
16.7% 
 
15% 
65% 
15% 
5% 
BMI  28.3 (6.6) 26.8 (7.6) 27.7 (4.1) 25.9 (5.2) 
Age (years) 60(16) 61.5 (13) 48(8.5) 37(15) 
CumPPD (mm) 61 (42) 12(6) 109(31) 5(12) 
PPD  (mm) 3.8 (0.7) 2.29 (0.4) 3.17(1) 1.56(0.3) 
BoP 0.25(0.29) 0.08(0.17) 0.39(0.25) 0.02(0.11) 
CAL (mm) 3.3(1.2) 2.48(1.04) 3.9(1.9) 1.7(0.28) 
DAS28 4.7(2.7) 2.8(2.4) - - 
ESR 21(30) 8(27) - - 
VAS 60(35) 41(30) - - 
Tender joints 9(15) 4.5(10) - - 
Swollen joints 1(3) 0.01(3) - - 
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Table 3. 2 Clinical parameters at baseline in the two randomization groups.  Values 
are represented as median (max, min) significant differences between visit 1, 
baseline (V1) and visit 2, 6 months after therapy (V2) are calculated using Mann-
Whitney U test (significance <0.05) and Pearsons Chi squared test for nominal data. 
N=22 delayed group, 19 immediate group. Abbreviations: PPD, probing pocket depth; 
CAL, Clinical Attachment level; BOP, bleeding on probing; DAS 28, disease activity 
score 28; ESR, Erythrocyte sedimentation rate.  
Delayed group 
baseline 
median  (IQR) 
Immediate group 
baseline median 
(IQR) 
Sig two 
tailed 
p value 
PPD (mm) 3.15 (0.57) 3.2 (0.88) 0.54 
CAL (mm) 3.42 (0.82) 3.59 (1.2) 0.36 
BOP  0.24 (0.26) 0.29 (0.44) 0.262 
Das 28 5.27 (1.9) 4.86 (2.4) 0.12 
ESR 26.5 (27) 25.5 (28.5) 0.18 
Tender 
joints 
13.5 (12.3) 8 (13.5) 0.5 
Swollen 
joints 
1.5 (4) 1 (2) 0.53 
CRP 3.9 (14.1) 3.7 (8.1) 0.77 
Age (years) 57 (11.8) 61 (16) 0.82 
% Female 86.4% 68.4% 0.17 
% Current 
Smokers 
18.2% 31.6% 0.97 
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3.2. Cross-sectional analysis 
 Antibodies to citrullinated and uncitrullinated human peptides 
group comparison 
The cyclic-citrullinated peptide (CCP) test is commonly used by rheumatologists 
to semi quantify overall levels of antibodies against citrullinated proteins for the 
classification of patients in ACPA+ and ACPA-. In this study, RA patients 
presented significantly higher levels of anti-CCP compared to the systemically 
healthy groups. In this latter group, all patients presented anti-CCP levels close 
to undetectable, even patients with periodontitis ( Figure 3. 2)  
 
Antibody levels to the specific citrullinated peptides studied followed the same 
tendency as the observed in the anti-CCP results (Figure 3. 2, Figure 3. 3). 
Antibody levels to the arginated (non-citrullinated) peptides were low in all the 
groups, and only antibodies to Fibrinogen were non-significantly increased in the 
RA groups.  
 
Previously, de Pablo et. al represented similar data classifying patients as ACPA 
positive or negative, if patients had ACPA levels above the 98th percentile of 
healthy controls. This was calculated here showing that 81% of the RA patients 
from both RAPD and RA noPD groups were anti-CCP positive (Figure 3. 4), From 
the 18 anti-CCP negative patients found in the RA group, no differences were 
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found between the two groups, as 24% from the RAPD group and 25% from the 
RA noPD group were anti-CCP negative (Pearsons Chi-squared test).  
 
Interestingly, the percentage of ACPA-positive patients in the RAPD compare to 
RA group, varies for each citrullinated antigen: C-Fib and C-TNC5 show a higher 
percentage of positivity in the RAPD group, while C-Vim and CEP1 show higher 
percentage of positivity in the RA group. However, differences between 
proportions of ACPA + patients in the RAPD group and the RA with healthy 
periodontium group were not significant for all the antigens studied (Pearsons 
Chi-squared test). 
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Figure 3. 2 Levels of antibodies detected in patient sera against citrullinated and 
arginated peptides in the different study groups: Rheumatoid arthritis with healthy 
periodontium (RA noPD) (n=24); baseline data from RA with Periodontitis (RAPD) 
(n=50); systemically healthy with periodontitis (NoRA PD) (n=17); systemically and 
periodontally healthy controls (NoRA NoPD) (n=18). Data represented in scatter plot 
graphs and coloured lines show the group mean and SEM. Each individual graph 
represents the results for each peptide, both citrullinated (C-) and uncitrullinated: a. 
Cyclic citrullinated peptide (CCP); b. and c. Fibrinogen (Fib). Significant differences 
(“*”) between groups were analysed using the Kruskal-Wallis test and Dunn’s 
comparison (significant if p<0.05). The“+” symbol represents an outlier. Methods 
described in section 2.2. 
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Figure 3. 3 Levels of antibodies detected in patient sera against citrullinated and 
arginated peptides in the different study groups: Rheumatoid arthritis with healthy 
periodontium (RA noPD) (n=24); baseline data from RA with Periodontitis (RAPD) 
(n=50); systemically healthy with periodontitis (NoRA PD) (n=17); systemically and 
periodontally healthy controls (NoRA NoPD) (n=18). ). Data represented in scatter 
plot graphs and colored lines show the group mean and SEM Each individual graph 
represents the results for each peptide, both citrullinated (C-) and uncitrullinated: a. 
and b. Vimentin (Vim); c. and d. Enolase 1 (CEP, REP); e. and f.Tenascin 5 (TNC5). 
Significant differences (“*”) between groups were analysed using the Kruskal-Wallis 
test and Dunn’s comparison (significant if p<0.05). “+” symbol represents an outlier. 
Methods described in section 2.2. 
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Figure 3. 4 Percentage of subjects with antibody levels above the 98th percentile 
of healthy controls per analyte. Analytes: citrullinated (C-) and uncitrullinated: 
Fibrinogen (Fib), Vimentin (Vim), Enolase 1 (CEP, REP), Tenascin 5 (TNC5), 
cyclic citrullinated peptide (CCP). Rheumatoid arthritis with healthy periodontium 
(RA noPD) (n=24); baseline data from RA with Periodontitis (RAPD) (n=50); 
systemically healthy with periodontitis (NoRA PD) (n=17); systemically and 
periodontally healthy controls (NoRA NoPD) (n=18). Significance (Pearsons Chi-
squared test) if p<0.05. 
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 Subgroup analysis  
 
3.2.2.1. ACPA+/- comparison  
 
As expected, in subgroup analyses stratified by ACPA status, the percentage of 
ACPA+ patients with antibody positivity against the rest of the citrullinated and 
non-citrullinated antigens was higher than in the ACPA negative group. However, 
there were no significant differences (Pearsons Chi-squared test) between the 
two RA groups with or without periodontitis, in both ACPA positive or negative 
stratification (Figure 3. 5).  
 
Interestingly, while a majority of RA patients were anti-CCP positive (81%), 40% 
of patients that were anti-CCP negative had antibodies to C-Vim (18 patients) 
and most of these anti-CCP-/CVim+ patients were periodontally healthy (Figure 
3. 5). This highlights the importance of testing specific ACPAs. 
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Figure 3. 5 Percentage of patients with antibody levels over the 98th percentile of 
healthy controls stratified in ACPA positive and negative for anti-CCP. Antibody levels 
tested against: both citrullinated (C-) and uncitrullinated: Fibrinogen (Fib), Vimentin 
(Vim), Enolase 1 (CEP, REP), Tenascin 5 (TNC5), cyclic citrullinated peptide (CCP). 
Significance (*) defined as p<0.05, test used Pearsons Chi-squared test. 
Abbreviations: ACPA, anti-citrullinated protein antibody; RA, rheumatoid arthritits; 
PD, periodontitis.  
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3.2.2.2. Periodontal health comparison 
Clear differences were found in the antibody levels to citrullinated peptides in the 
RA groups compared to systemically healthy controls (Figure 3. 2, Figure 3. 3) 
for all peptides investigated. However, the periodontal status did not seem to 
affect the antibody production in RA or in systemically healthy individuals. To 
further investigate this, all patients (RA and no-RA) were grouped according to 
their periodontal health (see section 2 for periodontal health definition) which 
showed no differences between the groups (Figure 3. 6). From all patients 
investigated (n=124) , 42 were classified as periodontally healthy, 15 patients as 
mild periodontitis and 67 as moderate to severe periodontitis. Although there are 
considerably less patients in the mild periodontitis group, shifting the results in 
the anti-CCP levels (Figure 3. 6.a), the patients with high antibody response 
(which represent the RA patients) are equally distributed in all groups for all 
analytes.  
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Figure 3. 6 Antibodies to citrullinated proteins according to periodontal status. 
Analytes investigated: a. cyclic citrullinated protein (CCP); b. citrullinated enolase 
(CEP); c. citrullinated Fibrinogen (C-Fib); d. citrullinated Vimentin (C-Vim); e. 
citrullinated tenascin 5. Differences between groups were tested using Kruskal-Wallis 
test with Dunn’s multiple comparison (significance (“*”) = p<0.05). “+” symbol 
represents an outlier. Methods explained in section 2. 
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3.2.2.3. Smoking comparison 
A similar analysis was performed to investigate the effect of smoking and smoking 
history in the antibody response in all patients (Figure 3. 7). From all patients 
investigated (n=116; 8 patients were excluded as no smoking data was 
available), 16 were current smokers, 33 patients were former smokers and 67 
patients had never smoked. Although no significant differences were found 
between the groups, an interesting similar trend was observed in the antibodies 
to CCP, C-Fib and CEP, with the highest mean antibodies in the smoker group, 
and increasing for former smoker group and with the lowest mean antibodies in 
the group never smoked. However, as there are considerably fewer patients in 
current smokers group, this could be the artefact that explains the higher mean 
found in this group as, in the smoker and former smoker groups with bigger 
number of patients, the patients with high or very low antibody response (which 
represent the RA patients) are similarly distributed in all groups for all analytes. 
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Figure 3. 7 Antibodies to citrullinated proteins according to smoking status. Analytes 
investigated: a. cyclic citrullinated protein (CCP); b. citrullinated enolase (CEP); c. 
citrullinated Fibrinogen (C-Fib); d. citrullinated Vimentin (C-Vim); e. citrullinated 
tenascin 5. Differences between groups were tested using Kruskal-Wallis test with 
Dunn’s multiple comparison (significance (“*”) = p<0.05). “+” symbol represents an 
outlier. Methods explained in section 2. 
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3.2.2.1. Cross-reactivity and overlapping of antibodies to 
citrullinated proteins 
In our study, the majority (78%) of RA patients were found to be positive to anti-
CCP and positive to at least one of the citrullinated antigens investigated (Figure 
3. 8). From all anti-CCP positive patients (n=68), 7 expressed antibodies to all 
the individual citrullinated antigens but also some of these anti-CCP positive 
patients were not positive for any of the citrullinated antigens studied (n=6). There 
did not seem to be a clear relationship with periodontal status as patients with 
and without periodontitis were equally distributed across all the citrullinated 
peptides. Furthermore, 4 of the anti-CCP negative patients expressed antibodies 
against at least one of the other citrullinated peptides (one patient anti-CCP 
negative was positive for anti-C-Fib, C-Vim and C-TNC5) but with no relationship 
to the presence of periodontitis. This represents 22% of the RA patients that were 
diagnosed as ACPA negative but who showed antibodies to specific citrullinated 
antigens. No clear pattern could be drawn on the cross-reactivity of the peptides 
in anti-CCP positive or negative patients or according to periodontal status.  
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Figure 3. 8 Heatmap of antibody positivity to citrullinated epitopes in each RA patient 
(n=87). Patients with positive antibodies to each antigen had antibody levels over the 
98th percentile of healthy controls. Graph created using a web tool 
(biit.cs.ut.ee/clustvis/) (Metsalu and Vilo 2015). Abbreviations: CCP, cyclic 
citrullinated peptide; C-TNC5, citrullinated tenascin; C-Fib, citrullinated fibrinogen; 
CEP, citrullinated enolase. 
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3.3. Longitudinal analysis 
 
  Effect of periodontal therapy on clinical parameters 
 
The effect of periodontal therapy on clinical parameters is represented in Table 
3. 3 (n=42).  A significant reduction of periodontal parameters in pocket depth 
and bleeding on probing was achieved after periodontal therapy. On the contrary, 
there was a significant increase of these parameters in the delayed group (Table 
3. 4). The RA parameters, such as the Disease Activity Score (DAS 28) were 
significantly reduced after periodontal therapy, while the delayed group 
experienced a non-significant increase of this parameter. ESR and CRP were 
correlated at baseline (Spearman’s correlation r=0.57, p<0.001), but these 
systemic markers of inflammation did not significantly decrease after 6 month of 
periodontal therapy. These markers, in the delayed group, both change 
significantly but not towards the same direction, but these changes might be due 
to RA flair ups, change of medication or other unaccounted systemic conditions 
and not necessarily related to the periodontal therapy (Table 3. 4).  
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Table 3. 3 Effect of periodontal therapy on clinical parameters in the immediate group. 
Values are represented as median (max, min) significant differences between 
baseline and 6 months after therapy are calculated using Wilcoxon test (significance 
<0.05). N=20 patients. Abbreviations: PPD, probing pocket depth; CAL, Clinical 
Attachment level; BOP, bleeding on probing; DAS 28, disease activity score 28; ESR, 
Erythrocyte sedimentation rate.     
Baseline median  (IQR) 6 months median (25, 75 
percentile) 
Sig two tailed 
p value 
PPD 3.15 (0.57) 2.84 (0.9) 0.01* 
CAL 3.42 (0.82) 3.55 (1.8) 0.162 
BOP 0.24 (0.26) 0.13 (0.19) 0.0001* 
Das 28 5.27 (1.9) 4.06 (1.8) 0.035* 
ESR 26.5 (27) 14 (16) 0.062 
Tender 
joints 
13.5 (12.3) 6 (10) 0.045* 
Swollen 
joints 
1.5 (4) 1 (2) 0.176 
CRP 3.9 (14.1) 2.7 (9.8) 0.98 
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Table 3. 4 Change of clinical parameters in the delayed group. Values are 
represented as median (max, min) and significant differences between visit 1, 
baseline (V1) and visit 2, 6 months after therapy (V2) are calculated using Wilcoxon 
test (significance <0.05). N=22 patients. Abbreviations: PPD, probing pocket depth; 
CAL, Clinical Attachment level; BOP, bleeding on probing; DAS 28, disease activity 
score 28; ESR, Erythrocyte sedimentation rate  
V1 median  (IQR) V2 median (IQR) Sig two tailed 
p value 
PPD 3.15 (2.6, 5.9) 3.4 (0.8) 0.004 * 
CAL 3.42 (2.6, 5.9) 3.7 (1) 0.013* 
BOP 0.24 (0, 0.6) 0.23 (0.4) 0.14 
Das 28 5.27 (3, 7.1) 5.1 (2.9) 0.79 
ESR 26.5 (7, 87) 17 (32) 0.011* 
Tender 
joints 
13.5 (0, 25) 12 (16) 0.9 
Swollen 
joints 
1.5 (0, 12) 0.5 (2) 0.39 
CRP 3.9 (0.4, 38.6) 6.09 (0.16, 22.6) 0.98 
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  Effect of periodontal therapy in levels of antibody to citrullinated 
proteins  
A total of 80 serum samples from 40 RAPD patients collected in two different 
visits were analysed for quantification of antibodies against human citrullinated 
proteins. Serum was collected at baseline, on the screening visit (V1) and 6 
months later (V2).  For the longitudinal study, 20 of these patients were 
randomised to receive periodontal therapy and 22 patients only received hygiene 
instructions.   
 
In the treatment group, no clear effect of periodontal therapy on the antibody 
levels against citrullinated proteins was observed compared to the delayed group 
(Figure 3. 9-3.9). Although no significant difference was observed between V1 
and V2 antibody levels for any of the antigens, some trends could be observed.  
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Figure 3. 9 Longitudinal analysis of levels of antibodies to citrullinated and arginated 
Vimentin. n Treatment group=20; n Delayed group=22. A and b show the antibodies 
to citrullinated vimentin (C-Vim) in the two randomization group; c and d show the 
antibodies to the arginated form. V1 represents antibody levels in serum collected at 
baseline and V2 collected 6 months after. Data presented in Arbitrary units per ml 
(AU/ml) or, if no standards available, Optical Density units (ODs). Statistical test used 
was Wilcoxon matched pair test (significance p<0.05). Methods described in section 
2.2. 
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Figure 3. 10 Longitudinal analysis of levels of antibodies to citrullinated and arginated 
fibrinogen. n Treatment group=20; n Delayed group=22. A and b show the antibodies 
to citrullinated fibrinogen (C-Fib) in the two randomization group; c and d show the 
antibodies to the arginated form. V1 represents antibody levels in serum collected at 
baseline and V2 collected 6 months after. Data presented in Arbitrary units per ml 
(AU/ml) or, if no standards available, Optical Density units (ODs). Statistical test used 
was Wilcoxon matched pair test (significance p<0.05). Methods described in section 
2.2. 
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Figure 3. 11 Longitudinal analysis of levels of antibodies to human citrullinated and 
arginated tenascin. n Treatment group=20; n Delayed group=22. A and b show the 
antibodies to citrullinated tenascin (C-TNC5) in the two randomization group; c and d 
show the antibodies to the arginated form. V1 represents antibody levels in serum 
collected at baseline and V2 collected 6 months after. Data presented in Arbitrary 
units per ml (AU/ml) or, if no standards available, Optical Density units (ODs). 
Statistical test used was Wilcoxon matched pair test (significance p<0.05). Methods 
described in section 2.2. 
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Figure 3. 12 Longitudinal analysis of levels of antibodies to human citrullinated and 
arginated enolase 1. n Treatment group=20; n Delayed group=22. A and b show the 
antibodies to citrullinated enolase (CEP) in the two randomization group; c and d 
show the antibodies to the arginated form. V1 represents antibody levels in serum 
collected at baseline and V2 collected 6 months after. Data presented in Arbitrary 
units per ml (AU/ml) or, if no standards available, Optical Density units (ODs). 
Statistical test used was Wilcoxon matched pair test (significance p<0.05). Methods 
described in section 2.2. 
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Figure 3. 13 Longitudinal analysis of levels of antibodies to Cyclic Citrullinated 
Peptyde (CCP). n Treatment group=20; n Delayed group=22. A and b show the 
antibodies to CCP in the two randomization V1 represents antibody levels in serum 
collected at baseline and V2 collected 6 months after. Data presented in Arbitrary 
units per ml (AU/ml. Statistical test used was Wilcoxon matched pair test (significance 
p<0.05). Methods described in section 2.2. 
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 Subgroup analysis ACPA+/- 
ACPA status from the rheumatologic clinics was available from the patients that 
were eligible for the longitudinal study.  A comparison between the ACPA status 
taken from different hospitals previous to the enrolment in the study versus the 
anti-CCP test done in this study, revealed that the two tests gave different 
classifications in only 6 out of 42 of the patients. Being confident that the two 
results give the same results in more than 85% of the patients, a subgroup 
analysis stratified in ACPA status was performed to investigate the effect of 
periodontal therapy in the two groups. 32 patients were classified as ACPA+, 17 
from the delayed group and 15 from the immediate group. Although previous 
reported that ACPA+ patients that undergo periodontal treatment have a better 
immunological response, however, this was not reflected in our study (Figure 3. 
14).  
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Figure 3. 14 Antibody changes after periodontal treatment in ACPA positive patients. 
n=15. V1 represents antibody levels in serum collected at baseline and V2 collected 
6 months after. Data presented in Arbitrary units per ml (AU/ml. Statistical test used 
was Wilcoxon matched pair test (significance p<0.05). Methods described in section 
2.2. 
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3.4.  Correlation analysis 
The Spearman rank correlation analysis was performed to investigate the 
relationship between the ACPA results and the clinical (rheumatologic and 
periodontal) parameters. No significant (p<0.05) and strong (ρ>0.7) correlations 
were found between ACPA production and clinical parameters, but numerous 
weak significant correlations were found between the different ACPAs tested (anti 
CCP, CVim, CEP and CFib) and between anti-CCP and the periodontal (PPD 
and CAL) in all study population and between anti-CCP and rheumatological 
(ESR) parameters in all RA patients (Figure 3. 15) 
 
Additionally, correlation analysis of the changes in the antibodies after treatment 
was investigated, testing Spearman's correlation of the difference between 
clinical data and antibody levels at baseline and 6 months after periodontal 
treatment. While some significant correlations were found (p<0.05), none of these 
correlations were strong (ρ>0.7) (Figure 3. 16) 
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Figure 3. 15 Correlation analysis between serum CCP levels and clinical parameters 
in study population at baseline (n=123). Positive weak but significant (p<0.05) 
correlations were found between levels of CCP and PPD (a), CAL (b) and ESR (n=80) 
(c). Spearman’s correlation was tested.  
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Figure 3. 16 Correlation analysis of the changes before and after periodontal therapy 
in serum ACPAs levels and clinical parameters (n=20). Negative weak but significant 
(P<0.05) correlations were found between changes in CAL and C-Fib levels (a) and 
between C-Vim levles and BoP (b). Spearman’s correlation was tested. 
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3.5. Discussion 
 
The hypothesis of this study was that, in rheumatoid arthritis, patients with 
periodontitis have a higher level of antibodies to citrullinated proteins compared 
to those with healthy periodontium and that, after periodontal therapy, these 
antibody levels are reduced. Our results did not support this hypothesis.  
 
 Cross-sectional study results 
While other studies have investigated the ACPA reaction in RA through antibody 
levels to anti-CCP only, it is important to test individual ACPA fine specificities 
together with anti-CCP and peptide controls in RA (Montgomery, Venables et al. 
2013). To our knowledge, the study presented here analyses the widest range of 
antibodies to human and P. gingivalis -related peptides, in different patients 
groups with and without RA and periodontitis. Also it is the only study that 
investigates the effect of periodontal treatment in antibodies to this range of 
specific antigens.  
 
Severity of periodontitis did not seem to be associated with anti-CCP positive 
(anti-CCP antibodies > 98th percentile of health) RA as previously described 
(Dissick, Redman et al. 2010) as the percentage of moderate and severe 
periodontitis in the anti-CCP negative group was greater than that in the anti-CCP 
positive group (31% compared to 18%). These findings contradict the results from 
the pilot study of Dissik and collaborators. However, the number of anti-CCP 
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negative patients in the RA group was very low and the analysis used here did 
not correct for different group sizes, so the results of these comparisons may not 
be as reliable as the ones from larger studies. Also, in this chapter severity of 
periodontitis was defined using the described modified definition of Eke&Page 
(Chapter 2). Yet, other grouping factors could be use such as number or 
percentage of sites with PPD > 5mm, which could show different results.  
 
Our results show that the antibody levels in the RAPD group were similar 
compared to the periodontally healthy RA group for the antigens tested in the 
study. This is also supported by the lack of difference in antibody response 
between periodontally healthy patients and the moderate to severe periodontitis 
groups. Whilst there are more patients ACPA-positive in the RAPD group 
compared to the RA noPD group with antibodies against C-Fib and CTNC5, the 
results for anti-CEP and C-Vim show the opposite. This slight difference between 
the analytes could be explained through the differences in the association to the 
human leukocyte antigen-shared epitope (HLA-SE). The development of anti-
CEP and C-Vim antibodies are strongly associated with HLA-SE (Lundberg, 
Bengtsson et al. 2012),(Kokkonen, Brink et al. 2015), but not C-Fib and there is 
no evidence of the association with C-TNC5. When no genetic factors are 
associated with the presence of antibodies, the environmental factor would 
become a fundamental feature for the production of antibodies, which in this case 
would be the presence of periodontitis. This could explain why, in RA, a higher 
proportion of patients with antibodies against C-TNC5 and C-Fib in the 
periodontitis group is found but not with anti-CEP and C-Vim antibodies. 
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Although cross-reactivity of the different ACPAs specificities is being widely 
debated, a previous study demonstrated only limited cross-reactivity between the 
specificities investigated here (low cross-reactivity degree between C-Fib and 
CEP only) (Lundberg, Bengtsson et al. 2012). In our study, only 7 patients from 
all anti-CCP positive patients (n=68) expressed antibodies to all the other 
antigens indicating low overlapping. Also some of these anti-CCP positive 
patients were not positive for any of the citrullinated antigens studied (n=6), 
showing that there are still some citrullinated antigens that need to be 
investigated. There did not seem to be a clear relationship with periodontal status 
as patients with and without periodontitis were equally distributed.  
 
Although the number of anti-CCP negative RA patients in our study is low (n=18), 
4 of the anti-CCP negative patients expressed antibodies against at least one of 
the other citrullinated peptides (one patient anti-CCP negative was positive for 
anti-C-Fib, C-Vim and C-TNC5), indicating that anti-CCP may fail to pick 
antibodies to citrullinated peptides and specific antigens should be investigated.  
 
In systemically healthy patients no association was found between ACPA 
production and chronic periodontitis, demonstrating similar findings to Hendler 
and collaborators (Hendler, Mulli et al. 2010). However this contradicts the results 
shown in the study from De Pablo and collaborators, which found a significant 
increase of antibody production to citrullinated and uncitrullinated antigens in 
periodontitis patients compared to controls (de Pablo, Dietrich et al. 2014). Also 
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Lappin and collaborators found significantly higher levels of CEP and anti-CCP 
in patients with periodontitis compared to controls (Lappin, Apatzidou et al. 2013). 
This difference might be due differences to the number of patients studied as, in 
the de Pablo study there were almost 200 patients enrolled, compared to less 
than 40 patients in the two studies that did not find the association.  
 
The lack of strong and significant correlations between antibody levels and 
clinical parameters contradicts previous studies (Fisher, Plant et al. 2011, 
Potikuri, Dannana et al. 2012, Lee, Choi et al. 2015). In the study conducted by 
Lee and colaborators, results show an association between antibodies to enolase 
and periodontal parameters. However, the correlations found in this paper and 
those found by Potikuri and colleagues, are also weak, with r values ranging 
between 0.05 and 0.18.  
 
Although the level of antibodies to uncitrullinated proteins are lower than the 
levels of antibodies to the citrullinated forms, our study also showed higher levels 
of anti-uncitrullinated peptides in the RA groups compared to the systemically 
healthy controls. Following the theory described by de Pablo and collaborators 
(de Pablo, Dietrich et al. 2014), this might be due to a loss of tolerance to un-
citrullinated proteins in RA due to periodontitis. However, as the amount of 
peptide available for this experiment was very limited, it was not possible to prove 
that the lack of antibody positivity to the uncitrullinated peptides was not due to a 
methodology problem such as poor peptide binding so this remains a possible 
explanation for the results found. 
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 Longitudinal study results 
Our hypothesis, following the theory of extra-articular citrullination in periodontitis 
triggering and exacerbating RA, was that periodontal treatment could bring down 
levels of citrullination and therefore, the production of ACPAs. This is supported 
by previous research that found that supragingival cleaning decreased levels of 
citrulline in RA patients (Okada, Kobayashi et al. 2013). However, our results did 
not support our hypothesis, as no changes were found in the ACPA production 
after periodontal therapy in any of the peptides tested.  
 
Another recent study published by Shimada and collaborators failed to find a 
reduction in anti-CCP levels and anti PPAD in RA 2 months after periodontal 
therapy (Shimada, Kobayashi et al. 2016). These negative results contradict 
those from Okada et al (Okada, Kobayashi et al. 2013), who found a significant 
decrease in antibodies to P. gingivalis in RA in the treatment group compared to 
control. These opposing results could be explained through the different 
methodology, as the study from Okada used a mild definition of periodontitis and 
provided supragingival scaling, while the paper from Shamada and our paper 
includes moderate to severe periodontitis patients and provided subgingival 
periodontal therapy. While it seems that in mild cases of periodontitis a simple 
supragingival scaling might be enough to reduce the level of P. gingivalis and 
therefore reduce citrullination, in periodontitis it might be more complex to 
demonstrate this effect. 
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 Limitations of the study 
Although our hypothesis was contradicted by the results, there are limitations in 
our study that could explain such negative results. Due to dropouts and difficulties 
in sample collection, only 20 patients from each treatment arm were included for 
the longitudinal study, while the study from Shimada (also showing negative 
results) includes 24 patients. This small sample size makes it very challenging to 
find any statistical significance when comparing the groups. 
 
Also, during the duration of the study, many of the subjects suffered changes in 
the medications or flair ups of RA. These fluctuations might be causing the abrupt 
changes observed in the antibody levels of some patients and diminishing the 
effect of periodontal therapy. However, these variations are very difficult to control 
in this type of study and due to the small sample size, doing regression or 
subgrouping was not appropriate. 
 
Moreover, although we see a significant reduction of the periodontal parameters 
after periodontal therapy, there are only 9 patients that achieve mild periodontitis 
or health, while the majority (65%), even with a significant reduction of bleeding 
and pocket depth, would still be classified as periodontitis patients. This might 
reflect the need of a more aggressive treatment and adjunctive treatment in the 
follow up visits, to ensure that all patients that fell in the treatment group finished 
the study with periodontal health.  
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Furthermore, 6 months might not be enough time to observe an the antibody 
response even when the stimulus has been reduced. At the beginning of an 
immune response, plasma cells only live for a few day or weeks. As B cells 
mature into plasma cells, they can survive for months or years, prolonging the 
secretion of antibodies (Bernasconi, Traggiai et al. 2002). For this reason, a 
longer and larger study, with patients progressing from moderate-severe 
periodontitis to health, might be needed to observe a possible change in the 
antibody response after periodontal treatment  
 
On the other hand, even considering the limitations of our study, periodontal 
therapy might not have an effect on antibody levels in RA as it might produce an 
effect too small to show a change in the B cell behaviour and antibody production. 
While in our study, there was a significant reduction of DAS28 after periodontal 
therapy, the mean change dropped from 4.6 to 4.06, clinically this is a very small 
difference. Although the benefits of maintaining oral health are clear, the effect of 
periodontal therapy in RA parameters have not yet been elucidated and it might 
be that considering the fluctuating and exacerbated auto-immune response 
observed in RA, once the autoimmune response has been settled over years of 
exposure to the triggering factors, eliminating periodontitis might not be enough 
for the immune system to reverse to a healthy status. As memory B cells persist 
years or even for a lifetime, once they have been activated involving a particular 
antigen (which could be citrullinated proteins by P. gingivalis) in a primary 
response, the continuous citrullination found in rheumatic joints will activate B 
cells that respond quickly upon second exposures to the antigen. Following this 
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hypothesis, removing Porphyromonas gingivalis with periodontal therapy, 
although beneficial for the oral health and decreasing the inflammation, might not 
change the antibody response in RA.  
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4. RESULTS - CIRCULATING 
ANTIBODIES TO PERIODONTAL 
BACTERIA IN RA AND 
PERIODONTITIS 
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4.1. Introduction 
The hypothesis of the study presented in this chapter was that in rheumatoid 
arthritis there is an elevated production of serum antibodies to periodontal 
bacteria compared to controls and that, in RA patients with periodontitis 
undergoing periodontal therapy, the level of these antibodies could be reduced. 
This is important, as periodontal bacteria have been described to be a key driver 
of the autoimmune response that originates and perpetuates the state of chronic 
inflammation in RA (Scher, Bretz et al. 2014).   
 
The aims were:  
 
1) To compare the level of serum antibodies to outer-membrane antigens (OMAs) 
from periodontal bacteria and P. gingivalis -related antigens in groups of patients 
diagnosed with RA and the appropriate control groups with and without 
periodontitis.  
 
2) To analyse the effect of periodontal therapy on the level of these antibodies in 
RA patients with periodontits compared to a control group that did not receive 
such therapy.  
 
This chapter presents the results from serum antibody ELISAs to OMAs from 
Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum 
conducted at the University of Nebraska Medical Center (methods described in 
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section 2.5) through a collaboration with Dr Ted Mikuls, and the results from 
serum antibody ELISAs to four P. gingivalis related proteins: Peptidyl Arginine 
Deiminase (PPAD) and its immunodominant citrullinated (CPP3) and arginated 
(RPP3) epitopes, gingipain (RgpB) and P. gingivalis enolase (ELISA methods are 
described in detail in chapter 2.2). P. gingivalis -antigens were provided by Prof 
Patrick Venables (Oxford University). 
 
4.2. Antibodies to PG-related antigens 
 
  Patient background and clinical results 
 
For this project, sera collected from 124 patients from the OPERA and INSPIRED 
cohorts (recruitment and study population explained in chapter 2) were analysed, 
of which 87 patients were diagnosed with RA and 37 patients were systemically 
healthy. Clinical data from the different patient groups are described in section 
3.2 (Table 3.1).  
 
 Cross-sectional group comparison 
 
In the RAPD group, antibody levels against all the PG-related peptides were 
higher than in the RA noPD group, although these differences were not 
statistically significant (Figure 4. 1). Interestingly, the RA group with healthy 
periodontium also showed higher levels of antibodies against PPAD close to 
significance (p=0.06), RPP3 and CPP3, compared to systemically healthy 
patients with PD. This suggests that, in RA, PPAD and its epitopes, could be 
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recognized as an antigen in a similar way to human ACPAs even with healthy 
periodontium. 
 
Previously, de Pablo et. al represented similar data as the percentage of patients 
that have ACPA levels over the 98th percentile of healthy controls (antibody 
positivity). The same analysis was applied here resulting in non-significant higher 
percentage of patients in the RA (compared to systemically healthy) groups, for 
the antibody response against PPAD, CPP3, RPP3 and PG Enolase, even in the 
periodontally healthy RA group (Figure 4. 2)  
 
Although the antibody reaction to most individual PG-antigens such as PPAD, 
CPP3 and RPP3 was non-significantly higher in both RA groups, with or without 
periodontitis, this was not observed in the case of antibodies to RgpB, which were 
elevated in the periodontitis groups, both RA and systemically healthy, compared 
to the periodontally healthy groups. This shows that in RA, PG antigens related 
to PPAD act as antigen but not RgpB, which only acts as antigen in periodontitis 
patients. 
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Figure 4. 1 Level of antibodies in the different study groups: Rheumatoid arthritis with 
healthy periodontium (RA noPD) (n=24); baseline data from RA with Periodontitis 
(RAPD) (n=50); systemically healthy with periodontitis (NoRA PD) (n=17); 
systemically and periodontally healthy controls (NoRA NoPD) (n=18). ). Data 
represented in scatter plot graphs and colored lines show the group mean and SEM. 
Each individual graph represents the results for each peptide: a. Porphyromonas 
gingivalis peptidylarginine deiminase  (PPAD); b. citrullinated and c. arginated 
epitope from PPAD (CPP3/RPP3); d. enolase from PG; e.  P. gingivalis virulence 
factor arginine gingipainB (RgpB). Significant differences between groups were 
analysed using the Kruskal-Wallis test and Tukey's comparison (singinficant if 
p<0.05, + symbol represents an outlier). Methods described in section 2.2. 
  
 135 | P a g e  
 
 
 
Figure 4. 2 Percentage of patients with antibody levels above the 98th percentile of 
healthy controls. Antibody levels tested against: Whole Peptydil-arginine deiminase 
(PPAD), CPP3 (citrullinated peptide3 from PPAD), RPP3 (arginated peptide 3 from 
PPAD), PG-enolase and arginine-gingipain B (RgpB). Rheumatoid arthritis with 
healthy periodontium (RA noPD) (n=24); baseline data from RA with Periodontitis 
(RAPD) (n=50); systemically healthy with periodontitis (NoRA PD) (n=17); 
systemically and periodontally healthy controls (NoRA NoPD) (n=18).Methods 
described in section 2.2. Significance defined as p<0.05, test used Pearsons Chi-
squared test. Abbreviations: ACPA, anti-citrullinated protein antibody; RA, 
rheumatoid arthritits; PD, periodontitis 
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 Subgroup analysis  
 
4.2.3.1. RA, periodontitis and smoking analysis 
The results from the analysis based on systemic disease (RA vs noRA) showed 
that RA patients had significantly higher levels of antibodies to PPAD (p=0.0013), 
PG-enolase (p=0.0031) and RPP3 (p=0.001). While a trend towards an increased 
antibody reaction against anti-PG antigens is seen with increasing severity of 
periodontal disease (Figure 4. 3), only anti-PG enolase and PPAD antibodies 
were significantly increased in the moderate/severe periodontitis patients 
compared to controls (PG Eno p=0.002; PPAD p=0.001). However, no significant 
differences were found in the antibody levels to PG-antigens between smokers, 
former smokers or patients that never smoked. This was an interesting finding as 
it was previously shown that in pre-RA patients, anti-RgpB and anti-PPAD 
antibodies were higher in smokers (Fisher, Cartwright et al. 2015) although 
smoking has been shown to reduce concentration of IgG antibodies in general 
due to its depletive effect on the immune system (Barbour, Nakashima et al. 
1997) (Kinane and Chestnutt 2000).  
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Figure 4. 3 Antibodies to PG antigens in RA patients compared to controls. PG-
antigens investigated: a. citrullinated epitope 3; b. arginated epitope 3; c. gingipain 
B; d. enolase from PG; e. peptydil arginine deimanase from PG. n RA= 88, n noRA= 
36. Data represented as scatter plots and lines represent the mean and SEM. 
Significance represented as * if p<0.05, ** if p<0.01. Statistical test used: Mann-
Whitney test.  ELISA methods described in section 2.2. Abbreviations: PG, 
Porphyromonas gingivalis. 
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Figure 4. 4 Antibodies to PG antigens according to periodontal status: no periodontitis 
(n noPD=42), mild periodontitis (n mild PD= 15), moderate and severe periodontitis 
(n mod/sev PD=67) PG-antigens investigated: a. citrullinated epitope 3; b. arginated 
epitope 3; c. gingipain B; d. enolase from PG; e. peptydil arginine deimanase from 
PG. Data represented as scatter plots and lines represent the mean and SEM. 
Significance represented as * if p<0.05, ** if p<0.01. Statistical test used: Kruskal 
Wallis with Dunn's multiple comparison.  ELISA methods described in section 2.2. 
Abbreviations: PD, periodontitis; PG, Porphyromonas gingivalis. 
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Figure 4. 5 Antibodies to PG antigens according to smoking status: smokers (n=18), 
former smokers (n PD=33), never smoked (n =67) PG-antigens investigated: a. 
citrullinated epitope 3; b. arginated epitope 3; c. gingipain B; d. enolase from PG; e. 
peptydil arginine deimanase from PG. Data represented as scatter plots and lines 
represent the mean and SEM. Significance represented as * if p<0.05, ** if p<0.01. 
Statistical test used: Kruskal Wallis with Dunn's multiple comparison.  ELISA methods 
described in section 2.2. Abbreviations: PG, Porphyromonas gingivalis 
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4.2.3.2. ACPA+ and ACPA- analysis 
  
There is data that suggest that ACPA positive and negative RA patients respond 
differently to therapy (van Dongen, van Aken et al. 2007) and have distinct 
pathophysiology and risk factors (Daha and Toes 2011). For that reason, a 
subgroup analysis stratified by ACPA status was used, showing that anti-CCP 
negative patients with healthy periodontium did not have antibodies to PPAD, 
CPP3, RPP3 or PG-Enolase (Figure 4. 6). In contrast, between 10 and 20% of 
the anti-CCP+ patients with healthy periodontium had antibodies to PPAD, CPP3 
and RPP3.  
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Figure 4. 6 Percentage of patients with antibody levels over the 98th percentile of 
healthy controls, stratified by ACPA positive and negative. Antibody levels tested 
against: Whole Peptydil-arginine deiminase (PPAD), CPP3 (citrullinated peptide3 
from PPAD), RPP3 (arginated peptide 3 from PPAD), PG-enolase and arginine-
gingipain B (RgpB). Data represented in column graph, showing mean group and 
SEM. Rheumatoid arthritis with healthy periodontium (RA noPD) (n=24); baseline 
data from RA with Periodontitis (RAPD) (n=50); systemically healthy with periodontitis 
(NoRA PD) (n=17); systemically and periodontally healthy controls (NoRA NoPD) 
(n=18).Methods described in section 2.2. No significant differences were found 
between the RAPD and RA groups in either ACPA positive or negative stratifications. 
Significance defined as p<0.05, test used Pearsons Chi-squared test. Abbreviations: 
ACPA, anti-citrullinated protein antibody; RA, rheumatoid arthritits; PD, periodontitis 
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4.3. Antibodies to OMA from Porphyromoas gingivalis, Prevotella 
intermedia, Fusobacteria nucleatum  
 
Following the methods previously described by Mikuls and collaborators (Mikuls, 
Payne et al. 2014), antibodies to outer membrane antigens (OMA) from 
periodontal bacteria were semi-quantified (methods explained in section 1.2). 
The aim of this experiment to measure antibodies against PG, and antibodies to 
FN and PI were also analysed as both bacteria are closely associated with PG in 
the deep pocket biofilm (Holt and Ebersole 2005).  
 
 Patient background 
 
A total of 239 serum samples from 197 patients were analysed in this study from 
the OPERA and INSPIRED trials (described chapter 2.1, Figure 2.1). From 142 
RA patients, 30 were diagnosed with RA and healthy periodontium (RA noPD), 
87 were diagnosed with RA and moderate/severe periodontitis (RAPD) and those 
with mild periodontitis were excluded for the baseline comparison (n=26) but the 
patients are included in Figure 4.10 for the periodontal status comparison. From 
a total of 28 patients systemically healthy, 18 were classified as periodontitis 
patients (NoRA PD) and 19 classified as periodontally healthy controls (NoRA 
noPD). 
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This subgroup of OPERA patients was selected from patients whose samples 
were used for the antibody analysis described in chapter 3 and for the microbiome 
analysis is described in chapter 5. This enabled the comparison between these 
results and the rest of the antibody levels and also the correlation between 
antibodies to membrane proteins to these 3 bacteria in sera and the relative 
abundance of these bacteria in subgingival plaque found with 16S analysis. 
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Table 4. 1 Clinical characteristics at baseline of study population groups (n=155). 
Ordinal data is represented as mean and IQR. Nominal data is represented as 
percentages.   
 RAPD 
(n=87) 
RAnoPD  
(n=30) 
noRAPD  
(n=18) 
NoRA NoPD 
(n=20) 
Female 
proportion 
71.3% 73.3% 55.6% 63% 
Ethnicity 
-%Asian 
-%White 
-%Black 
 
13.8% 
40% 
4.6% 
 
4% 
90% 
0% 
 
5.6% 
78% 
11% 
 
11% 
89% 
0 
Smoker 
-%current 
-%former 
-% never 
 
21.8% 
32.2% 
46% 
 
10% 
26.6% 
63.3% 
 
5.6% 
55.6% 
33.3% 
 
5% 
11% 
84% 
Alcohol 
-%Never 
-%1-4 
times/month 
-%1-4 
times/week 
-% >4 times/week 
 
37% 
56% 
3% 
4% 
 
 
23% 
46% 
20% 
10% 
 
11% 
16% 
44% 
16.7% 
 
15% 
65% 
15% 
5% 
Weight 74.4  77.35 (30.7) 82.6 (27) 76.42(24) 
Age 57 (16) 61.5 (17) 48(8.5) 37(15) 
PPD (median, 
IQR) 
3.01 
(0.74) 
2.26 (0.38) 3.17(1) 1.56(0.3) 
BoP 0.24 
(0.07) 
0.24 (0.09) 0.39(0.25) 0.02(0.11) 
CAL 3.29 
(1.09) 
2.24 (0.8) 3.9(1.9) 1.7(0.28) 
DAS28 3.49 (3.8) 3.06 (2.31) - - 
ESR 11 (29) 8 (24) - - 
VAS 55 (49) 41 (39) - - 
Tender joints 7 (15) 4.5 (10) - - 
Swollen joints 1 (2) 0.1 (2) - - 
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  Antibody levels to bacterial proteins group comparison 
 
No significant differences were found in antibody levels across the 4 groups, for 
anti-OMAs from PG and PI and significantly higher levels of anti-FN were found 
in RAPD compared to RAnoPD (Figure 4. 7). 
 
Antibodies to PG were elevated in the two periodontitis groups (RAPD and NoRA 
PD) and the highest levels were found in the NoRAPD with no significant 
differences to the RAPD group (Figure 4. 7.a). However, no significant 
differences were found among the study groups. 
 
No significant differences were found in the anti-PI levels among the study groups 
(Figure 4. 7.b). Although the patients with the highest levels belonged to the RA 
groups, the two systemically healthy groups had slightly elevated mean 
antibodies. 
 
Patients with RA and PD had the highest levels of antibodies against FN 
compared to the rest of the groups and the difference between the RAPD and 
RAnoPD was significant (Kruskal Wallis with Dunn’s test, p adjusted=0.014). 
However, anti-FN was not elevated in the PD group systemically healthy 
compared to periodontally healthy (Figure 4. 7.c).  
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Combining the two groups of periodontitis patients and the two groups 
periodontally healthy, significantly higher levels of anti-PG were found to be 
associated with periodontitis (Mann-Whitney test, p=0.005), and low levels were 
found in the periodontally healthy groups (Figure 4. 8). However, similar levels 
were found when grouping patients by systemic condition. This represents an 
antibody reaction to PG associated to periodontitis patients and not related to RA.  
 
Level of antibodies against PI were similar in all the groups, independently of 
periodontal status and slightly elevated in the RA group compared to systemically 
healthy (Mann-Whitney test, p=0.049) . Antibody levels against FN were elevated 
in the periodontitis group compared to periodontally healthy (Mann-Whitney test, 
p=0.014) but not in the RA group compared to the systemically healthy, 
suggesting that anti-FN is associated to periodontitis and not to RA.  
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Figure 4. 7 Levels of serum antibodies to outer-membrane antigens (OMA) from from 
PG, FN and PI in the different study groups. Data represented in ug/ml as scatter plot 
graphs and colored lines show the group mean and SEM. Each individual graph 
represents the results for each OMA: a. Porphyromoas gingivalis b., Prevotella 
intermedia, c. Fusobacteria nucleatum; Significant differences between groups were 
analysed using the Kruskal-Wallis test and Tukey's comparison (singinficant if 
p<0.05, + symbol represents an outlier). Methods described in section 2.2. 
Abreviations: PG, Porphyromoas gingivalis; PI, Prevotella intermedia; FN, 
Fusobacteria nucleatum; RA, rheumatoid arthritis; PD, periodontitis. 
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Figure 4. 8 Antibodies to OMAs from PG, FN and PI comparison according to periodontal or 
RA status. Mann-Whitney test, significance p<0.05. N RA=143; n noRA=37. Data represented 
in ug/ml as scatter plot graphs and colored lines show the group mean and SEM. Each 
individual graph represents the results for each OMA: a. Porphyromoas gingivalis b., 
Prevotella intermedia, c. Fusobacteria nucleatum; Significant differences between groups 
were analysed using the Man-Whitney’s test (singinficant if p<0.05, + symbol represents an 
outlier). Methods described in section 2.3. Abreviations: PG, Porphyromoas gingivalis; PI, 
Prevotella intermedia; FN, Fusobacteria nucleatum; RA, rheumatoid arthritis; PD, 
periodontitis.  
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  Antibody levels comparison subgroup analysis 
 
Further analysis was conducted to elucidate differences in the antibody repertoire 
against bacterial proteins depending on the degrees of periodontitis, from mild to 
severe, in both RA and noRA groups. Results showed a high level of antibodies 
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to PI in the three periodontitis groups (
 
Figure 4. 11) also high in the periodontally healthy groups in the previous section. 
Much lower levels of antibodies are shown against FN, with no differences 
according to degrees of periodontitis. However, a significant increase of 
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antibodies against PG was observed as the severity of PD increases (ANOVA 
test p=0.048). However, in the subgroup analysis according to systemic condition 
(RA vs no RA) or smoking status, no differences were found in the antibody levels 
to PG, FN or PI among the different groups (Figure 4. 9) 
ACPA positivity is independently associated to periodontitis and to antibodies to 
PG (Mikuls, Payne et al. 2014) and anti-PG levels are higher in ACPA-positive 
patients (Hitchon, Chandad et al. 2010). However, in our study, no differences 
were found in antibodies to periodontal bacteria between ACPA positive and 
negative patients (i.e. anti-CCP levels>98th percentile of health) in RA. Also an 
elevated antibody response to periodontal bacteria has been described to be 
associated with smoking status (Fisher, Cartwright et al. 2015), but this was not 
observed in our study for any of the bacterial OMA studied (Figure 4. 11). 
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Figure 4. 9 Effect of periodontitis and systemic condition in levels of antibodies to PG, 
PI and FN in RA and noRA periodontitis patients. Kruskal-Wallis analysis was tested 
for the 3 bacteria individually with Dunn’s multiple comparison (significance: p<0.05). 
Bar charts represent the mean with standard deviation of the mean. Abreviations: PI, 
Prevotella intermedia; PG, Porphyromonas gingivalis; FN, Fusobaterium nucleatum; 
PD, chronic periodontitis; RA, rheumatoid arthritis. 
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Figure 4. 10 Effect of severity of periodontitis in levels of antibodies to PG, PI and FN 
in RA and noRA periodontitis patients. Kruskal-Wallis analysis was tested for the 3 
bacteria individually with Dunn’s multiple comparison (significance: p<0.05). Bar 
charts represent the mean with standard deviation of the mean. Abreviations: PI, 
Prevotella intermedia; PG, Porphyromonas gingivalis; FN, Fusobaterium nucleatum; 
PD, chronic periodontitis. 
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Figure 4. 11 Subgroup analysis of antibody levels according to smoking status and 
ACPA. N ACPA+= 68; n ACPA - = 19 ; n Smoker=29; n former smoker= 55, n never 
smoked=96. Statistical tests: Kruskal-Wallis with Dunn’s test for multiple comparison 
and Mann-Whitney test for two group (significance: p<0.05). Abreviations: PI, 
Prevotella intermedia; PG, Porphyromonas gingivalis; FN, Fusobaterium nucleatum; 
PD, chronic periodontitis. 
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4.4. Longitudinal analysis 
 
  Patient background and effect of periodontal therapy on clinical 
characteristics 
 
The effect of periodontal therapy on clinical parameters and clinical 
characteristics of the immediate group compared to the delayed group are 
explained in Chapter 3 and the same study population was used in this chapter 
(n=42). 
 Effect of periodontal therapy on PG-related antibody levels  
 
The longitudinal analysis of the antibody levels against PG-antigens showed no 
clear effect of periodontal therapy and none of the antibodies evaluated showed 
a statistically significant change between levels at baseline (V1) and 6 months 
after (V2) in the treatment or delayed group (Wilcoxon paired test, significance 
p<0.05). The experiment that demonstrated the closest p value to significance 
was the change in antibody response to PPAD in the treatment group (p=0.06), 
which showed a decrease in the antibody levels after periodontal therapy. While 
there was a slight reduction of antibody levels to RgpB and PPAD (Figure 4. 12), 
it is difficult to see a pattern. On the contrary of the trend observed for anti-human 
citrullinated proteins (chapter 3), there was no increase of antibody levels after 
periodontal therapy for any of the PG-related antigens studied, but there was no 
clear effect on the CPP/RPP3 and PG-enolase antibody levels. While a majority 
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of patients showed a small or no variation of antibodies to these PG-antigens 
after 6 months in both groups, a few patients experience big variations towards 
both increase and decrease. Subgroup analysis stratifying in ACPA status did not 
show a reduction in antibodies to PG-related antigens after periodontal therapy.  
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Figure 4. 12 Longitudinal analysis of antibody levels to PG-related antigens; a. 
and b. arginine gingipain; b. and c. PG-enolase; d and e. PG-peptidyl arginine 
deiminase. n Treatment group=20; n Delayed group=22. Graphs represent V1 
represents antibody levels in serum collected at baseline and V2 collected 6 months 
after treatment in the immediate group and hygiene instructions in the delayed group. 
Statistical test used was Wilcoxon matched pair test (significance “*” p<0.05). 
Statistical test used was Wilcoxon matched pair test (significance p<0.05). Methods 
described in section 2.2. 
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Figure 4. 13 Longitudinal analysis of antibody levels to citrullinated (a. and b.) and 
arginated (c. and d.) peptide from PPAD. n Treatment group=20; n Delayed 
group=22. Graphs represent V1 represents antibody levels in serum collected at 
baseline and V2 collected 6 months after treatment in the immediate group and 
hygiene instructions in the delayed group. Statistical test used was Wilcoxon matched 
pair test (significance “*” p<0.05). Methods described in section 2.2. 
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Figure 4. 14 Effect of periodontal treatment in antibody levels to PG related antigens 
in ACPA positive patients. N=15. V1 represents antibody levels in serum collected at 
baseline and V2 collected 6 months after treatment in the immediate group. Statistical 
test used was Wilcoxon matched pair test (significance p<0.05). Methods described 
in section 2.2. 
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  Effect of periodontal therapy in OMAs antibodies 
Periodontal therapy led to a reduction of antibodies to OMAs (Figure 4. 15) that 
was significant in the anti-FN levels (mean -14.92, p=0.026) and not significant in 
anti-PI (mean -4.52, p=0.9) and PG (mean -85, p=0.25). 
 
However, although no significance changes were found in the anti-PG antibodies, 
it can be observed that while the majority of patients had antibody levels close to 
zero, the patients with higher antibody reaction all underwent a reduction of 
antibodies after periodontal therapy that is not observed in the delayed group 
(Figure 4. 15. a).  This pattern is not apparent in the antibody levels against PI 
and against FN. Although the last case showed significant changes, the changes 
seem rather small for the majority of patients (Figure 4. 15.e and f). 
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Figure 4. 15 Changes in antibodies to outer membrane antigens (OMA) from 
periodontal bacteria. Graphs represent changes in antibody levels (ug/ml) to OMAs 
from Porphyromonas gingivalis (PG), Prevotella intermedia (PI) and Fusobacterium 
nucleatum (FN)n Treatment group=20; n Delayed group=22. V1 represents antibody 
levels in serum collected at baseline and V2 collected 6 months after treatment in the 
immediate group and hygiene instructions in the delayed group. Statistical test used 
was Wilcoxon matched pair test (significance “*” p<0.05). Methods described in 
section 2.3. 
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4.5. Correlation analysis 
  Clinical parameters 
Periodontal and RA parameters were strongly and significantly correlated. 
Probing depth and CAL were significantly correlated with DAS28, ESR, number 
of swollen joints, number of tender joints and visual analogue scale related to RA 
activity (Figure 4. 16). 
 
Correlation analysis on the changes between V1 and V2 was performed to 
investigate weather there is a correlation between the reduction of periodontal 
and rheumatological parameters and the changes in antibody production. This 
analysis showed a positive correlation between BoP and antibody response to 
PPAD (p=0.009, spearman’s correlation=0.42) and negative correlation with 
antibodies to C-TNC5 (p=0.008, spearman’s correlation=0.439). Although, at 
baseline, strong correlations were found between RA parameters and periodontal 
parameters, no correlation was found between changes on these parameters. 
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Figure 4. 16 Correlation analysis between periodontal and RA clinical parameters. 
Spearman’s correlation (significance p<0.05). Abbreviations: CAL, clinical 
attachment loss; DAS28, disease activity score of 28 joints; ESR, erythrocyte 
sedimentation rate. 
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 Correlation analysis of antibodies to bacterial proteins and 
antibodies to citrullinated proteins  
Weak significant correlations were found between anti-OMAs to PG antibodies to 
citrullinated proteins. Antibody levels against PG were positively correlated with 
antibodies to C-TNC5 (R=0.287, p=0.002), CCP (R=0.215, p=0.023). Anti-OMAs 
to FN and PI were not correlated with any of the antibodies to citrullinated or 
arginated peptides tested. As expected, Anti-PG positively correlated with anti-
PPAD (R=0.196, p=0.032) and anti-RgpB (R=0.359, p<0.001). 
 
From the correlation analysis between the anti-OMAs to the 3 periodontal 
bacteria, only PI and PG significantly correlated (r=0.2, p=0.02) although antibody 
levels to PI were negatively correlated to PPAD (R=-0.208, p=0.023). Antibody 
levels to FN were positively correlated to PG-eno (R=0.420, p<0.001) and PPAD 
(R=0.302, p=0.001). 
 
 Correlation between antibodies to periodontal bacteria and clinical 
parameters 
 
Antibodies to OMA from PG were significantly and positively correlated to 
periodontal parameters such as cumulative pocket depth (R=0.288, p=0.002), 
bleeding on probing (R=0.217, R=0.019), and CAL (0.32, p<0.001) (Figure 4. 17). 
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Antibodies to FN were weakly but significantly positively correlated to some 
periodontitis parameters, such as pocket depth (R=0.288, p=0.002) and bleeding 
on probing (R=0.193, p=0.039) and also some of the RA parameters, such as 
DAS 28 (R=0.237, p=0.01) and ESR (0.239, p=0.01) (Figure 4.16). However, 
anti-PI was weakly negatively correlated to all the DAS28 (R=-0.91, p=0.034) and 
the parameters used for the DAS calculation and even age (R=-0.394, p<0.001). 
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Figure 4. 17 Correlation analysis between OMA antibodies to PG, FN and PI (AU/ml), 
and clinical parameters. Test: spearman's correlation (significance: p<0.05). 
Abbreviations: PG, Porphyromonas gingivalis; PI, Prevotella intermedia; FN, 
Fusobacterium nucleatum. PPD, probing pocket depth; CAL, clinical attachment loss; 
DAS28, disease activity score of 28 joints; ESR, erythrocyte sedimentation rate.  
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 Correlation between serum antibodies to PI, PG and FN and their 
relative abundance in subgingival plaque 
The relative abundance of these 3 bacteria (Porphyromonas gingivalis, Prevotella 
intermedia, Fusobacteria nucleatum) investigated with 16s rRNA methods 
(section 2) showed no significant change after periodontal therapy in the 
immediate group. While PG and FN were non-significantly reduced, PI was 
increased (Table 4. 2). However, this did not necessarily reflect the amount of 
bacteria present in the mouth of the patients, as after periodontal therapy, it has 
been described that there is a profound reduction of counts of both supra and 
sub-gingival bacteria (Ximénez‐Fyvie, Haffajee et al. 2000). As plaque score was 
not recorded in this study, the plaque reduction as a result of periodontal therapy 
cannot be confirmed and only the relative abundance could be analysed, showing 
no significant differences in the relative abundance of PI, PG or FN after 
periodontal therapy. 
 
Spearman’s correlation analysis was performed between the levels of antibody 
to membrane proteins from PG, PN and FN in serum and the relative abundance 
of these bacteria in subgingival plaque (Figure 4. 18). This analysis was 
performed in the data from all patients that had both types of samples analysed 
(N=148), from the 4 baseline groups (RAPD, RA noPD, NoRA PD, NoRA noPD). 
Levels of anti-PG antibodies correlated with the relative abundance of PG, FN 
and PI (p<0.05). The most significant and strongest correlation found was 
 168 | P a g e  
 
between anti-PG antibodies and relative abundance of PG (R=0.33, p<0.0001). 
However, no correlation was found between antibodies to the other 2 bacteria 
and their corresponding relative abundance. 
 
Results showed that levels of the antibody against proteins from the 3 bacteria 
are significantly and positively correlated with each other, however, these 
correlations were weak (r<0.4). 
 
 
Table 4. 2 Results of significance test between relative abundance of PG, PI,FN after 
periodontal therapy (Immediate group) after 6 months. Test: Wilcoxon rank test for 
related samples. 
 N Mean difference of relative 
abundance (baseline and 6 
months) 
P value 
(paired T-
Test) 
Prevotella 
intermedia 
18 0.005 0.91 
Porphyromonas 
gingivalis 
18 -0.007 0.27 
Fusobacterium 
nucleatum 
18 -0.024 0.22 
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Figure 4. 18 Correlation analysis between serum antibodies to OMA antibodies to 
PG, FN and PI (AU/ml), and their relative abundance in subgingival plaque. Test: 
spearman's correlation (significance: p<0.05). N=148. Abbreviations: PG, 
Porphyromonas gingivalis; PI, Prevotella intermedia; FN, Fusobacterium nucleatum; 
N, number of patients investigated. 
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 Correlation between the changes produced after periodontal 
treatment  
Spearman's correlation analysis was performed to investigate whether the 
changes in antibody response to periodontal bacteria after periodontal treatment 
were associated to the changes on the relative abundance to these bacteria. The 
non-significant reduction in relative abundance of PG and FN after periodontal 
therapy was positively correlated in the immediate group (R= 0.613, p=0.009) 
and also in the delayed group data. Changes in antibody levels to PG were also 
correlated to the relative abundance of FN in the immediate group (R=0.613, 
p=0.009) and PI (R=0.458, p=0.049) and antibodies to PPAD and anti-PG OMAs 
were correlated (R=0.672, p=0.003). 
 
In the delayed group the changes in antibodies to PG and anti-FN were 
significantly correlated (R=0.68, p<0.001) but the significant correlation between 
the change in relative abundance of FN and PI (R=0.53, p=0.012) in the 
immediate group did not appear in the delayed group.  
 
4.6. Overlap of antibody reactivity 
 
In RA, clustering of antibodies has been previously studied using a heatmap to 
compare pattern of autoantibody reactivities (Wegner, Wait et al. 2010). In our 
study, no clear patterns were observed in the antibody reactivity to PG-related 
antigens as a small group of patients were positive for the antibodies studied 
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(>95th percentile of healthy controls), regardless of periodontal or ACPA status 
(Figure 4. 19).  
Although the antibody levels to PG-related antigens are significantly elevated in 
RA compared to controls, the percentage of RA patients with antibody levels over 
the 95th percentile of healthy control was low for all the PG-antigens. 25 % of RA 
patients were antibody negative for all the antigens and no patient revealed 
antibodies to all the bacterial antigens studied, with a majority of patients (63%) 
being antibody positive to one or two antigens only. However, in the small group 
of anti-CCP negative patients, we see a majority of patients (61%) with antibodies 
to one or more of the bacterial antigens investigated, from both periodontally 
healthy and periodontitis groups. This shows that the antibody positivity against 
PG-related antigens was not only due to cross-reactivity with ACPAs, as patients 
with low detection of antibodies to citrullinated antigens can have high levels of 
antibodies to PG-related antigens (Figure 4. 19).  
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Figure 4. 19 Heatmap of RA patients showing antibody positivity (>95th percentile 
of healthy controls for each antibody titre) in all antibodies to periodontal bacteria 
studied classified according to anti-CCP positivity and presence of periodontitis. 
Each row represents one patient. The color scale shows the relative degree of 
antibody reactivity, from low reactivity (while) to high reactivity (purple). The order 
of the columns is according to their relationship with each other and anti-CCP. 
Abbreviations:  PG, Porphyromonas gingivalis; PPAD, PG peptidylarginine 
deiminase; CPP3/RPP3, citrullinated and arginated epitope from PPAD; Pg-eno, 
enolase from PG; RgpB, P. gingivalis virulence factor arginine gingipainB; CCP, 
cyclic citrullinated peptyde; PI, Prevotella intermedia; FN, Fusobacterium 
nucleatum. 
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4.7. Discussion 
 
  Anti-PG Crossectional comparison 
 
The study of antibodies against different antigens from Pg is of special 
importance, not only to elucidate the role of Pg in RA but because it has been 
suggested that antibodies against Pg are associated to non-respondent reactions 
to DMARDs in RA (Kobayashi, Ito et al. 2016). The hypothesis of the cross-
sectional study comparison was that patients with RA have elevated antibodies 
to periodontal bacteria, which was corroborated by our results.  RA patients had 
significantly higher levels of antibodies against PG-antigens (Figure 4. 3). This 
antibody reaction, occurred in both periodontitis and periodontally healthy groups, 
however did not occur in anti-CCP negative patients who were periodontally 
healthy (Figure 4. 6). These findings support the hypothesis that, in RA, PG 
triggers an immune reaction that, by epitope spreading, becomes an auto-
antibody reaction against citrullinated proteins in the joint.  
 
Our results suggest that, PPAD and its epitopes (CPP3 and RPP3), act as an 
antigen in RA but not RgpB, which is targeted mostly in periodontitis patients 
(Figure 4. 1). These findings are in accordance with those from Quirke et al 
(Quirke, Lugli et al. 2014) and Johansson et al. (Johansson, Sherina et al. 2016) 
whose papers show that RgpB and CPP3 antibody levels follow different trends, 
being anti-RgpB antibodies elevated in PD but not RA, and anti-PPAD antibodies 
elevated in RA.  
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It could be argued that the anti-CPP3 antibody response in RA, rather than being 
P. gingivalis specific, could simply belong to the generic ACPA response, or 
rather represents cross-reactivity with another citrullinated antigen. However, the 
non-citrullinated epitope from PPAD, RPP3, was also elevated in RA noPD 
compared to NoRA PD, which would not correspond to a typical ACPA response. 
Although these differences in RPP3 could be questioned, as the ODs detected 
were low for all patients and no standard curve could be selected, the heatmap 
of the anti-PG antigens and anti-CCP positivity (Figure 4. 19) showed no patterns 
between those patients that were anti-CCP positive and the patients that were 
anti-PG positive and a majority of patients anti-CCP negative were antibody 
positive to one or more PG-related antigens. Considering all this, it could be 
suggested that the antibody reaction against PG observed in this study was not 
just due to cross-reactivity but an antibody response significantly enhanced in 
RA.  
 
The lack of differences found in antibody levels to PG-antigens according to 
smoking status contradicts previous findings (Mikuls, Payne et al. 2014) but this 
could be explained due to the small number of smokers in our study (Figure 4. 
5). The elevated antibody reaction in the moderate to severe periodontitis group 
was not unexpected as there was also an elevated abundance of PG in these 
patients (Figure 4. 4).  
 
 OMAs cross-sectional comparison 
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The identification of the outer membrane antigens (OMA) studied in the study 
was accomplished in a periodontitis case-control by Curtis and colleagues 
(Curtis, Slaney et al. 1991). Following the methods previously described by 
Mikuls and collaborators (Mikuls, Payne et al. 2014), antibodies to OMA from PG, 
were studied in this chapter as it has been hypothesized that these are increased 
in RA, and antibodies to FN and PI were also analysed as both bacteria are 
closely associated with PG in the deep pocket biofilm (Holt and Ebersole 2005).  
 
Porphyromonas gingivalis manipulates the immune system by different 
mechanisms to perpetuate inflammation with the help of other periodontal 
bacteria from the so-called “orange complex” or 2nd group, which includes PI and 
FN (Socransky, Haffajee et al. 1998). Prevotella intermedia can evade immunity 
through degradation of C3 and other key components of the complement, by 
capturing complement factor H and by inhibit complement and it is associated 
with deep periodontal pockets with bleeding on probing (Zambon 1996). 
However, in our study, antibodies to PI seemed to be associated with health 
instead of disease. This could represent a healthy protective antibody response 
that is reduced in disease. 
 
Fusobacterium nucleatum is a Gram-negative bacillus that acts as an 
opportunistic pathogen in periodontal disease, breaking through the gingival 
epithelium and interfering with the host defences (supression of ROS release and 
B-defensine expression) and fibroblast proliferation and it facilitates the 
colonization of other periodontal pathogens. It is also related to adverse 
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pregnancy outcomes. FN has been found to be in high concentrations in RA 
patients compared to controls (Schmickler, Rupprecht et al. 2017). In our study 
FN was significantly elevated in the RAPD group compared to the RAnoPD group 
and there was a clear large group in the RAPD with high levels of anti-FN 
compared to the rest of the groups, and also in the systemically healthy group 
with periodontitis. The conditions of both RA and PD seemed to favour the growth 
of FN, as its relative abundance and antibody response was elevated in these 
groups, and periodontal therapy seemed to significantly reduce the load of this 
bacteria in the periodontal pocket. 
 
There is a clear correlation between periodontitis and high levels of antibodies to 
P. gingivalis in both RA or noRA groups. This bacterium showed the strongest 
correlation to periodontitis of the ones studied here, in agreement with the theory 
of Socransky et al., which describes P. gingivalis as a red complex bacteria, 
closely associated with severe periodontitis. However, neither the relative 
abundance of P. gingivalis or the antibodies to P. gingivalis were significantly 
elevated in RA patients compared to control, and antibodies to any of the PG-
related peptides or OMAs were not significantly reduced after periodontal 
therapy. Although the relative abundance of P. gingivalis was not reduced after 
periodontal therapy, the amount of P. gingivalis present in the oral cavity of the 
patients that were treated may be reduced as the amount of plaque was reduced.  
 
The lack of a reduction in the immune reaction against P. gingivalis could mean 
that, while in the initial stages of RA, P. gingivalis is still a possible candidate to 
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trigger the autoimmune reaction that leads to ACPA formation, once RA is 
established, even if P. gingivalis is reduced by periodontal therapy, the 
autoimmune reaction that occurs in the joint perseveres.    
 
  Correlation analysis 
 
In our study, there were significant associations between antibodies to P. 
gingivalis and OMAs from FN and clinical parameters (Appendices Table 8. 1). 
While antibodies to FN seemed to be associated with both RA and periodontitis 
parameters, anti-PG antibodies were mostly associated to periodontal 
parameters, also it was also significantly but weakly associated to anti-CCP 
antibodies. Mikuls and collaborators found similar weak but significant 
associations between OMAs to P. gingivalis and anti-CCP (Mikuls, Payne et al. 
2014). Also Lappin and collaborators found correlations between anti-CCP, anti-
PG and anti-CCP and CEP/REP. When smokers were included, the correlation 
between anti-CCP and anti-PG was negative, when smokers were excluded, the 
correlation was positive which the authors attributed to smoking acting as 
confounding factor, which was not seen in our study. This latter paper also 
observed a reduction of anti-PG and anti CCP after periodontal therapy, which 
contradicts our results, although they did not include RA patients (Lappin, 
Apatzidou et al. 2013). Lee found correlations between anti-enolase and anti-PG 
(Lee, Choi et al. 2015), however this correlations were similarly weak to the ones 
found in this study.  
 178 | P a g e  
 
 
In our study, it was not observed higher anti-PG antibody levels in anti-CCP 
positive patients (Hitchon, Chandad et al. 2010). This might be due to the small 
number of anti-CCP negative patients included, resulting in a lack of power to 
detect significances between groups with very different numbers.  
 
The significant correlation between anti-PG and relative abundance of P. 
gingivalis (R=0.33, p<0.0001) suggested that anti-PG OMAs could be used as an 
indicative parameter for the presence of P. gingivalis. Thus, considering this weak 
but consistent correlations through numerous publications, it could be stated that 
antibodies to citrullinated proteins are associated with anti-PG and therefore, the 
presence of P. gingivalis, strengthening the theory of P. gingivalis as being the 
driver of the antibody reaction in RA.  
 
 Longitudinal study results 
Our hypothesis, following the theory of extra-articular citrullination in periodontitis 
triggering and exacerbating RA, was that periodontal treatment could bring down 
levels of P. gingivalis and therefore, the production of antibodies against P. 
gingivalis. This is supported by previous research that found significant reduction 
of anti-PG after periodontal therapy (Okada, Kobayashi et al. 2013) (Lappin, 
Apatzidou et al. 2013). 
Numerous studies have examined the changes in antibodies to periodontal 
bacteria after periodontal therapy. In the studies from Ebersole (Ebersole, 
Taubman et al. 1985) and Okamura (Murayama, Nagai et al. 1988), the authors 
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found an elevation of serum antibody levels to periodontal bacteria immediately 
after periodontal therapy, but after a few months, antibodies to PG and other 
periodontal bacteria seem to be reduced and correlated with clinical parameters 
(Horibe, Watanabe et al. 1995). Other authors defend that in Rapidly Progressive 
Periodontitis (RPP), periodontal therapy stimulates the production of high avidity 
antibodies to PG, replacing low avidity antibodies (Chen, Johnson et al. 1991). 
However, in our study, we did not find a significant effect of periodontal therapy 
on levels of antibodies to any of the human and PG-related peptides studied. 
Likewise, a recent study published by Shimada and collaborators failed to find a 
reduction in anti-CCP levels and anti PPAD in RA, 2 months after periodontal 
therapy (Shimada, Kobayashi et al. 2016). These negative results contradict 
those from Okada et al (Okada, Kobayashi et al. 2013), who found a significant 
decrease in antibodies to PG in RA in the treatment group compared to control. 
Nevertheless, in contrast with our results, Okada did not include periodontitis 
patients and only conducted supra gingival cleaning. These opposing results 
could be explained by differences in methodology, as the study from Okada used 
a mild definition of periodontitis and provided supragingival scaling, while the 
paper from Shimada and our paper included moderate to severe periodontitis 
patients and provided subgingival periodontal therapy. While it seems that in mild 
cases of periodontitis a simple supragingival scaling might be enough to reduce 
the level of P. gingivalis and therefore reduce citrullination, in periodontitis it might 
be more complex to demonstrate this effect. While supragingival cleaning seems 
to be beneficial in levels of citrullination and antibody response to P. gingivalis, in 
periodontitis patients with RA this decrease was not observed. 
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5. RESULTS – SUBGINGIVAL 
MICROBIOME IN RA 
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5.1. Introduction 
The hypothesis of the present chapter was that there is a cross-talk between the 
oral microbiome and the immune system in RA that produces changes in the 
microbiome of these patients compared to systemically healthy individuals. 
These changes could partially be restored by periodontal treatment.  
 
The aims of this project were: 
 
1) To characterize the subgingival microbiota of RA patients who are 
periodontally healthy compared to controls (RA no PD vs no Ra no PD). 
2) To characterize the subgingival microbiome of RA patients with periodontitis 
compared to the appropriate controls (RA no PD and No RA PD) 
 3) To investigate the effect of periodontal treatment in the subgingival microbiota 
of RA patients with periodontitis compared to controls (Delayed group) after 3 
and 6 months. 
 
Secondary aims were proposed in order to investigate differences in the oral 
microbiome, comparing groups such as systemically healthy with and without 
periodontitis, periodontitis microbiome from shallow sites vs deep sites and the 
effect of clinical parameters (smoking, age, ACPA status, etc). To these ends, 
the subgingival community was explored using 16S rRNA through Ilumina MiSeq 
platform and different groups of patients were compared according to each 
research question (Figure 5. 1, Table 5. 1). Methods are described in chapter 2.5.  
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Figure 5. 1 Diagram of scientific questions of the cross-sectional study comparison 
(aims 1, 2 and subgroup analysis). Abbreviations: RA, rheumatoid arthritis; PD, 
periodontitis; H healthy controls. Methods described in section 2.5. 
  
RA
RAPD
PD
H
How does PD affect the 
RA microbiome? 
How does RA affect 
the PD microbiome? How does PD affect the 
systemically healthy 
microbiome? 
How does RA affect the 
periodontally healthy 
microbiome? 
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Table 5. 1 Different comparisons presented in this chapter, the section where 
investigated and aim as the effect of the different parameters in the oral microbiome. 
Abbreviations: RA, rheumatoid arthritis; PD, periodontitis. 
Group comparison N Section Aim 
All patients (crossectional) 160 5.2 Effect of each clinical parameter 
+/-RA +/-PD 111 5.3 Effect of both RA and PD 
RAnoPD vs noRAPD 41 5.4 Effect of RA in noPD 
RAPD vs noRAPD  5.5 Effect of RA in PD 
RAnoPD vs RAPD  5.6 Effect of PD in RA 
Immediate group: V1 vs V2  5.7.2 Effect of periodontal therapy after 3 
months 
Immediate group: V1 vs V3  5.7.3 Effect of periodontal therapy after 6 
months 
Delayed group: V1 vs V2 vs V3  5.7.5 Changes after 3 and 6 months in 
control group 
noRAPD vs noRAnoPD  5.8.1 Effect of PD in noRA 
Shallow vs deep pockets  5.8.2 Effect of pocket selection 
Curette vs paperpoint  5.8.4 Effect of method of collection 
DMARDs vs DMARDS+biologics 
vs biologics 
 5.8.4 Effect of RA medication 
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5.2. Cross-sectional analysis of study population 
 Rarefaction analysis 
 
Rarefaction analysis is used to assess the richness of the species as a function 
of number of samples, which plots a curve that grows rapidly as the common 
species are identified and plateau once the most rare species remain.  To 
demonstrate that the differences in diversity are not due to differences in 
sequencing depth, rarefaction analysis investigates alpha diversity (diversity 
within a sample) of randomly selected samples and different matrices can be 
used such as observed OTUs, Chao 1, Shannon index or Simpson's diversity 
(using alpha_diversity.py). The results from these analysis showed that all the 
diversity was captured from the sequencing depth utilised, so this demonstrated 
that all samples approached saturation or had plateaued using all metrics 
investigated. As all graphs using the different matrices showed saturation, only 
observed OTUs was represented here. (Figure 5. 2).  
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Figure 5. 2 Rarefaction analysis of samples tested according to OTUs and samples. 
Methods described in section 2.5.  
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  Patient background 
 
An initial cross-sectional analysis was performed on all patients included in this 
project (n=160) to investigate which clinical characteristics differentiate clusters 
of the oral microbiome. All RA patients (n=123) were classified according to their 
periodontal status: 23 periodontally healthy patients (15% of total RA diagnosed) 
and 100 patients with different degrees of periodontitis, from mild (n=49) to 
moderate (n=21) and severe (n=30).  
 
From all patients in the systemically healthy group (n=37), 19 patients were 
classified as periodontally healthy (NoRA noPD), 17 patients were diagnosed 
with moderate to severe periodontitis (NoRAPD) and one patient had mild 
periodontitis. Clinical characteristics of the study population are represented in 
Table 5. 2. 
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Table 5. 2 Clinical characteristics of study population (n=160) according to 
periodontal and systemic condition. RA data not available in systemically healthy 
controls (-). Abbreviations: RA, rheumatoid arthritis; PD, periodontitis; CumPPD, 
cumulative probing depth; PPD, probing pocket depth; BoP, bleeding on probing; 
CAL, clinical attachment level; DAS, disease activity score; ESR, erythrocyte 
sedimentation rate; VAS, visual analogue score; IQR, inter-quartile range; n, number 
of patients per group. Methods described in section 2.5. 
 RAPD (n=100) RAnoPD (n=22) noRAPD (n=18) NoRA NoPD 
(n=19) 
Female 
proportion 
72% 78% 55.6% 63% 
Ethnicity 
proportion 
-Asian 
-White 
-Black 
 
 
15% 
53% 
6% 
 
 
4% 
91% 
0% 
 
 
5.6% 
78% 
11% 
 
 
11% 
89% 
0% 
Smoking 
proportion 
-Current 
-Former 
-Never 
 
 
21% 
30% 
49% 
 
 
13% 
21% 
61% 
 
 
5.6% 
55.6% 
33.3% 
 
 
5% 
11% 
84% 
Alcohol 
consumption 
-Never 
-1-4 
times/month 
-1-4 
times/week 
- >4 
times/week 
 
 
38% 
37% 
19% 
3% 
 
 
13% 
47% 
26% 
13% 
 
 
11% 
16% 
44% 
16.7% 
 
 
15% 
65% 
15% 
5% 
Age: median 
(IQR) 
59 (18) 60 (14) 49 (9) 36 (16) 
CumPPD: 
median (IQR) 
86 (45) 12 (12) 111 (31) 10 (4) 
PPD: median 
(IQR)  
2.83(0.86) 2.34(0.34)  3.17(0.96) 1.5(0.29) 
BoP: median 
(IQR) 
0.19(0.29) 0.5(0.19) 0.38(0.24) 0.02(0.1) 
CAL: median 
(IQR) 
3.2(1.2) 2.4(0.64) 3.9(1.9) 1.7(0.24) 
DAS28: 
median (IQR) 
4.28(2) 3.42(2) - - 
ESR: median 
(IQR) 
14(24) 8(23) - - 
VAS: median 
(IQR) 
55(40) 41(24) - - 
Tender joints: 
median (IQR) 
7(13) 3.5(5) - - 
Swollen joints: 
median (IQR) 
1(2) 0(1) - - 
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  Beta diversity analysis 
Beta diversity studies the differences in bacterial communities between groups. 
This can be measured by simply studying the bacterial taxa that overlap (Bray 
Curtis dissimilarity matrix) or by using the phylogenetic distribution of species in 
each group (Unifrac distances) (Morgan and Huttenhower 2012). 
 
To investigate which of the clinical characteristics studied create clustering on the 
oral microbiome, OTU data was plotted using Principal Coordinate analysis with 
different distance matrices (weighted and unweighted unifrac, Bray Curtis). The 
different clinical parameters, such as CAL, BoP, PPD, cumPPD, age, gender and 
smoking, were analyzed using the ANOSIM method (compare_categories.py) 
which tests the strength and statistical significance of the sample groupings 
(Table 5. 3). From all the groupings, the only parameters that significantly shifted 
the oral microbiome were the systemic condition of RA (ANOSIM p value <0.001), 
periodontal classification (ANOSIM p value <0.001), cumulative PPD higher or 
lower than 40mm (ANOSIM p value =0.001), and CAL (ANOSIM p value =0.005) 
in both weighted and unweighted Unifrac distances. As both distances showed 
the results, Unweighted unifrec distances are represented as they illustrate better 
clustering (Figure 5. 3, Figure 5. 4, Figure 5. 5). In the 160 patients investigated 
here, there was no evidence that age, gender or smoking status significantly 
changed the oral microbiome. 
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ACPA status from 60 patients was available and only 13 patients were ACPA 
negative. For this reason, 15 ACPA positive patients, matched for gender, age 
and DAS28 severity, were selected. No significant differences in beta diversity 
between ACPA negative and positive patients were found. 
Therefore, only RA and PD appeared to drive changes in the oral microbiome 
from all clinical characteristics included, 
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Table 5. 3 Grouping parameters tested for significance in clustering the oral 
microbiome. Test=ANOSIM of weighted unifrac distances (unweighted giving same 
results), significance if p<0.05. Abbreviations: BoP, bleeding on probing; CAL, clinical 
attachment level; RA, rheumatoid arthritis; PPD, pocket probing depth. Methods 
described in section 2.5. 
Grouping factor Groups ANOSIM significance 
Periodontal 
classification 
Eke&page 2012 p=0.001 
BoP Mean <10% vs 10-40% 
vs >40% 
p=0.02 
CAL Mean <3mm, 3-4mm, 
>4mm 
p=0.005 
RA RA vs systemically 
healthy 
p=0.001 
PPD Mean 1-3 mm vs 3-4 
mm vs >4 mm 
Not significant 
Age 20-40years old vs 40-60 
vs >60 years old 
Not significant 
Gender Male vs female Not significant 
Smoking status Never vs current vs 
former 
Not significant 
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Figure 5. 3 Beta diversity of oral microbiome represented by principal coordinate 
analysis of unweighted unifrac distances according to significant categorisations 
(n=160). Abreviations: RA, rheumatoid arthritis; PD, periodontitis. Significant 
clustering analysed with ANOSIM test (significance p<0.05). Methods described in 
section 2.5. 
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Figure 5. 4 Beta diversity of oral microbiome represented by principal coordinate 
analysis of unweighted unifrac distances according to significant periodontal 
categorisations (n=160). Significant clustering analysed with ANOSIM test 
(significance p<0.05). Methods described in section 2.5. 
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Figure 5. 5 Non significant parameters for categorization of oral microbiome. Principal 
Coordinates Analysis (PCoA) plots of unweighted unifrac distances according to age 
categorisaztion (a.), gender (b.) and smoking habits (c.). Significant clustering 
analysed with ANOSIM test (significance p<0.05). Methods described in section 2.5. 
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5.3. RA and PD beta diversity analysis 
Once evidenced that RA and PD were the main factors for changing the oral 
microbiome in the study population, all patients were classified according to their 
periodontal and RA status, resulting in 4 groups: 19 patients noRA noPD, 18 
patients noRAPD; 23 patients RAnoPD; 100 patients RAPD. Various degrees of 
periodontitis were found in the latter RAPD group but, as 49 mild 
periodontitis/gingivitis patients did not belong to either periodontitis or health, 
those samples were removed from this cross-sectional analysis, leaving a total 
of 51 RAPD (moderate and severe periodontitis) samples remaining for further 
analysis. 
 
Firstly, a beta diversity analysis was performed between the four groups using 
principal coordinate analyses of unifrac distances (Figure 5. 6). Beta diversity 
analyses measures the whole community between groups and there are different 
approaches to measure the distances between the species in each sample. 
Unifrac distances use the phylogenetic tree to measure the distances between 
the species depending on the evolutionary branches. While unweighted unifrac 
just accounts for presence and absence of lineages (community membership), 
weighted unifrac takes into account the relative abundances of the species, so 
that the branches are weighted depending on how much species there are in 
each branch. Weighted unifrac empathises on the very abundant species), while 
unweighted unifrac also shows the not so abundant or rare species, so analysis 
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of both distances is useful to elucidate which species are contributing to the 
difference (Lozupone, Lladser et al. 2011).  
 
Principal Coordinate Analysis for both weighted and unweighted unifrac showed 
significant differences in the communities for both approaches (ANOSIM 
p<0.001), demonstrating that the differences are not attributable to the rare 
biosphere only. Other distances can be used that do not account for 
phylogenetics but just look at the differences or similarities between species, 
such as bray Curtis, which also showed significant differences in this comparison 
(p<0.001).  
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Figure 5. 6 Principal Coordinates Analysis (PCoA) plots of unweighted (a.) and 
weighted (b.) unifrac distances according to RA and periodontitis grouping. 
Significant clustering analysed with ANOSIM test (if p<0.05). Methods described in 
section 2.5. 
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5.4. Effect of RA in periodontally healthy microbiome 
At least two next-generation sequencing studies have investigated the RA 
microbiome (Zhang, Zhang et al. 2015) (Scher and Abramson 2011) showing 
differences in diversity and structure of the oral microbiome of RA compared to 
controls. However, due to the high prevalence of periodontitis in the RA 
population compared to the controls, these differences could be due to the 
periodontal factor and not to the systemic condition, as periodontitis was not 
controlled in previous studies.  
 
To investigate the association between RA and the oral microbiota, the 
subgingival microbiome of periodontally healthy patients with Rheumatoid 
arthritis (RA) was compared to the appropriate systemically healthy controls. A 
total of 3,963,291 16S rDNA sequences were analyzed from 41 periodontally 
healthy volunteers. The mean number of sequences per sample was 107,115 
(minimum 69,626 and maximum 18,293,000).   
 
  Clinical data of study volunteers 
 
The clinical characteristics of the 22 RA and systemically healthy 19 controls are 
represented in Table 5. 2. A total of 41 periodontally healthy patients were 
included in the study, composed by 19 systemically healthy controls and 22 RA. 
 199 | P a g e  
 
No significant differences in smoking history, alcohol consumption, sex or 
ethnicity were found. Only mean age was found to be significantly higher in the 
RA group (mean age RA=60, mean age NoRA=36; p<0.01 Mann-Whitney U test), 
and periodontal parameters such as CAL (mean RA=2.4, mean NoRA=0.7; 
p<0.01 Mann-Whitney U test) and PPD (mean age RA=2.3, mean age 
NoRA=1.6; p<0.01 Mann-Whitney U test). However, although these periodontal 
parameters were statistically significantly higher in the RA group, the difference 
was very small and clinically insignificant and all patients were periodontally 
healthy (i.e. no pockets of 4mm or more). 
 
 Beta diversity 
 
Principal Coordinate Analysis (PCoA) of both unweighted and weighted UniFrac 
distances demonstrated significant clustering of the microbiomes based on RA 
status (Figure 1a, p=0.001, ANOSIM test), indicating that these groups differed 
both in presence or absence of lineages (community membership), as well as in 
the relative abundances of lineages within communities (community structure). 
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Figure 5. 7 Differences in beta diversity between periodontally healthy subjects with 
and without Rheumatoid Arthritis (RA). Principal Coordinates Analysis (PCoA) plots 
of unweighted  (a.) and weighted (b.) of unifrac distances. n NoRA NoPD=19, n RA 
NoPD=22. Abbreviations: PD, chronic periodontitis. Methods described in section 
2.5. 
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  Alpha diversity 
Alpha diversity investigates the diversity of the species found in a sample or 
group, including the count of OTUs found (richness) and the distribution 
(evenness). Alpha diversity was investigated using Abundance Coverage 
Estimator (ACE) analysis, which showed no significant differences between the 
groups. However, there were differences in the distribution of the samples, as the 
no-RA group was homogeneously distributed (Levene test for homogeneity of 
variances p<0.05) while the RA group showed high variances between the 
groups (Figure 5. 8). When performing the Welsh-ANOVA test for different 
variances, a total of 171 OTUs were found to be significantly different distributed 
in abundance between the two groups (30.64% of OTUs).  
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Figure 5. 8  Differences in alpha diversity between periodontally healthy subjects with 
and without Rheumatoid Arthritis (RA). Kernel plots of alpha diversity (Abundance-
based Coverage Estimator (ACE). The peak indicates the median values for each 
group, and the x-axis shows the data range. n NoRA NoPD=19, n RA NoPD=22. 
Methods described in section 2.5. 
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  Gram and oxygen characteristics 
 
Once established that the oral microbiome from RA patients differed from controls 
in both community membership and structure, group analysis was performed to 
investigate if these differences were reflected in the Gram staining characteristics 
and oxygen requirements of the two communities. In the gingival pocket, 
anaerobic bacteria (grows in the absence of oxygen) are typically related to 
disease, while facultative anaerobes (capable of replicating in aerobic and 
anaerobic conditions) are associated with health (Wade 2013). 
 
The Gram staining characteristics and oxygen requirements of the two microbial 
communities are represented in Figure 5. 9, which is explored based on the 
taxonomic composition. Significant differences were found (p<0.05 Wilcoxon 
rank-sum test), showing that RAnoPD had more abundance of anaerobic species 
compared to NoRAnoPD, both Gram-negative anaerobes (46.7% in RA, 39.9% 
in No RA; Mann-Whitney U test p=0.001) and more Gram-positive facultative 
(24% in RA, 28% in No RA; Mann-Whitney U test p=0.042)  
 
The No RA patients presented a higher abundance of facultative species (43.49% 
in NoRA vs 35.27%in RA), especially Gram-negative aerobes (15.34% vs 
11.29%; Mann-Whitney U test p=0.007). However, qualitatively (not considering 
abundance, just the bacteria found in each group) there were no differences in 
gram staining characteristics and oxygen requirement between groups, showing 
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that the determinant factor to differentiate the characteristics of the two 
communities was the abundance of the species. 
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Figure 5. 9 Differences between RA and no RA in abundance of species by gram 
staining and oxygen requirement characteristics. Mann-Whitney U-test, significance 
if p<0.05. Abbreviations: RA, rheumatoid arthritis; PD, periodontitis. Methods 
described in section 2.5. 
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  Core microbiome 
Due to the heterogenity of the subgingival microbiome among individuals, the 
most common species (species found in ≥80% of subjects) were identified in each 
group, to compare stable associations between the RA microbiome and healthy 
controls. In the RA group, 364 OTUs were discovered as core microbiome and 
27.7% of these (101 OTUs) differed significantly in relative abundance 
(community structure) with the control group and 38 species were unique in the 
RA group. In the No RA group, 326 core OTUs were identified and 16% of the 
core No RA microbiome differed significantly in structure (54 OTUs) and 11.7% 
were unique for the NoRA (38 OTUs). 
 
Recent investigations demonstrate that while substantial microbial heterogeneity 
exists among healthy individuals, a robust core microbiome is identifiable in 
individuals who smoke or are pregnant (Mason, Preshaw et al. 2015), (Paropkari, 
Leblebicioglu et al. 2016). These findings suggest that RA, similarly to smoking 
and pregnancy, imposes a habitat that promotes the growth of certain organisms 
and shifts the microbial community typically associated with disease. 
 
  Differences in relative abundance and unique species 
 
To identify which species contribute to the differences found between the two 
communities, DESeq2 analysis was used to identify differentially abundant 
OTUs, with p-values <0.05 adjusted for multiple testing. The relative abundance 
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of 558 OTUs was identified as significantly different between the two groups, from 
3,963,291 classifiable sequences. 41.9% of the community (229 OTUs) differed 
significantly in community structure and 19% (105 OTUs) in membership 
(absence/presence). 
 
From the group of OTUs significantly more abundant in the RA group, the 
predominant species belonged to the genera Actinomyces, Cryptobacterium (the 
genera with the highest OR=36), Dialister, Desulfovibrio, Fretibacterium, 
Leptotrichia, Prevotella, Selenomonas, Treponema, and Veillonellaceae [G1]. In 
patients with RA, these significantly abundant species accounted for a median of 
28% (range from 12-82%) of each individual’s microbiome, indicating that these 
differences are not attributable to the rare biosphere. 
 
In contrast, species from the genera Aggregatibacter, Gemella, Granulicatella, 
Hemophilus, Neisseria and Streptoccoci not only demonstrated lower 
abundances in RA but were also less frequently detected in these subjects.  
 
  Network correlations 
 
Bacterial presence in a biofilm is driven by inter-dependent nutritional and 
metabolic interactions and the study of these inter-species associations helps 
understand health and disease microbial communities (Duran-Pinedo, Paster et 
al. 2011).  For this reason, Spearman's correlation analysis was performed on 
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the presence of core microbiome of each group and significant OTUs (with 
p<0.05 and r>0.7) were identified. Using Gephi (Bastian, Heymann et al. 2009), 
parse, congeneric networks were observed in controls, indicating that this is an 
ecological niche in equilibrium (Figure 5. 10, methods detailed in section 2.6). 
However, in the RA group, the network topology of RA patients revealed a highly 
connected grid with a robust intergeneric hub (Figure 5. 11). 83 of the 157 core 
species were incorporated in this hub with known pathogenic species belonging 
to Treponema, Selenomonas, Filifactor, Campylobacter and Fretibacterium 
tightly interwoven into this hub.  
 
The identification of species with the highest modularity and degree of a network 
is interesting as it shows the OTUs that provides stability and robustness to the 
community (Duran-Pinedo, Paster et al. 2011). The modularity measurement 
indicates which OTUs are more densely connected and the degree shows the 
OTUs with the highest number of connections and the top 10 species were 
identified for each group (Figure 5. 10,Figure 5. 11). Therefore, network graph 
analysis was combined with DESeq and core microbiome analysis to examine 
co-occurrence patterns and identify important community members (network 
anchors). In the noRA noPD controls no network anchors were identified. In the 
RA group, 12 gram-negative species were identified as network anchors. 
 
This data suggests that a small group of anaerobic bacteria play an important 
role controlling the flow of resources in the RA-influenced microbiome, implying 
that even small changes in these anchors could impact upon community 
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assembly in people with RA. Interestingly, species traditionally associated with 
RA, for example, P. gingivalis and A.actinomycetemcomitans, were not part of 
the network cluster.  
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Figure 5. 10 Co-occurrence networks in periodontally and systemically healthy 
subjects (noRA noPD). Edges colored green for positive correlation and red for 
negative correlation and thickness represents the strength of the correlation. Nodes 
darkness and size represent the abundance of the species-level OTUs with 
significant and robust Spearman’s correlation (p<0.05, ≥0.75). Number of 
edges=324; number of nodes=263. Graph created with Gephi (Bastian, Heymann et 
al. 2009). 
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Figure 5. 11 Co-occurrence networks in periodontally healthy rheumatoid arthritis 
patients (RA noPD). Edges colored green for positive correlation and red for negative 
correlation and thickness represents the strength of the correlation. Nodes darkness 
and size represent the abundance of the species-level OTUs with significant and 
robust Spearman’s correlation (p<0.05, ≥0.75). Number of edges=561; number of 
nodes=227. Graph created with Gephi (Bastian, Heymann et al. 2009). 
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5.5.  Effect of RA on the periodontitis microbiome 
It has been shown that, RA patients, as well as having a higher prevalence of 
periodontitis, their periodontal disease is more severe than in the healthy 
population (27% of severe periodontitis in RA patients compared to 12% in non-
RA) (de Smit, Westra et al. 2012). However, it is not known why in periodontitis 
patients, having RA is associated with a more severe periodontal phenotype. 
Studying the differences in the microbiome of periodontitis patients with and 
without RA could help elucidate why a more severe disease is associated with 
RA. 
 
 Study volunteers  
 
In the study of the differences in the community of the microbiome, similar sample 
sizes must be selected to avoid bias. As the RAPD group had 100 patients and 
the noRA PD group had 18 patients, the bias problem was solved by selecting 
20 RAPD patients that were matched for age, gender and smoking status with 
the 18 noRA PD available patients . Periodontitis patients with mild disease were 
not included in this analysis as only moderate and severe patients were included. 
A total of 37 patients were selected and clinical parameters are described in Table 
5. 4. No significant differences (p<0.05) were found when analysing differences 
in mean PPD, BoP and mean CAL between the groups (Mann Whitney-U test) 
but differences were found in age (p=0.04) with a mean difference of 5 years 
(standard error of difference=0.15) older in the RA group (Table 5. 4).  
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Table 5. 4 Clinical characteristics of study population (n=37) according to 
systemic condition. RA data not available in systemically healthy controls (-). The 
percentage not shown for each proportion represents missing data. 
Abbreviations: RA, rheumatoid arthritis; PD, periodontitis; CumPPD, cumulative 
probing depth; PPD, probing pocket depth; BoP, bleeding on probing; CAL, 
clinical attachment level; DAS, disease activity score; ESR, erythrocyte 
sedimentation rate; VAS, visual analogue score; IQR, inter-quartile range; n, 
number of patients per group. Methods described in section 2.5. 
 RAPD (n=20) noRAPD (n=18) 
Female proportion 65% 55.6% 
Ethnicity proportion 
-Asian 
-White 
-Black 
 
10% 
55% 
10% 
 
5.6% 
78% 
11% 
Smoking proportion 
-Current 
-Former 
-Never 
 
10% 
50% 
40% 
 
5.6% 
55.6% 
33.3% 
Alcohol consumption 
-Never 
-1-4 times/month 
-1-4 times/week 
- >4 times/week 
 
30% 
35% 
25% 
5% 
 
11% 
16% 
44% 
16.7% 
Age: median (IQR) 52 (13) 49(9) 
CumPPD: median (IQR)  89(56) 111(24) 
PPD: median (IQR)  3.47(1.6) 3.17(0.96) 
BoP: median (IQR) 0.26(0.35) 0.38(0.24) 
CAL: median (IQR) 3.65(1.9) 3.9(1.9) 
DAS28: median (IQR) 4.43(2.27) - 
ESR: median (IQR) 14 (25) - 
VAS: median (IQR) 55 (50) - 
Tender joints: median 
(IQR) 
7 (12) - 
Swollen joints: median 
(IQR) 
1(2) - 
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 Beta diversity 
Beta diversity analysis of the oral microbiome was performed to analyse 
differences between periodontitis patients with RA and without RA. From the 38 
patients included, a total of 565 OTUs were identified. 
 
Principal Coordinate analysis (PCoA) of both unweighted and weighted unifrac 
distances demonstrated significant clustering based on RA status using the 
ANOSIM test (p=0.001: R= 0.24 for weighted, R=0.5 for unweighted), indicating 
that these two periodontitis groups differed in both community membership 
(presence or absence of lineages) as well as in the community structure (relative 
abundances of lineages within communities).  
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Figure 5. 12 Differences in beta diversity between periodontitis patients with and 
without Rheumatoid Arthritis (RA). Principal Coordinates Analysis (PCoA) plots of 
unweighted  (a.) and weighted (b.) of unifrac distances. Clustering significance tested 
with ANOSIM test (significance if p<0.05). n RAPD=20, n NoRA PD=18. 
Abbreviations: PD, chronic periodontitis. Methods described in section 2.5. 
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  Alpha diversity 
Since it was discovered that in periodontitis, the RA microbiome (RAnoPD) differs 
from systemically healthy (NoRAnoPD), comparison between alpha diversities 
was performed.  
 
No significant difference was found between both alpha diversity curves (Mann-
Whitney U test of ACE p=0.1) (Figure 5. 13). However, similarly to section 5.3, 
the graphs showed different distribution, while noRA_perio follows a skewed but 
symmetric distribution, RA_perio had a higher diversity (0.8 to 8 compared to 3.5 
to 7 range of Shannon Diversity) and two peaks of density, showing a more 
uneven distribution of the diversity in the RAPD group similarly to the RAnoPD 
group. 
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Figure 5. 13 Differences in alpha diversity between periodontitis patients with and 
without Rheumatoid Arthritis (RA). Kernel plots of alpha diversity (Abundance-based 
Coverage Estimator (ACE). The peak indicates the median values for each group, 
and the x-axis shows the data range. n RA_perio=18, n noRA_perio=20. Methods 
described in section 2.5. 
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  Gram and oxygen characteristics 
The Gram staining characteristics and oxygen requirements of the periodontitis 
patients with and withour RA are represented in Figure 5. 14. Following the 
opposite trend to the comparison between RA and noRA with healthy 
periodontium, systemically healthy periodontitis patients (RA noPD) presented a 
significantly higher proportion of obligate anaerobes (especially Gram negative, 
Mann-Whitney U test p=0.002) and a lower proportion of Gram positive facultative 
(Mann- U test, p=0.003). 
 
This is interesting as it could show that, while in periodontal health, RA shifts the 
microbiome towards a more anaerobic environment, in periodontitis, the 
differences between RA and noRA are not due to an accumulated effect of 
anaerobic environment. In the case of patients with periodontitis and RA, it seems 
that the predominant bacteria are different.  
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Figure 5. 14 Differences between RA and no RA patients with periodontitis in 
abundance of species by gram staining and oxygen requirement characteristics. 
Mann-Whitney U-test, significance if p<0.05. Abbreviations: RA, rheumatoid arthritis; 
PD, periodontitis. Methods described in section 2.5. 
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  Core microbiome 
 
The core microbiome of each group was defined as the microorganisms present 
in at least 80% of the patients in each group (Kumar, 2011). A total of 335 OTUs 
were discovered as core microbiome in the No RA (PD_noRA) group and 313 
OTUs as core microbiome in the RA group (RA_PD). While these two core 
microbiomes had a majority of species in common, 56 (17%) of the RA core OTUs 
were not part of the noRA core, and 40 (13%) of no NoRA core microbiome was 
not part of the RA core.  
 
The core community that was unique for RA was dominated by species belonging 
to Caphnocytophaga, Leptotrichia and Prevotella. Interestingly, P. gingivalis was 
not part of the core microbiome of neither group, although these patients were 
diagnosed with moderate to severe periodontitis. While 
A.actynomicetemcomitans was part of the core microbiome in the systemically 
health periodontitis patients (noRA_PD) but not the RAPD group, C.curtum was 
part of the core microbiome of RAPD but not the controls. This demonstrates that 
although the two groups had periodontitis, they differ in microbial community 
composition.  
 
 Differences in relative abundance and unique species 
Differential analysis (using DESeq2 from Qiime package) of the relative 
abundance of all OTUs were studied and 220 (23%) species were identified as 
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significantly different between the two groups, with p-values <0.05 adjusted for 
multiple testing, and Fisher’s exact test to examine the frequency of detection. 
Only 7% of the species (37 OTUs) differed significantly in membership, 30 
appearing uniquely in the RA group. Cryptobacterium curtum (OR=9.6, 95% CI 
2.1-43.5) was again significantly more abundant in the RA group.  
 
  Network correlations 
 
Although similar network structures could be observed between the two groups, 
there were also differences. In the RAPD group, 250 core species were 
significantly and strongly correlated and 249 species were identified from the 
noRAPD. However, the systemically healthy group had more than 3 times higher 
number of correlations (354 correlations in the RAPD group, 1,195 correlations 
in noRAPD group), showing that in the systemically healthy group with 
periodontitis the species interconnected have a higher density of connections 
with each other and a more robust cluster is responsible for the disease.  
In the RAPD group, species from the genera Prevotella, Capnocytophaga, 
Treponema and Fusobacterium were the species with the highest and strongest 
number of connections. 8 network anchors were found in the RAPD group which 
were species part of the core microbiome, significantly differently distributed 
compared to the noRAPD group and part of the top 20 species with highest 
modularity and degree in the network analysis. These species belonged to the 
genera Treponema, Peptostreptococcus, and Lachnospiraceae.  
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In the noRAPD group, 249 core species were significantly and strongly 
correlated. P. gingivalis was the most abundant species of the top 10 OTUs with 
highest modularity, which represents a species very densely connected with 
other OTUs and therefore a key OTU in the network of noRAPD microbiome. 
Interestingly, A. actynomicetenscomintas showed a low degree and low 
modularity.  
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Figure 5. 15 Co-occurrence networks patients with periodontitis and systemically 
healthy (noRAPD). Edges colored green for positive correlation and red for negative 
correlation and thickness represents the strength of the correlation. Nodes darkness 
and size represent the abundance of the species-level OTUs with significant and 
robust Spearman’s correlation (p<0.05, ≥0.75). Number of edges=1183; number of 
nodes=249. Graph created with Gephi (Bastian, Heymann et al. 2009). 
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Figure 5. 16 Co-occurrence networks in rheumatoid arthritis patients with 
periodontitis (RAPD). Edges colored green for positive correlation and red for 
negative correlation and thickness represents the strength of the correlation. Nodes 
darkness and size represent the abundance of the species-level OTUs with 
significant and robust Spearman’s correlation (p<0.05, ≥0.75). Number of 
edges=1193; number of nodes=249. Graph created with Gephi (Bastian, Heymann 
et al. 2009). 
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5.6. Effect of PD in RA microbiome 
 
  Study volunteers 
 
Clinical characteristics of periodontally healthy RA (RAnoPD) and all RA patients 
with periodontitis (RAPD) are described in Table 5. 2. To study the effect of 
periodontitis in the RA microbiome, all RA patients were studied and categorized 
depending on the periodontal status (Eke&Page classification). From the total RA 
patients (122), 22 were periodontally healthy, 49 had mild periodontitis, 21 had 
moderate periodontitis and 30 had severe periodontitis.  
 
Due to the big differences in sample sizes between the groups, a subgroup of the 
RAPD mild/slight cohort was selected to equalize samples sizes, matching for 
age, smoking status and gender. The clinical characteristics of the study groups 
are represented in Table 5. 5, showing no differences in the demographics and a 
trend towards an increase of the RA disease markers with periodontal severity. 
This association between increased ESR or tender joints with periodontal 
severity, is not likely to be explained by other confounding factors such as 
smoking and age, as these factors did not differ between the groups.  
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Table 5. 5 Clinical characteristics of selected subjects with RA grouped by periodontal 
status. Abbreviations: RA, rheumatoid arthritis; PD, periodontitis; CumPPD, 
cumulative probing depth; PPD, probing pocket depth; BoP, bleeding on probing; 
CAL, clinical attachment level; DAS, disease activity score; ESR, erythrocyte 
sedimentation rate; VAS, visual analogue score; IQR, inter-quartile range; n, number 
of patients per group. Methods described in section 2.5. 
 RA 
noPD 
(n=22) 
RA mild 
PD 
(n=30) 
RA 
moderate 
PD (n=21) 
RA severe 
PD (n=30) 
Female 
proportion 
78% 77% 71% 60% 
Ethnicity 
proportion 
-Asian 
-White 
-Black 
 
 
5% 
92% 
3% 
 
 
10% 
83% 
3% 
 
 
14% 
70% 
15% 
 
 
13% 
80% 
7% 
Smoking 
proportion 
-Current 
-Former 
-Never 
 
 
13% 
21% 
60% 
 
 
20% 
43% 
27% 
 
 
19% 
23% 
57% 
 
 
23% 
33% 
44% 
Alcohol 
consumption 
-Never 
-1-4 
times/month 
-1-4 times/week 
- >4 times/week 
 
 
13% 
47% 
26% 
13% 
 
 
26% 
39% 
27% 
4% 
 
 
33% 
27% 
24% 
5% 
 
 
47% 
30% 
17% 
4% 
Age: median 
(IQR) 
60 (17) 61 (20) 56 (17) 56 (12) 
CumPPD: 
median (IQR) 
12 (12) 35 (33) 69 (44) 71 (48) 
PPD: median 
(IQR)  
2.3 (0.3) 2.7 
(0.38) 
3.3 (0.5) 3.5 (1.5) 
BoP: median 
(IQR) 
0.06 
(0.2) 
0.14 
(0.16) 
0.33 (0.2) 0.26(0.4) 
CAL: median 
(IQR) 
2.5 (0.7) 2.9 (0.8) 3.3 (0.5) 4.03 (2.3) 
DAS28: median 
(IQR) 
3.4 (2.3) 4.2 (2.4) 3.6 (2.6) 4.8 (1.8) 
ESR: median 
(IQR) 
8 (23) 12 (23) 20 (28) 21 (0.7) 
VAS: median 
(IQR) 
45 (24) 55 (40) 50 (53) 60 (43) 
Tender joints: 
median (IQR) 
3.5 (5) 6.5 (14) 7 (13) 9 (13) 
Swollen joints: 
median (IQR) 
0 (1) 1 (4) 1 (3) 0 (2) 
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  Beta and alpha diversity analysis according to different degrees 
of periodontitis 
 
Analysis of the beta diversity of the oral microbiome of the 4 RA groups according 
to periodontal status was performed and significant differences were found 
(ANOSIM p= 0.02, Figure 5.17). To visualize the differences in beta diversity, the 
PCoA of different distance matrices were used, such as Bray Curtis, which 
measures the distances accounting for the evolutionary branches of the species 
and the relative abundance, or the bray curtis which assigns a value to the 
species in each sample and measures the differences. The ANOSIM results of 
both analysis were statistically significant (p=0.02), however, the R values were 
low (0.05), which showed that the differences inside groups were high.  
 
Although due to the differences in distribution, differences in alpha diversity 
between the groups were not significant, the graphs of the periodontally healthy 
RA and mild periodontitis microbiome seemed to be similarly homogeneously 
distributed, while the RAPD moderate and severe were more heterogeneous 
(Figure 5.18). This showed that, periodontal status shapes the RA microbiome 
differentiating their beta diversity in community and membership and distribution 
of species with similarities between RA mildPD and RA noPD, and RA moderated 
and RA severe PD. 
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Figure 5.17 PCoA of weighted Unifrac (a) and Bray Curtis distances in RA patients 
grouped by periodontal status. n RA no PD=22; n RA mild PD=30, n RA moderate 
PD=21 ;n RA severe PD= 30. Test: ANOSIM, significance if p<0.05. Abbreviations: 
RA, rheumatoid arthritis; PD, chronic periodontitis. Methods described in section 2.5. 
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Figure 5. 18 Differences in alpha diversity between rheumatoid arthritis (RA) patients 
according to periodontal health. Kernel plots of alpha diversity (Shannon diversity 
analysis). The peak indicates the median values for each group, and the x-axis shows 
the data range. n RA no PD=22; n RA mild PD=30, n RA moderate PD=21 ;n RA 
severe PD= 30. Methods described in section 2.5 
  
 230 | P a g e  
 
 
 Beta diversity analysis of RAPD compared to RA noPD 
Once it was clear that severity of periodontitis shaped both the RA clinical 
characteristics and the microbiome, a more in-depth analysis was performed to 
investigate what contributes to the differences between periodontal health and 
periodontitis (Figure 5.19), according to the definition of moderate and severe 
periodontitis (Eke&Page 2007). The RA no PD (n=22) and the RAPD (moderate 
and severe) groups were compared. To reach similar sample sizes, 26 RAPD 
patients were selected (moderate-severe, table 5.4), matching age, gender and 
smoking status. Significant differences were found in the oral microbiome of RA 
patients with and without periodontitis. 
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Figure 5. 19 Differences in beta diversity between rheumatoid arthritis patients (RA) 
with and without periodontitis (PD). Principal Coordinates Analysis (PCoA) plots of 
unweighted  (a.) and weighted (b.) of unifrac distances. Test: ANOSIM, significance 
if p<0.05. n RAnoPD=21; n RAPD=26. Methods described in section 2.5. 
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  Alpha diversity 
The alpha diversity analysis shows significant differences (ACE and Shannon 
equitability Mann-Whitney U test p=0.05) between the distribution of the two 
groups (Figure 5.20). The Shannon diversity measures the diversity within each 
group, accounting for richness and evenness. This analysis showed uneven 
distribution of both RA groups with a more skewed RAPD profile compared to a 
more homogeneous RAnoPD.  
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Figure 5. 20 Differences in alpha diversity between rheumatoid arthritis (RA) patients 
with and without periodontatis (PD). Kernel plots of alpha diversity (Shannon diversity 
analysis). Test: Mann-Whitney U, significance if p<0.05. The peak indicates the 
median values for each group, and the x-axis shows the data range. n RA no PD=22; 
RA PD= 26. Methods described in section 2.5 
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  Gram and oxygen characteristics 
 
To investigate what characteristics contribute to differentiate the oral microbiome 
in RA patients with and without periodontitis, group analysis was performed to 
investigate if these differences were reflected in the Gram staining characteristics 
and oxygen requirements of the two communities (Figure 5. 21). While the RAPD 
group had a higher percentage of Anaerobes compared to the periodontally 
healthy, only the Gram-positive species were significantly elevated (Mann-
Whitney U test, p=0.01) and the Gram-positive facultative species were in 
significantly higher percentage in the periodontally healthy group (p=0.008).  
 
While the RA noPD group had a higher percentage of anaerobes compared to 
the systemically and periodontally healthy group (Figure 5. 9), these results show 
that the periodontitis condition in RA brings a higher percentage of anaerobes. 
However, this pattern is not the same as in systemically healthy, as there is a 
lower percentage of Gram negative anaerobes in RAPD compared to noRAPD 
and no difference between RAPD and RAnoPD. This corroborates that in RAPD, 
the predominant bacteria driving the periodontal tissues to disease are different 
compared to systemically healthy. 
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Figure 5. 21 Differences between RAPD and RA noPD patients with periodontitis in 
abundance of species by gram staining and oxygen requirement characteristics. 
Mann-Whitney U test, significance if p<0.05. Abbreviations: RA, rheumatoid arthritis; 
PD, periodontitis. Methods described in section 2.5. 
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  Core microbiome 
As in the previous sections, the core microbiome (shared by >80% of the patients 
in the group) was identified. In the RAPD group, 335 OTUs were identified as 
core bacteria with 34 of those unique for RAPD and not found in the core 
microbiome of RAnoPD, and with numerous species from the genera Prevotella, 
Treponema and Porphyromonas were part of this community. In the RAnoPD 
group, 325 OTUs were identified as core microbiome with 24 of those unique for 
the core of RAnoPD, numerous species from the Actynomices (including A. 
actynomicetenscomitans), Streptoccoccus, Enteroccoccus and Neisseria 
genera. 
 
  Differences in relative abundance and unique species 
 
A total of 176 OTUs were found to be significantly different in abundance 
(DESeq2) between the RAPD group and RA no PD (p adjusted value p<0.05).  
As this could be attributed to the rare species, the different analysis performed 
between the core species for each group, showed 134 species that were 
significantly different between the core microbiomes of the two groups. 
Porphyromonas gingivalis was part of the core microbiome of both RAnoPD and 
RAPD groups with no statistically significant differences in the relative abundance 
between the groups. Cryptobacterium curtum, while it was part of both core 
microbiomes and was significantly (p<0.048) elevated in the RAnoPD group 
(mean RAnoPD 28.2, mean RAPD 6.5).  
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  Differences in network correlations 
 
The network correlations from the two groups have been described in section 
5.4.7 and 5.3.7.  Different network structures are found between the two groups, 
as a large tight cluster of numerous species inter-correlated form the main node 
in the RAPD group, no the RA periodontally healthy group a smaller cluster was 
found. However, the species in both clusters were predominantly Gram negative 
anaerobes, from the genra Prevotella, Treponema, Porphyromonas, etc. While 
periodontal health shows a a microbial community a network with lower degree 
and modularity class, the bacteria that seemed to lead the community assembly 
in people with RA were similar.  
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5.7. Effect of periodontal therapy in RA microbiome 
The change in the subgingival microbiome of RA patients diagnosed with 
periodontitis before and after periodontal treatment was investigated. Samples 
were collected at baseline and 3 and 6 months after the hygiene appointment as 
part of OPERA study (chapter 2). After the baseline appointment, patients were 
randomised into the treatment group (immediate), which received periodontal 
therapy, or control group, which received hygiene instructions. 21 patients were 
randomised in the immediate group and 25 patients in the delayed group. 
However, due to drop outs or patients that did not give plaque samples in one of 
the visits, only 41 patients donated plaque samples in the 3 visits (baseline, 3 
months after and 6 months after), so some of the analysis included a reduced 
number of patients. 
 
5.8.  Clinical characteristics 
 
The effect of periodontal therapy on the clinical characteristics of the immediate 
group are represented in Table 5. 6. A significant reduction in cumulative probing 
depth (cumPPD) and BoP was found after 3 and 6 months of periodontal therapy. 
However, although a significant reduction of pocket depth was achieved 3 months 
after the periodontal treatment, the significance was lost after 6 months. Although 
there was a reduction of all the RA parameters after periodontal therapy, these 
changes were not significant, except for number of tender joints after 3 months.  
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The baseline comparison between the 2 groups resulted in significant differences 
in DAS28 and VAS between the 2 groups, with the control group having a higher 
DAS28 (Mann-Whitney U test, p=0.02) and VAS (Mann-Whitney U test, p=0.03).  
The rest of the parameters showed no difference at baseline between the two 
groups. These differences at baseline were also found after 6 months of therapy 
(or hygiene instructions for the control group) as significant differences were 
found in DAS28 (Mann-Whitney U test, p=0.009) and VAS (Mann-Whitney U test, 
p=0.04).   
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Table 5. 6 Clinical parameters in the immediate group before and after periodontal 
therapy. Test: Wilcoxon paired test, significance if p<0.05.  
 Immediate 
group 
baseline 
(N=20) 
Immediate 
group 
visit 2 
(N=16) 
Immediate 
group 
visit 3 
(N=15) 
Significant 
Baseline 
vs V2  
Significant 
Baseline 
vs V3 
CumPPD 
median 
(IQR) 
67.5 (64) 41.5(47) 44 (47) 0.006 0.03 
PPD 
median 
(IQR) 
3.4 (1.3) 2.9 (0.8) 3.1 (0.9) 0.005 ns 
CAL 
median 
(IQR) 
3.7 (2.02) 3.6 (1.9) 3.8 (2.7) ns ns 
BoP 
median 
(IQR) 
0.25 (0.4) 0.15 (0.2) 0.1 (0.3) 0.002 0.01 
DAS28 
median 
(IQR) 
4.4 (1.6) 3.7 (1.5) 4.3 (2.1) ns ns 
ESR 
median 
(IQR) 
14.5 (28) 13.5 (15) 13 (25) ns ns 
VAS 
median 
(IQR) 
60 (38) 40 (36) 50 (45) ns ns 
Tender 
median 
(IQR) 
7.5 (8) 5.5 (9) 9 (7) 0.03 ns 
Swollen 
median 
(IQR) 
0.5 (2) 0.5 (2) 0 (2) ns ns 
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Table 5. 7 Clinical parameters in the delayed group before and after oral hygiene 
instructions. Test: Wilcoxon paired test, significance if p<0.05. 
 Delayed 
group 
baseline 
(N=25) 
Delayed 
group visit 
2 (N=25) 
Delayed 
group 
visit 3 
(N=22) 
Significant 
Baseline 
vs V2  
Significant 
Baseline 
vs V3 
CumPPD 
median 
(IQR) 
65 (38) 85 (39) 72 (44) ns ns 
PPD 
median 
(IQR) 
3.15 (0.6) 3.4 (0.9) 3.3 (1.1) ns ns 
CAL 
median 
(IQR) 
3.4 (0.8) 3.6 (1.7) 3.7 (1.3) ns ns 
BoP 
median 
(IQR) 
0.24 
(0.21) 
0.2 (0.4) 0.13 (0.37) ns ns 
DAS28 
median 
(IQR) 
5.4 (1.8) 4.9 (2.6) 4.9 (1.8) ns ns 
ESR 
median 
(IQR) 
22 (25) 16 (28) 23 (19) 0.007 ns 
VAS 
median 
(IQR) 
70 (28) 65 (23)  65 (35) ns ns 
Tender 
median 
(IQR) 
14 (14) 13 (15) 10 (15) ns ns 
Swollen 
median 
(IQR) 
1 (4) 1 (3) 1 (4) ns ns 
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5.9. Longitudinal analysis of immediate group: change with periodontal 
treatment 
18 patients from the immediate group donated plaque samples at baseline (V1) 
and 3 months after treatment (V2). Between V1 and V2, there were significant 
differences in the PCoA analysis of weighted unifrac distances (p=0.03) but not 
unweighted (p=0.8) or Bray Curtis (p=0.053), which implied that periodontal 
treatment changed the microbiome in community structure but not community 
membership (Figure 5. 22). These changes resulted in a significant reduction in 
the percentage of anaeobes that were both Gram positive (p=0.0003) and Gram 
negative (0.01) and a significant increase of Gram positive facultatives (p=0.005). 
 
To further analyze this difference in community structure (group-wise), paired 
differences were analyzed and 42 OTUs were discovered to significantly change 
after periodontal treatment (out of 548) with the majority of those changes (28 
OTUs) representing a reduction in relative abundance and a minority (14OTUs) 
increasing their abundance. Among numerous bacteria from the Fretibacterium 
genera, Tanerella forsythia and Treponella denticola were significantly reduced 
after periodontal therapy. Aggregatibacter actinomycetemcomitans was reduced 
non-significantly (p=0.06) as well as Porphyromonas gingivalis (p=0.1). 
 
In total, 19 patients donated plaque samples at both V1 and V3 (6 months after 
periodontal therapy) and only 11 OTUs were different (pair wise). No significant 
differences were found either weighted, unweighted or bray curtis distances 
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matrices, showing that the changes found 3 months after periodontal therapy may 
be reversed if periodontal therapy is not continued.  
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Figure 5. 22 Differences in beta diversity between baseline (V1) and 3 months after 
periodontal therapy (V2) in RA patients (N=18). Principal Coordinates Analysis 
(PCoA) plots of unweighted  (a.) and weighted (b.) of unifrac distances. Clustering 
significance tested with ANOSIM test (significance if p<0.05). Methods described in 
section 2.5. 
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Figure 5. 23 Differences between baseline (V1) and 3 months after periodontal 
therapy (V2) in RA patients (N=18) in abundance of species by gram staining and 
oxygen requirement characteristics. Wilcoxon matched-paired signed ranked test, 
significance(*) if p<0.05(** if p<0.01; *** if p<0.001).. Methods described in section 
2.5. 
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5.10.  Change of relative abundance 
Group wise, 42 OTUs changed significantly after periodontal therapy. 40 of these 
OTUs were part of the core microbiome (present in 80% of patients), which 
showed that these changes did not only occur in the rare microbiome. 40% of 
these core OTUs were reduced after periodontal therapy, predominated by 
species from the Fretibacterium genra, Veillonacea, Treponema and Tanerella. 
The group of bacteria that significantly increases in relative abundance after 
periodontal treatment is predominated by Streptoccoccus, Actinomyces and 
Neisseria. 
 
10 OTUs were found only at baseline and not V2 and 8 OTUs were found only at 
visit 2, but these OTUs were not part of either core microbiome so those OTUs 
represented rare species.  
 
 
5.11. Delayed group 
 
In the control group (25 patients), beta diversity analysis showed no significant 
differences between microbiome at baseline (V1) and 3 months (V2) (Figure 5. 
24) or 6 months after the appointment with the hygienist (V3) and only 3 OTUs 
changed significantly in a paired-wise analysis of differential abundance (one-
sample t-test Bonferroni corrected) after 3 months and 16 OTUs changed 
significantly after 6 months (out of 560 OTUs in total).  
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Figure 5. 24 Differences in beta diversity of the control group between baseline (V1) 
and 3 months after hygiene instructions given (V2) in RAPD patients (N=25). Principal 
Coordinates Analysis (PCoA) plots of unweighted  (a.) and weighted (b.) of unifrac 
distances. Clustering significance tested with ANOSIM test (significance if p<0.05). 
Abreviations: RA, rheumaotid arthritis,; PD, periodontitis. Methods described in 
section 2.5.  
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5.12. Other analyses 
 
   5.12.1 Effect of periodontitis in systemically healthy microbiome 
 
Clinical characteristics of systemically healthy study volunteers are represented 
in table Table 5. 2. While in the periodontally healthy groups, samples were 
collected from the deepest sites, plaque samples from both deep and shallow 
pockets were collected from the periodontitis group in separate vials, allowing the 
comparison between healthy and disease sites. 
 
When comparing shallow sites of periodontitis patients and deepest sites of 
healthy controls significant differences were found in beta diversity analysis by 
both weighted and unweighted unifrac (Figure 5. 25). However, no differences 
were found in the distribution of Gram staining or oxygen requirements of the 
species (Figure 5. 28.a). 
 
When comparing the deep sites of periodontitis patients and the deep sites of 
healthy controls, differences were found in beta diversity (Figure 5. 26) gram 
staining and oxygen characteristics (Figure 5. 28.b) and alpha diversity (Figure 
5. 27).  
 
The core microbiome of shallow sites comparison showed no unique core OTUs 
for either groups but 70 OTUs were significantly different in abundance out of 317 
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shared OTUs in both core microbiomes. This shows that although obvious 
differences exist between deep sites of periodontitis patients and healthy 
controls, there are also differences in periodontitis patients even when comparing 
healthy sites. 
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Figure 5. 25 Differences in beta diversity between shallow sites of systemically 
healthy patients with and without periodontitis. Principal Coordinates Analysis (PCoA) 
plots of unweighted  (a.) and weighted (b.) of unifrac distances. Clustering 
significance tested with ANOSIM test (significance if p<0.05). N Healthy controls=21; 
n Healthy periodontitis=17. Abbreviations: PD, chronic periodontitis. Methods 
described in section 2.5.  
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Figure 5. 26 Differences in beta diversity between deep sites of systemically healthy 
patients with and without periodontitis. Principal Coordinates Analysis (PCoA) plots 
of unweighted (a.) and weighted (b.) of unifrac distances. Clustering significance 
tested with ANOSIM test (significance if p<0.05). N Healthy controls=21; n Healthy 
periodontitis=17. Methods described in section 2.5. 
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Figure 5. 27 Differences in alpha diversity between deep sites of systemically healthy 
periodontitis patients compared to controls. Kernel plots of alpha diversity (Shannon 
diversity analysis). Test: Mann-Whitney U, significance if p<0.05. The peak indicates 
the median values for each group, and the x-axis shows the data range. N Healthy 
controls=21; n Healthy periodontitis=17. Methods described in section 2.5 
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Figure 5. 28 Differences between shallow (a.) or deep (b.) pockets of periodontitis 
patients and healthy controls in abundance of species by gram staining and oxygen 
requirement characteristics. Mann Whitney U test, significance if p<0.05.. Methods 
described in section 2.5.  
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  5.12.2 Microbiome comparison between shallow and deep 
pockets in noRAPD patients 
 
Further analysis was carried out to investigate the differences between shallow 
and deep pockets in periodontitis patients (clinical data presented in Table 5. 2). 
Plaque samples from both shallow and deep pockets were analyzed from 17 
periodontitis patients and significant differences were found in the beta diversity 
analysis of the two groups (Unweighted and weighted unifrac, ANOSIM p=0.001).  
 
Paired analysis was conducted and 113 OTUs were found to be different and 24 
OTUs were unique for either group (9 unique for deep sites, 16 unique for shallow 
sites) although none of these unique OTUs were part of the core microbiome, so 
the unique OTUs represent rare species. Significantly higher percentage of 
anaerobes (both Gram negative and positive) was found in the deep pockets 
compared to shallow pockets of the same patients, which was not a surprise as 
in the deep pockets the conditions are more anaerobic.  
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Figure 5. 29 PCoA of unweighted (a) and weighted (b) Unifrac distances in RAPD 
patients grouped by type of site where plaque was collected (deep vs shallow). n =17. 
Test: ANOSIM, significance if p<0.05. Abbreviations: RA, rheumatoid arthritis; PD, 
chronic periodontitis. Methods described in section 2.5. 
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Figure 5. 30 Differences between deep and shallow sites from RAPD patients (N=17) 
in abundance of species by gram staining and oxygen requirement characteristics. 
Wilcoxon matched-paired signed ranked test, significance (*) if p<0.05(** if p<0.01; 
*** if p<0.001). Methods described in section 2.5. 
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5.13.  Curette vs paper point 
 
It has been investigated whether the method of plaque collection determines the 
type of species identified using molecular microbiological analysis or real-time 
PCR, showing a strong positive agreement between the two techniques for oral 
microbiology analysis (Belibasakis, Schmidlin et al. 2014) (Jervøe-Storm, 
AlAhdab et al. 2007). However, it is not clear in the case of microbiomic analysis. 
Two plaque samples collected with curette and paper point from the same site in 
one patient (NoRA noPD) were compared. While beta diversity analysis was not 
possible, differential expression analysis (DESeq2) was performed and none of 
the 467 OTUs found in both samples were significantly different between the two 
collection methods. However, 130 OTUs were unique for one sample compared 
to the other, these OTUs were rare species not highly abundant (0.47% of relative 
abundance in the paper point sample and 0.55% of the curette sample). To 
further investigate the differences, the core microbiome of the two samples 
(represents 80% of the sample) were compared and no OTUs were unique or 
significantly different in abundance between the two samples.  
From this small analysis we could conclude that both methods could be used in 
the same analysis, as only a number of OTUs that represent rare species are 
found through one method of sample collection and not the other.  
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5.14. Secondary analysis of randomized group: effect of medication 
In RA, drug therapy plays an essential role in controlling the inflammation and 
symptoms. The RA treatment is often a combination of two or more drugs from 
each type: analgesics, non-steroid anti-inflammatory medication (NSAIDs), 
glucocorticoids, Disease-modifying anti-rheumatic drugs (DMARDs) and biologic 
response modifiers (a type of DMARDs). While analgesics and NSAIDs are fairly 
common and glucocorticoids was one of the exclusion criteria for the OPERA 
study, the differences between patients with DMARDs therapy and biologics 
drugs can alter the microbial community composition in the oral cavity (Zhang, 
Zhang et al. 2015). 
 
For this reason, subgroup analysis was performed from 31 RAPD patients whose 
medication data was available as part of the longitudinal data from the OPERA 
study. To compare if the microbiome at baseline was different depending on the 
type of medication, patients were divided into 3 groups: patients on DMARDs (12 
patients), patients on biologics (6 patients) and patients on DMARDs and 
biologics (13 patients). No significant differences were found (ANOSIM 
unweighted unifrac p=0.5; weighted unifrac p=0.4).  
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Figure 5. 31 PCoA of unweighted (a) and weighted (b) Unifrac distances in RAPD 
patients grouped by type of medication. n =31. Test: ANOSIM, significance if p<0.05. 
Abbreviations: RA, rheumatoid arthritis; PD, chronic periodontitis, DMARDs, 
Disease-modifying anti-rheumatic drugs. Methods described in section 2.5. 
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5.15. Discussion 
 
   Cross-sectional comparisons of oral microbiome 
 
The results presented in this chapter showed that there are differences in the oral 
bacteria composition and community structure in RA that is changed with 
periodontal status. This supports the existence of cross-talk between the 
immunological condition of RA and the oral microbiome. This cross-talk that 
results in changes in the conditions of the oral cavity in RA, facilitating the growth 
of anaerobic bacteria compared to healthy controls. These differences found in 
the RA microbiome could be due to differences in the clinical characteristics of 
the population studied, such as the differences in age between the study groups 
or the RA medication. However, in our study, none of the clinical parameters 
seemed to explain the shift in the microbiome other than the periodontal and 
rheumatological features. Nevertheless, other non-RA medication and other 
comorbidities might have an effect on the oral bacteria and as we did not have 
such extensive record of patient's comorbidities and medications, it cannot be 
concluded from our study that these conditions did not alter the oral microbiome 
and future research is needed to investigate this.  
 
It has been described that the oral microbiome in RA is altered compared to 
controls (Scher, Ubeda et al. 2012, Zhang, Zhang et al. 2015). However, the lack 
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of differentiation between periodontally healthy patients and patients with chronic 
periodontitis in these studies could explain the differences found between the 
groups, as RA patients have a much higher prevalence of periodontitis compared 
to the systemically healthy population (Tang, Fu et al. 2017). In section 5.3, the 
oral microbiome in periodontally healthy RA patients was investigated and 
significant differences were found compared to controls.  
 
The main hypothesis connecting the oral microbiome and RA is based on the 
presence of Porphyromonas gingivalis. However, studies have found no 
differences in P. gingivalis levels in RA compared to controls (Mikuls, Payne et 
al. 2014) (Zhang, Zhang et al. 2015) and it is also not elevated in new-onset RA 
patients (Scher, Ubeda et al. 2012). This was also discovered in this chapter, as 
it was found that in non-periodontitis patients (noRAnoPD) P. gingivalis was not 
elevated nor correlated with RA. In non-periodontitis patients, P. gingivalis is part 
of the core microbiome in both RA and NoRA groups but although the abundance 
is higher in the RA group (0.4 fold2 ), the difference is not significant. Other 
species such as P. intermedia are significantly more abundant in NoRA  vs  RA 
(3.5 fold2). Another species described to be elevated in RA is Lactobacillus 
salivarius (Zhang, Zhang et al. 2015) but although its abundance is increased in 
RA, the difference is not statistically signifficant.  The difference between our 
findings and the literature might be explained by the absence of periodontitis in 
our study population.  
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Interestingly, we found that in periodontally healthy patients (RAnoPD), RA 
provides a more anaerobic environment in the gingival pocket, facilitating the 
growth of obligate anaerobes. This could be a pre-clinical phase of periodontitis. 
However, in periodontitis patients, RA does not contribute towards a more 
anaerobic environment but on the contrary, the group diagnosed with PD alone 
(no RA) presented the highest proportion of anaerobes (Figure 5. 32).  This is 
interesting as it shows that periodontal bacteria in RA might be different to the 
periodontal bacteria in systemically healthy.  
 
Conclusions from the human microbiome project estimate that inter-individual 
differences are greater than differences between sites of the same area of the 
body and that the microbiome of individuals is relatively stable in time 
(Turnbaugh, Ley et al. 2007). This is supported by our research, which founds a 
stable microbiome showing no major changes after 3 and 6 months in the control 
group, and no major differences between the shallow and deep pockets. 
However, this contradicts a recent study that shows big differences between 
shallow and deep sites of periodontitis patients, although they only investigate 9 
subjects (Turnbaugh, Ley et al. 2007). More research is needed to elucidate the 
differences between deep and shallow sites in periodontitis with bigger sample 
sizes and robust bioinformatic methodologies.  
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Figure 5. 32 Anaerobes proportion comparison between the 4 study groups.  
 
One of the most intriguing findings was the identification of Cryptobacterium 
curtum as a predominant member of the RA-influenced periodontal microbiome. 
This Gram-positive, assacharolytic, anaerobic rod (which was previously 
classified as Eubacterium saburreum) degrades arginine through the arginine 
deiminase pathway and produces substantial amounts of citrulline, ornithine and 
ammonia (Uematsu, Sato et al. 2006). More importantly, C. curtum is enriched in 
the oral and gut RA microbiomes and in early RA cases (Scher, Ubeda et al. 
2012, Zhang, Zhang et al. 2015). Furthermore, early investigations have 
demonstrated that 48% of the variation in alveolar bone loss in RA patients could 
be attributed to an organism that was then identified as E.saburreum and later 
reclassified as C.curtum (Uematsu, Sato et al. 2003). In the present investigation, 
this species was a member of the core microbiome in RA patients, demonstrated 
a 100-fold greater abundance in this cohort when compared to controls with a 39-
fold greater odds of detection in this cohort. While this unusually high association 
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does not necessarily suggest an aetiopathogenetic role for C.curtum, this 
organism is a candidate for further studies.  
However, although 16S rRNA is an accepted method to investigate the oral 
microbiome, there are limitations, as the taxa are predicted based on 
associations of the 16S gene sequences with taxa defined as OTUs. Therefore, 
this method is valid to analyze microbiome at phyla or genera level but can loose 
precision at species level. Whole genome shotgun sequencing has been shown 
to have numerous advantages over 16S detecting at bacteria species and an 
enhance capacity to detect diversity (Ranjan, Rani et al. 2016). 
 
In summary, our data suggest that rheumatoid arthritis plays a major role in 
shaping the oral microbiome, enriching this environment for inflammophilic 
organisms and those capable of producing substantial amounts of citrulline. Our 
findings lend further credence to a link between the oral microbiome and RA; 
however, the directionality or causality cannot be explored with this cross-
sectional study design.  
 
  Longitudinal comparison: effect of periodontal therapy 
In this group of RAPD patients, there was no effect of periodontal therapy in the 
RA parameters such as DAS or ESR, and the reduction observed in the other 
chapters (Chapter 3,4 and 6) did not occur. While these differences were 
surprising it could be explained as, although these patients came from the same 
trial, not all patients donated the same type of samples for different reasons 
(some patients had difficult veins, others had to leave before we collected the 
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plaque, etc) and there were 11 patients which samples were not included for both 
experiments. In such small sample sizes (<20), 11 patients can drastically change 
the group outcomes. 15% of the patients that donated bloods for the Chapter 3 
and 4 were not in part of the cohort presented in this chapter and 27% of the 
patients included for the microbiome analysis were not part of the cohort included 
in chapters 3 and 4. That could explain the difference between the longitudinal 
outcomes between the chapters.  
 
Even with such small sample size, the periodontal parameters and beta diversity 
of plaque structure were significantly reduced 3 months after periodontal therapy, 
leading to a lower proportion of Gram negative anaerobes. These differences 
were only significant considering the abundance of the species present 
(community structure) and not the absence-presence (community composition).  
 
However, after 6 months, these periodontal parameters non-significantly 
increased, and the differences between baseline and 6 months after are not 
significant for beta diversity or periodontal parameters. This is supported by 
previous microbiological findings showing that a single course of scaling and root 
planning is insufficient as periodontal bacteria recolonized the periodontal pocket 
after 2 months (Sbordone, Ramaglia et al. 1990). The results from this chapter 
shows that the oral microbiome related to periodontitis and the clinical 
characteristics return in RA patients so periodontal maintenance treatment 
should be provided.   
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In this chapter, we show that periodontal therapy, in RA, is effective in changing 
the abundance of the species, but not the composition of the biofilm that causes 
disease. Nevertheless, if periodontal care is not continued with oral hygiene and 
periodical visits to the dentist, the community structure can return to a disease 
state and therefore worsen the clinical parameters of disease.  
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6. RESULTS - CHANGES IN GCF 
CYTOKINES AFTER 
PERIODONTAL THERAPY 
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6.1. Introduction 
The hypothesis of the study presented in this chapter was that, in patients with 
rheumatoid arthritis and periodontitis undergoing periodontal therapy there are 
changes in the GCF cytokine profile, correlated with systemic markers of RA 
disease and periodontal bacteria.  
 
The aims of this chapter were:  
 
1) To compare the level of GCF cytokines before and after periodontal therapy 
compared to a control group that did not receive such therapy.  
 
2) To analyse the correlations between the local cytokine response changes and 
systemic markers of RA inflammation and periodontal bacteria.  
 
This chapter presents the results from a commercially available multiplex bead-
based assay designed to semi-quantify multiple cytokines. Gingival crevicular 
fluid (GCF) was used to measure 27 cytokines in RA patients with periodontitis 
collected before and 6 months after randomisation (Table 6. 1). Patients that fell 
into the immediate group received non-surgical periodontal therapy and the 
delayed group received oral hygiene instructions. Methods are described in detail 
in chapter 2.4. 
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Table 6.1 Cytokines investigated in this chapter. 
IL-1β  IL-10 IFN-γ IL-5 IL-17A MIP-1β 
IL-1ra IL-12 
(p70) 
IP-10  IL-6 Eotaxin PDGF-
BB 
 IL-2  IL-13 MCP-1 
(MCAF) 
 IL-7 FGF 
basic 
RANTES 
 IL-4 IL-15  MIP-1α IL-8 G-CSF TNF 
    IL-9 GM-
CSF 
VEGFs 
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6.2.  Study volunteers 
 
Patients with periodontitis and active RA were selected for the OPERA 
longitudinal study (exclusion/inclusion criteria described in Chapter 2.1) and GCF 
from 44 patients were analysed in this chapter. From the 44 eligible patients, 22 
patients were randomly allocated in the immediate group and 22 in the delayed 
group. Clinical and demographical characteristics of the study population are 
described in chapter 3, with the exception of two patients included in the 
immediate group in this chapter, which donated GCF samples but not serum. 
Differences in clinical parameters at baseline between immediate and delayed 
group were not significant (Table 3.2 section 3). A significant reduction of 
periodontal and some of the RA parameters was achieved after periodontal 
therapy (Table 3.3).  
 
6.3. Longitudinal analysis 
 
  Effect of periodontal therapy on cytokine production   
A panel of 27 cytokines was selected, including Th1 and Th2 cytokines 
(interleukin-2 [IL-2] and gamma interferon [IFN-γ]), pro-inflammatory cytokines 
(IL-1β, IL-6, and granulocyte-macrophage colony-stimulating factor [GM-CSF]), 
and chemokines (IL-8). 
 
Calibration curves for each cytokine were interpolated to calculate the 
concentration of the cytokines studied. Blank values were subtracted from the 
raw data and results were presented as Arbitrary Units per ml (AU/ml).  
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The longitudinal analysis of the GCF cytokines in the immediate group revealed 
a significant decrease of IL8, IL9, VEGF, MP1-α after periodontal therapy that did 
not occur in the control group. Other cytokines decreased close to significance 
(p<0.06) after periodontal treatment, such as IL-10, IL-12 and TNF and RANTES. 
Decreases close to statistical significant could be of interest in studies with such 
small sample size (n=22).  
 
Interestingly, there was a significant increase of cytokines IL-2 and IL-15 in the 
treatment group after periodontal therapy, which did not occur in the control 
group. 
 
The rest of the cytokines studied, including IL-1 (α and β), IL-6 and IL-17 non-
significantly decreased after periodontal therapy and, in the control group, no 
significant changes were found in any of the 27 cytokines studied, in GCF 
collected 6 months after randomization.  
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Figure 6. 1 Longitudinal analysis of the cytokines that significantly decrease after 
periodontal therapy. V1 represents antibody levels in GCF collected at baseline and 
V2 collected 6 months after. Data presented in Arbitrary units per ml (AU/ml). n 
Immediate treatment group=22; n Delayed group=22. Statistical test used was 
Wilcoxon matched pair test (significance * p<0.05; **, p<0.01). Methods described in 
section 2.2. Abbreviations: GCF, gingival crevicular fluid; IL, interleukin.  
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Figure 6. 2 Longitudinal analysis of the cytokines that significantly decrease after 
periodontal therapy. V1 represents antibody levels in GCF collected at baseline and 
V2 collected 6 months after. Data presented in Arbitrary units per ml (AU/ml). n 
Immediate treatment group=22; n Delayed group=22. Statistical test used was 
Wilcoxon matched pair test (significance * p<0.05; **, p<0.01). Methods described in 
section 2.2. Abbreviations: GCF, gingival crevicular fluid; VEGF,.vascular endothelial 
growth factor; MIP, macrophage inflammatory protein. 
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Figure 6. 3 Longitudinal analysis of cytokines that significantly increase after 
periodontal therapy. V1 represents antibody levels in GCF collected at baseline and 
V2 collected 6 months after. Data presented in Arbitrary units per ml (AU/ml). n 
Immediate treatment group=22; n Delayed group=22. Statistical test used was 
Wilcoxon matched pair test (significance * p<0.05; **, p<0.01). Methods described in 
section 2.2. Abbreviations: GCF, gingival crevicular fluid; IL, interleukin.  
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Figure 6. 4 Longitudinal analysis of cytokines that decreased close to significance (p<= 0.06) 
after periodontal therapy in the immediate group. V1 represents antibody levels in GCF 
collected at baseline and V2 collected 6 months after. Data presented in Arbitrary units per 
ml (AU/ml). n Immediate treatment group=22; n Delayed group=22. Statistical test used was 
Wilcoxon matched pair test (significance * p<0.05; **, p<0.01). Methods described in section 
2.2. Abbreviations: GCF, gingival crevicular fluid; IL, interleukin; TNF, tumor necrosis factor.  
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6.3.1.1. Effect of periodontal therapy on cytokine production 
according to smoking and ACPA status 
 
In ACPA positive patients, there was a significant decrease of IL-1b, IL-8, IL-9, 
IL-10, IL-12, VEGF and TNF and significant decrease of IL-15 after periodontal 
therapy. The cytokines that revealed significant changes only in ACPA+ patients 
but not when investigating totality of RA patients were IL-1b, IL-10, IL-12, VEGF 
and TNF, which, in the main longitudinal analysis, showed p values close to 
significance. No significant differences were found in the ACPA- patients 
probably due to the small sample size (N=4).  
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Table 6. 2. Significant changes in cytokine production after periodontal therapy in 
ACPA+ patients. Positive values in median of differences represent increase, 
negative values represent decrease. Test: Wilcoxon paired test, significance p<0.05  
Median of differences (AU/ml) P value 
IL-1b -382.055 0.009 
IL-8 -388.79 0.014 
IL-9 -8.78 0.029 
IL-10 -2.35 0.049 
IL-12 -12.64 0.006 
IL-15 4.34 0.003 
VEGF -330.05 0.001 
TNF -2.31376 0.05 
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As smoker individuals have been shown to have an increased release of 
pro-inflammatory cytokines in the GCF (Giannopoulou, Kamma et al. 
2003), subgroup analysis stratified by smoking status was performed, 
which revealed that in smokers, only IL-4 decreased significantly 
(p=0.027, median of differences -2.27) after periodontal therapy although 
the small number of current smoker patients (N=4) might be the reason for 
the lack of significances in the rest of the cytokines. Interestingly, it has 
been shown that although IL-4 is elevated in health, this cytokine is also 
significantly correlated with smoking (Giannopoulou, Kamma et al. 2003). 
 
In non-smoker patients, there was a significant decrease of IL-b, IL-12, IL-
8 and VEGF, and a significant increase in IL-15 after periodontal therapy. 
IL-1b and IL-12 appear as significant in this subgroup analysis while it was 
not significant in the analysis of the whole treatment group (Table 6.3).  
  
 279 | P a g e  
 
 
Table 6. 3 Significant changes in cytokine production after periodontal therapy in non-
smoker patients. N= 13. Positive values in median differences represent increase, 
negative values represent decrease. Test: Wilcoxon paired test, significance p<0.05  
Median of differences P value 
IL-1b  -586.06 0.045 
IL-8  -247.38 0.037 
IL-12 -10.73 0.009 
IL-15  0.43 0.013 
VEGF  -319.60 0.001 
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Figure 6. 5 Cytokines that significantly decreased after periodontal therapy in ACPA+ 
patients only. after periodontal therapy. N= 18. V1 represents antibody levels in GCF 
collected at baseline and V2 collected 6 months after. Data presented in Arbitrary 
units per ml (AU/ml). Statistical test used was Wilcoxon matched pair test 
(significance * p<0.05; **, p<0.01). Methods described in section 2.2. Abbreviations: 
GCF, gingival crevicular fluid; 
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Figure 6. 6 Cytokines that significantly decreased after periodontal therapy when 
stratifying by smoking status only. V1 represents antibody levels in serum collected 
at baseline and V2 collected 6 months after. Data presented in arbitrary units per ml 
(AU/ml). N Treatment group=23; n Delayed group=22. Statistical test used was 
Wilcoxon matched pair test (significance * p<0.05; **, p<0.01). Methods described in 
section 2.2 
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6.4.  Correlation analysis 
The Spearman rank correlation analysis was performed to investigate the 
relationship between the local cytokine production in the crevicular space and the 
clinical (rheumatologic and periodontal) parameters at baseline for both groups 
(immediate and delayed), but no significant (p<0.05) positive correlations were 
found (Table 6.4).  
 
Additionally, correlation analysis of the changes on cytokine production and 
changes on clinical parameters after periodontal therapy was investigated, and 
only one correlation was found significant, between RANTES and ESR 
(p=0.02,r= 0.57). 
 
To investigate what bacteria participates in the inflammatory response of the 
gingival crevice in these patients, the relative abundance of the red complex 
bacteria (Socransky, Haffajee et al. 1998) (studied using 16s rRNA techniques, 
explained in chapter 5) was correlated to cytokines produced in the crevicular 
fluid baseline of all randomized patients that provided both GCF and plaque 
samples (n=40). Although various weak but significant associations were 
discovered, the strongest and most significant association found was between 
the relative abundance of Cryptobacterium curtum (CC) and TNF. CC was also 
correlated to a high number of pro-inflammatory cytokines including IL-8, IP-10 
and MIP-1α. Porphyromonas gingivalis (PG) was correlated with pro-
inflammatory cytokines such as IL-6, TNF and IL-1β. Tanerella forsythia (TF), 
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although has been described as red complex bacteria that induces pro-
inflammatory cytokine production (Bodet, Chandad et al. 2006), was negatively 
correlated with IL-9, MIP and TNF in our study. 
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Figure 6. 7 Significant correlations between periodontal bacteria from plaque samples and 
cytokines from GCF samples. Test: Spearman's rank correlation, significance p<0.05. N=40. 
Abbreviations: GCF, gingival crevicular fluid; IL, interleukin; TNF, tumor necrosis factor; IP-
10, inducible protein 10; MIP, macrophage inflammatory protein.  
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Table 6. 4 Correlation analysis between periodontal bacteria and cytokines and 
clinical parameters at baseline 
Relative 
abundance 
Cytokine r p 
TF IL-9 -0.35 0.026 
TF IL-10 -0.31 0.048 
TF MIP-1α -0.32 0.04 
TF MIP-1β -0.36 0.02 
TF TNF-α -0.32 0.045 
PG IL-6 0.34 0.02 
PG G-CSF 0.34 0.03 
PG IL-1b 0.38 0.02 
CC IL-8 0.32 0.04 
CC IL-10 0.34 0.009 
CC IP-10 0.38 0.01 
CC MIP-1α 0.31 0.048 
CC TNF-α 0.5 0.002 
AA IL-7 0.31 0.049 
AA G-CSF 0.36 0.032 
AA IFN-g 0.32 0.045 
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6.5. Discussion 
 
The study of the cytokines and inflammatory mediators in RA has been crucial to 
understand the pathogenesis of the disease and the development of new drugs 
and therefore, it is important to understand the effect of periodontal therapy on 
these cytokines, and its association with systemic markers of inflammation. The 
hypothesis of this study was that, in RA patients undergoing periodontal therapy 
there is a reduction of local production of cytokines and that these cytokines are 
correlated to periodontal bacteria and markers of inflammation.  
 
While significant differences were found in pro-inflammatory cytokines after 
periodontal therapy, these local cytokines were not correlated with systemic 
markers of inflammation at baseline of all patients included in this project. 
Furthermore, we did not find a correlation between the changes on cytokine 
production after periodontal therapy and changes on clinical parameters.   
 
However, the local cytokine profile was correlated with some of the most 
important periodontal pathogens. The most significant correlation found was 
between Cryptobacterium curtum and TNF. As explained in chapter 5, this 
bacterium is highly associated to RA with the highest OR of all bacteria and other 
studies have found this bacterium in RA patients (Zhang, Zhang et al. 2015). The 
correlation between this bacteria and pro-inflammatory cytokines is the GCF of 
RA patients shows that more research is needed to elucidate what is the exact 
role of this bacterium in RA. Also P. gingivalis is significantly correlated with pro-
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inflammatory cytokines such as IL-6 and IL-1b. These findings could demonstrate 
that periodontal pathogens orquestrate the immunological response in the 
periodontal pocket that can be modified with periodontal treatment. In our study, 
this local inflammatory response was not correlated with clinical parameters such 
as the DAS28 or ESR, after 6 months of periodontal therapy. Our results, do not 
contradict the main hypothesis, as there are limitations in this chapter such as 
the short follow up time, small sample size or the lack of corrections for multiple 
correlations (i.e. bonferroni). 
 
Some of the most important pro-inflammatory mediators in RA are TNF, IL-1 and 
IL-6, which have autocrine, paracrine and endocrine effects and induce the 
synthesis of other cytokines, inflammatory mediators (prostaglandins, MMP, etc), 
acute phase response (CRP and ESR), B-cells and activation of osteoclast 
(Feldmann, Brennan et al. 1996).  Our results show that most of these cytokines 
were reduced after periodontal therapy. 
 
 IL-8 is a potent chemokine produced as a response to an inflammatory stimuli 
that has different functions on cells of the immune system, particularly, recruiting 
and activating neutrophils in acute inflammatory conditions (Harada, Sekido et al. 
1994) but also, in RA IL-8 is increased in synovial fluid (SF) of patients with active 
disease and its concentration is correlated with the number of neutrophils 
infiltrating the SF (Endo, Akahoshi et al. 1991). IL-9 is also a pro-inflammatory 
cell and anti-apoptotic, impeding the resolution of the inflammatory response, and 
it has been found to be significantly elevated in pre-RA patients and RA patients 
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compared to controls (Kokkonen, Söderström et al. 2010). These two pro-
inflammatory cytokines, in our study, experience a significant decrease (p=0.02) 
after periodontal treatment in RA. 
Also IL-12 and TNF were non-significantly (p=0.06) reduced but in ACPA+ 
patients and in non-smokers, these reductions became significant (Figure 6.4 and 
6.5). IL-12 is an interesting cytokine as has functions in the early inflammatory 
response against bacteria and also in the activation of the antigen-specific 
immunity.  
 
VEGF (vascular endothelial growth factor) is a potent pro-inflammatory cytokine 
in chronic conditions and it has been described to play a key role in RA, being 
significantly elevated in RA patients relative to control subjects, and correlated 
with disease activity. Treatment of RA patients with anti-TNF significantly 
decreased serum VEGF, and this effect was enhanced by cotreatment with 
methotrexate (Paleolog, Young et al. 1998). In our study, VEGF was significantly 
decreased after periodontal treatment in GCF of RA patients (Figure 6.2). 
 
MIP-1α (macrophage inflammatory protein) acts as chemotractant and 
proinflammatory cytokine and it is in high concentrations in the gingiva of 
periodontitis patients (Gemmell, Carter et al. 2001). In our study, MIP-α was 
significantly decreased after periodontal treatment in GCF of RA patients. 
 
Conversely, in the control group, none of the cytokines investigated changed 
significantly or close to significance. These findings might reflect that the state of 
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local inflammation in the gingiva of patients with chronic periodontitis is relatively 
stable if not treated and that, after periodontal therapy, the cytokine profile can 
be reverse into a healthier state.  
 
IL-2 and IL-15 play important roles in the control of lymphocytes, as IL-2 and T-
cell responses for the maintenance of self-tolerance and IL-15 as an anti-
apoptotic factor (Waldmann 2015). Moreover, IL-2 and IL-15 deficient mice were 
associated with dysregulated proliferation of T and B-cells. In our study, we see 
a reduction of IL-15 and IL-2 after periodontal therapy that could be fundamental 
to the reduction of the inflammatory response in RA demonstrated by the 
significant reduction of RA parameters. Other investigators also found lower 
levels of IL-2 in RA synovia compared to health (Firestein, Xu et al. 1988). 
 
 In RA, synovial fluid and blood has decreased production of IL-2 compared to 
healthy individuals, supports the notion that T-cells are involved in pathogenesis 
of RA that may lead to defective T suppressor and B cell hyperactivity (Combe, 
Pope et al. 1985). Ebersole and colleagues found a significant increase of IL2, 
five months after the resolution of periodontitis (Ebersole, Kirakodu et al. 2014), 
which is in agreement with the results presented. Absence of IL-2 leads to 
susceptibility to inflammatory disorders, as there is a decline in Treg cells and 
increase of Th17. 
 
It is important to mention that, in our study, some patients were on biologic drugs, 
which target specific molecules such as TNF (i.e. Adalimumab, infliximab) or IL-
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6 (i.e. Tolizumab) and even stops the costimulation process of T-cells (i.e. 
Abatacept). Although this data was available for some of the patients, the 
heterogeneity of the drugs used made impossible an statistical analysis in such 
small sample size. However, this drugs could also affect the cytokine production 
in the GCF.  
 
IL-4 is the only cytokine that is increased after periodontal therapy in smokers. 
Interestingly, this cytokine has been shown to be reduced in health compared to 
RA, periodontitis and aggressive periodontitis (Havemose-Poulsen, Westergaard 
et al. 2006) and the absence of this cytokine enhances de expression of CD4 and 
macrophages and an increase of this cytokine is related to re-install the balance 
of inflammation and decrease of production of pro-inflammatory cytokines (Salvi, 
Brown et al. 1998). In smokers, this might mean that the balance of cytokines 
might take more than 6 months but it is initiated by IL-4 increase.  
 
Another flaw of this chapter was that the levels of cytokines detected in GCF 
should have been normalized with the volume of fluid detected by the Periotron®. 
However, the instrument utilized for the measurement of GCF fluid was calibrated 
3 years prior to finishing the study, which makes the volumes annotated 
unreliable (Ciantar and Caruana 1998). For this reason, these results present a 
semi-quantitative measurement of GCF cytokines and the units used are AU/ml 
instead of total amounts (pg/30 s).  
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7. CONCLUSIONS AND FINAL 
REMARKS 
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7.1. Summary of main findings 
The aim of this thesis was to investigate the role of periodontitis in RA and the 
effect of periodontal therapy on immunological and microbiological parameters. 
To do that, different biological samples were collected from two pilot studies, 
comparing RA and periodontitis patients to the appropriate controls (i.e. RA 
periodontally healthy, no RA periodontitis and no RA no periodontitis) and from a 
selected group of randomized RAPD patients before and after periodontal 
therapy.  The specific aims were: 
 
Objective 1: To investigate the antibody response to citrullinated and un-
citrullinated peptides in sera of patients with RA and periodontitis compared to 
RA alone, periodontitis alone and the systemically and periodontally healthy 
controls and possible changes after periodontal treatment. 
 
Objective 2: To investigate the antibody response to periodontal bacteria 
antigens in sera of patients with RA and periodontitis compared to RA alone, 
periodontitis alone and the systemically and periodontally healthy controls and 
possible changes after periodontal treatment. 
 
Objective 3: To compare the subgingival microbiota of patients with RA and 
periodontitis, RA alone, periodontitis alone and the systemically and periodontally 
healthy controls and effect of periodontal therapy. 
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Objective 4: To investigate the differences in the cytokine response in gingival 
crevicular fluid in patients with periodontitis and RA (compared to controls: RA 
alone, periodontitis alone) and how non-surgical periodontal therapy changes 
immune response signatures. 
 
To examine these objectives, antibodies to citrullinated proteins and bacterial-
related antigens were quantified in serum using ELISA methods, local 
inflammatory markers were measured from GCF using a multiplex assay of 27 
cytokines and plaque microbiome was identified using 16S rRNA analysis using 
the Ilumina MiSeq platform.  
 
The findings from the study of the antibodies to citrullinated and uncitrullinated 
human proteins in serum showed no significant difference between the RA group 
with or without periodontitis and the systemically healthy patients with and without 
periodontitis (Chapter 3). Although a slight elevation of antibodies was observed 
in the periodontitis groups, it could not be confirmed that periodontitis produces 
an elevation of antibodies to citrullinated proteins. In the longitudinal analysis, 
although periodontal therapy significantly reduced RA and periodontal clinical 
parameters, there was no effect on the level of antibodies against citrullinated 
proteins. 
 
The findings from the study of antibodies to bacterial proteins from serum showed 
that RA patients have an increased production of antibodies against periodontal 
bacteria, in both periodontally healthy and periodontitis groups (Chapter 4). 
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Although the number of patients with antibody positivity was low, these results 
suggest that Fusobacterium nucleatum, Porphyromonas gingivalis and PPAD but 
not RgpB or Prevotella intermedia, act like an antigen in RA provoking an 
antibody reaction that does not appear to be due to ACPA cross reactivity. 
However, periodontal therapy did not reduce the production of antibodies to PG-
antigens or FN after 6 months. 
 
The findings from the microbiome analysis of RA patients showed that both RA 
and PD (and not age, gender or other clinical parameters) shift the oral 
microbiome, facilitating the growth of anaerobic bacteria (Chapter 5). 
Interestingly, even in periodontally healthy patients, RA leads to a more 
anaerobic and Gram-negative oral microbiome, with species such as 
Cryptobacterium curtum being highly elevated (100-fold greater abundance) in 
RA. While PD also have a major role in shaping the oral microbiome in RA and 
systemically healthy patients, periodontal therapy only affected the bacterial 
composition after 3 months but not after 6 months, following the same pattern 
that the clinical parameters. This reinforces the importance of periodontal 
maintenance and continuous treatment to reach periodontal health.  
 
The findings from the study of inflammatory cytokines before and after 
periodontal therapy in RA showed a significant reduction of pro-inflammatory 
cytokines after periodontal therapy (Chapter 6). Cytokines such as IL-8, IL-9, 
VEGF and MIP-1a were significantly reduced 6 months after periodontal therapy, 
and others such as IL-10, IL-12 and TNF were reduced with p values lower than 
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0.6 (close to significance). Considering the small sample size, it can be concluded 
that in RA, periodontal therapy lead to a reduction of local pro-inflammatory 
cytokines that did not occur in the control group, significantly and positively 
correlated with the relative abundance of some periodontal bacteria, such as P. 
gingivalis and Cryptobacterium curtum.  
 
7.2. Limitations  
The study design used in this thesis had numerous flaws, which makes difficult 
the interpretation of the results presented in this thesis. As a pilot study, the 
OPERA trial aimed to collect feasibility information and was not powered or 
designed for the realization of the aims of this thesis. For that reason, certain 
limitations such as the number of patients or certain methodologies need to be 
considered when assessing the relevance of the results presented here. 
 
The inclusion criteria for the OPERA study aimed to ensure a minimum of RA and 
periodontal disease activity. However, we believe that both the RA criteria 
(minimum of 3.2 DAS28) and periodontal criteria (minimum of 40 mm of 
cumulative probing depth) represent in some cases a mild disease spectrum. 
Having a mild disease group impedes finding differences with the healthy control, 
which could explain the results found in Chapter 3 and 4. Also, having low disease 
activity impedes finding a significant effect of periodontal therapy in the 
longitudinal part of the study, as although both RA and PD parameters were 
reduced in all chapters in the control group, the differences are rather small.  
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Measuring the effect of any treatment in RA patients is challenging due to the 
nature of RA. If patients are not in remission, this chronic disease is characterized 
by numerous immunological changes due to flair ups and changes in 
medications.  These changes could be silencing the effect of periodontal therapy 
and adds to the great patient variability observed in this thesis. 
 
The results of this thesis support that P. gingivalis remains a candidate for the 
trigger of autoimmune response in RA. While antibodies to P. gingivalis were 
elevated in RA, the presence and abundance of PG in plaque was not correlated 
with antibodies against P. gingivalis, which indicates that there seem to be a 
specific immunological response to this periodontal bacterium in RA, not due to 
an increase of P. gingivalis in periodontitis but because it is recognized as an 
antigen. This specific antigen recognition could therefore be the trigger for the 
antibody reaction in RA but more research is needed in longitudinal trials with 
pre-RA patients. While it has been discussed that this elevation of antibodies 
against P. gingivalis could represent a cross-reaction with antibodies to 
citrullinated proteins, the elevation of antibodies to non-citrullinated proteins from 
P. gingivalis (such as RPP3, PG-eno and OMA-PG) shows this is unlikely but to 
truly verify this, a cross-reactivity experiment should be conducted, so our 
hypothesis cannot be confirmed. 
 
The methodology used in each chapter also revealed some limitations. In the 
antibody analysis, no standard curve was available for some of the antigens, such 
as RPP3 and a low concentration of antibodies was found in all subjects. Thus, 
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the results from those experiments are not as robust and conclusions should be 
made cautiously. For the analysis of the cytokine array, the data should have 
been normalized using the volume of GCF collected in 30 seconds measured 
with the Periotron®. Unfortunately, as this instrument was not appropriately 
calibrated, cytokine concentration was presented in AU/ml instead of total 
amounts (pg/30 s), being a semi-quantitative method. Also, the microbiome 
analysis using 16S phylogenetic marker is considered the gold standard, this 
method has limitations, such as the production of PCR artifacts, and the relatively 
low resolution at species level (Pontes, Lima-Bittencourt et al. 2007). Also, using 
16S sequencing does not provide information about functions or sub-species of 
bacteria, which can be obtained through other methods such as whole-
metagenome shotgun sequencing, which studies the entire genetic microbial 
composition of an environment.  
 
The small sample size in the longitudinal groups amplifies the impact of the 
patient variability found in our results. Although all experiments were conducted 
using biological samples collected from the same randomized group of patients, 
when evaluating the effect of periodontal therapy in DAS28 or ESR levels, a 
change of a few patients due to drop outs or due to inexistence of certain sample, 
changes the significance. This loss of significance is due to the small group of 
patients and high heterogeneity and a larger group needs to be investigated to 
overcome this limitations. 
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Effectiveness of one single course of periodontal therapy has been previously 
discussed and some periodontologists insist that continuous treatment has to be 
offered or the clinical and microbiological signs of periodontitis return after 2 
months (Sbordone, Ramaglia et al. 1990). As this periodontal maintenance was 
not provided in our study and plaque scores were not recorded, the effect of 
periodontal therapy in the microbiome or immune system after 6 months is 
expected to be low, which can explain our negative results. 
 
7.3. Conclusions and future research 
The findings from this thesis lend further credence to the link between RA and 
the oral microbiome, with RA patients having a disrupted and more anaerobic 
microbiota and an exacerbated immunological reaction against periodontal 
bacteria and citrullinated proteins. However, the directionality or causality cannot 
be explored with this cross-sectional study design. Longitudinal studies that 
follow up RA and PD patients before and after they are diagnosed, are necessary 
to identify the directionality and the driver species (such as Cryptobacterium 
curtum) that could serve as markers for RA diagnosis and stratification of patients 
and to assess if oral dysbiosis occurs as a pre-clinical phase of periodontitis, RA, 
both or none. The results presented in the longitudinal study sets the basis to 
follow for a larger and controlled randomized controlled trial that, by increasing 
the sample size and correcting the errors from our protocol, overcomes the 
limitation of studying such variable disease.  
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8. Appendices 
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8.1.  Calibration curves for antibody ELISAs 
Preliminary experiments were necessary to find appropriate positive contros to 
use in the plates that tested the antibody levels against ACAPAs and PG-
antigens. To that end, patient sera was diluted following a standard curve and 
plates were tested (Figure 8. 1, Figure 8. 2, Figure 8. 3, Figure 8. 4). However, 
no appropriate control was found for the arginated peptides (non-citrullinated) or 
RPP3 and PPAD, due to the lack of patients with strong antibody reaction against 
this antigens.  
These results demonstrate low antibody reaction to the arginated human proteins 
in this study and limits the reliability of the results found from the non-controlled 
antigens tested. 
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Figure 8. 1 Failed attempts to find calibration curves for antibody ELISAs to human 
antigens. Methods explained in section 2.2.3. Optical densities (ODs) are measured 
at 450 nm and data is represented as relative concentrations of diluted standards.  
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Figure 8. 2 Calibration curves for antibody ELISAs to human antigens. Methods 
explained in section 2.2.3. Optical densities (ODs) are measured at 450 nm and data 
is represented as relative concentrations of diluted standards. 
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Figure 8. 3 Calibration curves for antibody ELISAs to PG-related antigens. Methods 
explained in section 2.2.3. Optical densities (ODs) are measured at 450 nm and data 
is represented as relative concentrations of diluted standards. 
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Figure 8. 4 Failed attempts to find calibration curves for antibody ELISAs to PG-
related antigens. Methods explained in section 2.2.3. Optical densities (ODs) are 
measured at 450 nm and data is represented as relative concentrations of diluted 
standards. 
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8.2. Correlation analysis between circulating antibodies and clinical 
parameters 
Weak significant correlations were found between the antibody production 
against proteins from PG, FN and PI which suggests that these bacteria, in 
agreement with the current literatre, are positively and significantly correlated 
(Table 8. 1). Clinical parameters related to periodontitis are strongly and 
significantly associated with RA parameters. 
However, although some of these significant correlations are strong and others 
are weak, the small sample size limits the reliability of the results. Although this 
study suggests a correlation between circulating antibodies to periodontal 
bacteria and clinical parameters in RA, a pivotal study with a bigger sample size 
is needed to verify this results. 
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Table 8. 1 Significant correlations of crossectional variables at baseline (Spearman’s 
correlation, p<0.04). 
Variable 1 Variable 2 r p 
anti-PG C-TNC5 0.287 0.02 
anti-PG RgpB 0.359 0.001 
anti-PG CCP 0.215 0.023 
anti-PI anti-PG 0.2 0.02 
anti-PI anti-FN 0.19 0.03 
anti-PI PPAD -0.2 0.02 
anti-FN anti-PG 0.39 0.001 
anti-FN PG-eno 0.4 0.001 
anti-FN PPAD 0.3 0.01 
anti-PI DAS28 -0.197 0.034 
anti-PI ESR -0.226 0.015 
anti-PI Age -0.394 0.001 
anti-PG cumPPD 0.288 0.002 
anti-PG Cal 0.32 0.001 
anti-PG BoP 0.217 0.019 
anti-FN BoP 0.193 0.039 
anti-FN PPD 0.276 0.003 
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anti-FN DAS28 0.273 0.01 
anti-FN ESR 0.239 0.01 
PPD DAS28 0.81 0.001 
PPD ESR 0.77 0.001 
CAL DAS28 0.344 0.001 
CAL ESR 0.32 0.001 
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Abstract 
Objectives 
Studies that demonstrate an association between rheumatoid arthritis (RA) and dysbiotic 
oral microbiomes are often confounded by the presence of extensive periodontitis in 
these individuals. Therefore, the present investigation sought to investigate the role of 
RA in modulating the periodontal microbiome by comparing periodontally healthy 
individuals with and without RA.   
Methods 
Subgingival plaque was collected from was collected periodontally healthy individuals 
(22 with and 19 without RA), and 16S gene sequenced on the Ilumina MiSeq platform. 
Bacterial biodiversity and co-occurrence patterns were examined using the QIIME and 
PhyloToAST pipelines. 
Results 
The subgingival microbiomes differed significantly based on both community 
membership and as well as the abundance of lineages, with 41.9% of the community 
differing in abundance and 19% in membership. In contrast to the sparse and 
predominantly congeneric co-occurrence networks seen in controls, RA subjects 
revealed a highly connected grid containing a large inter-generic hub anchored by known 
periodontal pathogens. Predictive metagenomic analysis (PICRUSt) demonstrated that 
arachidonic acid and ester lipid metabolism pathways might partly explain the robustness 
of this clustering. As expected from a periodontally healthy cohort, Porphyromonas 
gingivalis and Aggregatibacter actinomycetemcomitans were not significantly different 
between groups, however, Cryptobacterium curtum, another organism capable of 
producing large amounts of citrulline, emerged as a robust discriminant of the 
microbiome in individuals with RA.   
Conclusions 
Our data demonstrates that the oral microbiome in RA is enriched for inflammophilic and 
citrulline producing organisms, which may play a role in the production of autoantigenic 
citrullinated peptides in RA. 
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INTRODUCTION 
Rheumatoid arthritis (RA) has been associated with periodontal disease (PD), a 
bacterially initiated chronic inflammation that leads to destruction of tooth-supporting 
tissues(Kaur, White et al. 2012). Although PD and RA share similar inflammatory 
pathways as well as genetic and environmental risk factors, these are insufficient to 
explain this connection(Kaur, White et al. 2012).   
While the cause of RA remains unknown, it has been hypothesized that oral 
microbiota(de Pablo, Chapple et al. 2009, de Pablo, Dietrich et al. 2014) in particular the 
periodontal pathogens Porphyromonas gingivalis and Aggregatibacter 
actinomycemtemcomitans, may play a critical role in its pathogenesis(Wegner, Wait et 
al. 2010, Konig, Abusleme et al. 2016) 
Studies using next generation sequencing methods demonstrate the oral 
microbiome is altered in RA(Scher, Ubeda et al. 2012, Zhang, Zhang et al. 2015). 
However, the majority of these studies included individuals with   moderate to severe 
periodontitis(Scher, Ubeda et al. 2012) or individuals whose periodontal health status 
was not established(Zhang, Zhang et al. 2015). Periodontitis, by itself, is a significant 
modifier of the oral microbiome(Griffen, Beall et al. 2012), making it difficult to dissect 
the relative contributions of periodontitis and RA to the microbial dysbiosis. 
 Given the potential role of oral bacteria may play in the etiopathogenesis of RA, 
we set out to characterize the periodontal microbiome in periodontally healthy individuals 
with and without RA, using next generation sequencing. 
 
METHODS 
 
The study sample included patients with RA and non-RA controls. All participants were 
periodontally healthy. Subgingival plaque samples were collected and analyzed using 
16S rDNA sequencing. Detailed methods are described in supplementary information. 
The sequences are deposited in the Sequence Read Archive of NCBI (project number: 
PRJNA391575). 
 
RESULTS  
We examined 22 patients with RA and 19 non-RA controls. There was a statistically 
significant but clinically inconsequential difference between groups in periodontal 
measures, in particular PPD and CAL (Table 1). Principal Coordinate Analysis (PCoA) 
of both unweighted and weighted UniFrac distances demonstrated significant clustering 
of the microbiomes based on RA status (Figure 1, p=0.001, Adonis test), indicating that 
these groups differed both in presence or absence of lineages (community membership), 
as well as in the relative abundances of lineages within communities (community 
structure).  
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Table 1: Clinical and demographic characteristics in periodontally healthy subjects with 
rheumatoid arthritis (RA) and without RA (non-RA). Data represented as mean (25, 75 
percentile) for ordinal data and percentage for categorical data. P values are calculated 
using Mann-Whitney test for ordinal data and Fisher's test for categorical data and 
significant differences (p<0.05) indicated with an asterisk (*).  Abbreviations: BMI, body 
mass index; PPD probing pocket depth; BoP, bleeding on probing; CAL, clinical 
attachment loss; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale for 
patients global assessment of disease activity; DAS, disease activity score 
 RA 
n=22 
Non-RA 
n=19 
Age in years, mean (IQR) 60 (54.1, 63.4)* 36 (32.9, 41.6) 
Gender (% Male) 23 32 
Ethnicity (%) 
White 95 89 
Asian 5 11 
Smoking history (%) 
Never 62 90 
Former 29 5 
Current 9 5 
Alcohol consumption (%) 
Never 11 14 
1-4 times/month 73 45 
1-4 times/week 16 41 
Clinical periodontal characteristics 
PPD in mm, mean (IQR) 2.3 (2.2, 2.4)* 1.6 (1.5, 1.7) 
Number of sites with PPD>4mm 1.2 (0, 2) 0.9 (0,3) 
Number of sites with BoP, mean (IQR) 6 (0, 19) 4 (1, 16) 
Gingival recession in mm, mean (IQR) 0.28 (0.01, 0.26)* 0.13 (0.04, 0.2) 
Measures of RA severity 
ESR 8 (8.7, 21.7)  
VAS (global assessment of disease activity) 41 (31.7, 58.5)  
DAS28 3.4 (2.7, 3.9)  
 
Since patients with RA differed from controls in both community membership and 
structure, we identified species level operational taxonomic units (s-OTUs) that 
contributed to this difference using an increasingly granular top-down approach.  
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Patients with RA presented had greater abundances of obligate anaerobes (both gram-
positive and gram-negative) while facultatives (especially gram-negative) were identified 
in greater abundance in non-RA controls (p<0.05 Wilcoxon signed rank test, Figure 1).  
 
We then used DESeq2(Love, Huber et al. 2014) to identify differentially abundant OTUs; 
with p-values <0.05 after adjusting for multiple testing, and Fisher’s exact test to examine 
the frequency of detection. We identified 558 OTUs from 3,963,291 classifiable 
sequences (mean of 107115 sequences per sample, range 69626-182993). Rarefaction 
curves demonstrated that all samples approached saturation or had plateaued. 229 
OTUs (41.9% of the community) differed significantly in structure and 105 OTUs (19%) 
differed significantly in membership between groups (Figure 1 and supplementary table 
1). Certain species were significantly more abundant in patients with RA, including those 
belonging to the genera Actinomyces (odds ratios (OR) varying from 4-9 for each species 
within the genus), Cryptobacterium (OR=36), Dialister, Desulfovibrio (ORs of 4 and 26), 
Fretibacterium (OR 9 to 12), Leptotrichia (OR 7 to 26) Prevotella (OR 0.04 to 6), 
Selenomonas (OR 0 to 7), Treponema (OR 0 to 7), and Veillonellaceae [G1] (OR 0 to 6).  
 
In contrast, several species belonging to the genera Aggregatibacter, Gemella, 
Granulicatella, Hemophilus, Neisseria and Streptoccoci not only demonstrated lower 
abundances but also were less frequently detected in RA. These significantly abundant 
species accounted for a median of 28% (range 12-82%) of each individual’s microbiome 
in patients with RA, indicating that these differences are not attributable to the rare 
biosphere. 
 
Since the subgingival microbiome is known to be significantly heterogeneous among 
individuals(Paster, Boches et al. 2001), we used the core microbiome (suite of species 
identified in ≥ 80% of subjects) to compare stable associations between groups. 326 
OTUs were identified in the core microbiome of all study participants and 364 in patients 
with RA.  27.7% of the community (101 OTUs) differed significantly in structure and 
10.9% (40 OTUs) in membership, with 38 species unique to the RA core microbiome 
(Figure 1). Importantly, 157 of the 229 species identified above belonged to the core 
microbiome.  
 
Sparse, congeneric networks were observed in non-RA controls (Figure 2). On the other 
hand, the network topology of individuals with RA revealed a highly connected grid with 
a robust intergeneric hub. 83 of the 157 core species were incorporated in this hub, 
further reinforcing our observation that in subjects with RA, the environment imposes a 
selection drive. Importantly, known pathogenic species belonging to Treponema, 
Selenomonas, Filifactor, Campylobacter and Fretibacterium were tightly interwoven into 
this hub, and 12 gram-negative species were identified as network anchors. Interestingly, 
species traditionally associated with RA, for example, P.gingivalis (Pg) and 
A.actinomycetemcomitans (Aa), were not part of the network cluster.  
 
Since there is little literature-based information to provide insights into the biological 
basis for this tight clustering, we combined predictive metagenomic analysis 
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(PICRUSt(Langille, Zaneveld et al. 2013)) with network graph theory and core 
microbiome analysis to explore if shared functionality could explain co-occurrence 
(Figure 2). Bacterial arachidonic acid and ether lipid metabolism genes exhibited the 
greatest betweenness centrality (reflecting the amount of control that these node exerts 
over the interactions of other nodes in the network(Yoon, Blumer et al. 2006)), and the 
highest degree centrality (an indication that they are the central focal point of the 
structure).   
 
DISCUSSION 
Gram-negative anaerobes are known to play important roles in initiating periodontitis, 
and emerging evidence also implicates them in the etiopathogenesis of RA(Mikuls, 
Payne et al. 2014, Zhang, Zhang et al. 2015). Our results show that even in periodontally 
healthy RA patients, gram-negative anaerobes are significantly more abundant in RA, 
consistent with a dysbiotic state. Such a status might indicate a pre-clinical phase of 
periodontitis. As expected from a periodontally healthy adult cohort, Pg and Aa were 
neither dominant members of the microbiome nor significantly different between groups. 
Taken together with previous studies(Mikuls, Payne et al. 2014), our data implies that 
gram-negative bacteria other than Pg and Aa may play a role in initiation of RA, while 
the evidence from literature suggests that these two species may be critical to disease 
perpetuation. 
 
Recent investigations demonstrate that while substantial microbial heterogeneity exists 
among healthy individuals, a robust core microbiome is identifiable in individuals who 
smoke or are pregnant(Mason, Preshaw et al. 2015, Jetté, Dill-McFarland et al. 2016, 
Paropkari, Leblebicioglu et al. 2016). The findings of the present study parallel these 
previous observations and support the ecological plaque hypothesis(Marsh 1994), 
suggesting that RA imposes a habitat filtering on the subgingival environment, 
preferentially promoting the growth of certain organisms. 
 
Traditional statistical methods assume bacterial presence and abundance to be 
independent variables, but in reality bacterial presence in a biofilm is driven by inter-
dependent nutritional and metabolic interactions. Therefore, we combined network graph 
theory with DESeq and core microbiome analysis to examine co-occurrence patterns 
and identify important community members (network anchors). No network anchors were 
identifiable in controls (since betweenness centrality was homogeneous between 
species), indicating that this is an ecological niche in equilibrium. However, the tightly 
woven hub of anaerobes suggest that a small group of anaerobic bacteria play an 
important role controlling the flow of resources in the RA-influenced microbiome, 
implying that even small changes in these anchors could impact upon community 
assembly in people with RA. These species may be potential targets for microbial 
disruption. 
 
Arachidonic acid (AA) is essential for cell membrane integrity. It is metabolized to 
prostaglandin E2 (PGE2) and other pro-inflammatory eicosanoids, which are implicated 
in the development of RA. The ability to metabolize AA into pro-inflammatory eicosanoids 
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is an emergent property of opportunistic pathogens(Fourie, Ells et al. 2016). AA is also 
known to inhibit the growth and epithelial adhesion of beneficial species in the 
gut(Kankaanpaa, Yang et al. 2004). Taken together, the data indicate that the 
subgingival microbiome is both influenced by, and influences, the inflammatory burden 
of RA. 
 
One of the most intriguing findings was the identification of Cryptobacterium curtum as 
a predominant member of the RA-influenced periodontal microbiome. This gram-
positive, assacharolytic, anaerobic rod (which was previously misclassified as 
Eubacterium saburreum) degrades arginine through the arginine deiminase pathway and 
produces substantial amounts of citrulline, ornithine and ammonia(Uematsu, Sato et al. 
2006). We have previously identified this as a periodontal pathogen(Kumar, Griffen et al. 
2003), and translocation from oral sources has been implicated in the etiology of distant 
infections such as pelvic abscesses, gynecologic infections, and wounds(Brook and 
Frazier 1993). More importantly, C. curtum is enriched in the oral and gut microbiomes 
of early RA cases(Vaahtovuo, Munukka et al. 2008, Zhang, Zhang et al. 2015). In line 
with previous studies, we observed that this species was a member of the core 
microbiome in RA patients. Compared to non-RA controls, this species demonstrated a 
100-fold greater abundance in RA with 39-fold greater odds of detection. While this 
unusually high association does not necessarily suggest an etiopathogenic role for 
C.curtum, this organism is certainly a candidate for further studies. In light of evidence 
that antibodies against citrullinated protein and peptides (ACPA) precede the clinical 
onset of RA by several years, have high specificity for RA at over 95%(Schellekens, de 
Jong et al. 1998, Schellekens, Visser et al. 2000) and that we previously observed 
antibodies characteristic of RA, including citrullinated and uncitrullinated peptides of the 
RA autoantigens in individuals with periodontitis(de Pablo, Dietrich et al. 2014), the ability 
of C.curtum to degrade arginine via the arginine deiminase pathway and to produce 
substantial amounts of citrulline is of particular interest. Presence of C.curtum in the 
plaque may therefore be a contributing factor in the development of RA autoantigens 
and warrants further investigation. 
 
In summary, our data suggest that RA plays a major role in shaping the oral microbiome. 
The microbiome in RA is enriched for pro-inflammatory organisms and those capable of 
producing substantial amounts of citrulline (pro-antigenic). An ability to metabolize 
arachidonic acid and ether lipids appears to be a shared function among the species 
observed in individuals with RA. Our findings lend further credence to a link between the 
oral microbiome and RA; however, longitudinal studies are needed to understand 
directionality and causality, and also to characterize potentially "driver species" that 
could serve as biomarkers for RA.  
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TABLES AND FIGURES 
 
 
 
Figure 1: Differences in alpha and beta diversity metrics between periodontally healthy 
subjects with and without rheumatoid arthritis (RA). (A): Principal Coordinates Analysis 
(PCoA) plots of unweighted and weighted Unifrac distances (B): Kernel plots of alpha 
diversity (Abundance-based Coverage Estimator (ACE)). The peak indicates the median 
values for each group. The x-axis indicates the data range.  (C): Distribution of species 
by gram staining and oxygen requirement characteristics. Groups that share the same 
symbol are significantly different from each other (p < 0.05, Kruskal Wallis test) (D): 
Phylogenetic tree representing normalized mean relative abundance (NMRA, stacked 
bar chart), core species (circles represent species present in 80% of samples in a 
group), significant frequency of detection (stars) and phylum-level taxonomic annotation 
(colored-strips and text) for significantly different and differentially abundant species-
level OTUs (tree leaves). Data for figure 1D is presented in supplemental table 1. 
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Figure 2: Co-occurrence networks in periodontally healthy subjects with or without 
rheumatoid arthritis (RA): Each network graph contains nodes (circles) and edges 
(connections representing Spearman’s ρ). Edges are colored green for positive 
correlation and red for negative correlation. Nodes represent species-level OTUs in 2A 
and 2B and genes encoding for metabolic functions in 2C; and are sized by relative 
abundance. Edges represent significant and robust Spearman’s correlation (p<0.05, 
≥0.75). Data for figure 2C is presented in supplemental table 2.  
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